|
Archive 2009
News from Brogan Inc.
Provincial Formulary Updates
PMPRB News - Regulations
News from Brogan Inc.
CDR Statistics, CDR Recent Recommendations: Prezista®, Copaxone® and Inspra®
Brogan Inc a Sponsor of the 8th Annual Market Access Summit
CDR Recent Recommendations: Forteo, Duodopa, Levemir, Lyrica and Pristiq
CDR Recent Recommendations: Vesicare, Stelara and Fosavance 70/5600
CDR Recent Recommendations: Olmetec and Olmetec Plus
CDR Recent Recommendations: Enablex, Orencia and Remicade
CDR Recent New Recommendations: Tysabri and Viread
CDR Published a New Recommendation on February 20, 2009: Apidra
CDR published four final recommendations on Jan 30, 2009: Pradax, Relistor, Thelin and Xyrem
CDR Statistics, CDR Recent Recommendations: Prezista®, Copaxone® and Inspra®
CDR made final recommendations on three products since October. Prezista® received a positive recommendation while Copaxone® and Inspra® both attained “Do not list” recommendations.
As for most HIV infection treatment drugs, Prezista® (darunavir, submitted by Janssen-Ortho Inc.) received a positive listing recommendation for its new indication for use in treatment-naive adults with HIV-1. The CEDAC decision was based on better clinical results with lower adverse events at a similar cost level when compared to existing treatment regimens.
Copaxone® (glatiramer acetate, by Teva Pharmaceutical Industries Ltd.) was submitted to CDR for the treatment of patients with clinically isolated syndrome (CIS), suggestive of multiple sclerosis (MS). Since not all patients with CIS will be subsequently diagnosed with MS, there will be no clinical benefit to treat non-MS patients at an annual cost of $15,700. Also, due to the uncertainty of the effect of Copaxone® on disability, the cost-effectiveness of Copaxone® in CIS could not be determined.
Pfizer Canada Inc.’s diuretic product Inspra® (eplerenone) is indicated to reduce the risk of mortality following myocardial infarction. The committee considered spironolactone as the most appropriate comparator for Inspra® because of the same mechanism of action. The "Do not list" recommendation was a result of the lack of relevant RCT comparisons and unknown cost-effectiveness of Inspra® when compared to spironolactone.
| CDR Activity as of November 30, 2009 |
| Number of CDR Submissions |
176 |
| Number of CDR Completed Submissions |
151 |
| Number of CDR Active Submissions |
14 |
| Number of CDR Submissions Withdrawn/Suspended |
11 |
| |
|
| Number of CEDAC Recommendations |
145 |
| Number of Positive CEDAC Recommendations |
68 |
| Number of Negative CEDAC Recommendations |
74 |
| Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
|
| Number of Priority Reviews Requested/Granted |
32/12 |
| Number of PreNOC Pilot Submissions/Positively Recommended |
1/1 |
| |
|
| Number of Unique Products Receiving Recommendations |
116 |
| Number of Unique Products Receiving Positive Recommendations |
59 |
| Number of Unique Products Receiving Negative Recommendations |
57 |
| |
|
| The Newest CEDAC Recommendations from the Latest Update |
Prezista®
(New indication, Positive) |
Copaxone®
(Negative) |
Inspra®
(Negative) |
| The Newest CDR Submissions from the Latest Update |
Nplate®
(Chronic immune ITP) |
Januvia®
(Diabetes Mellitus (Type 2)) |
Janumet®
(Diabetes Mellitus (Type 2)) |
Abilify®
(Schizophrenia) |
Onglyza®
(Diabetes Mellitus (Type 2)) |
Brogan Inc a Sponsor of the 8th Annual Market Access Summit
Brogan Inc. Is proud to be a sponsor of the 8th Annual Market Access Summit, to be held Nov. 4th and 5th in Toronto. This prestigious summit will provide solutions to improve patient outcomes, reduce time to listing, health economics, optimizing reimbursement & pricing and innovative listings & risk sharing.
The summit will focus on new PMPRB and CDR directions and includes solutions from leaders such as Alberta Health Services, Manitoba health, Canadian Cancer Society, Sun Life Financial, Manulife Financial, Ontario Teachers insurance Plan and Walmart. As well, Brogan’s Joan McCormick, Principal Consultant, Price Regulation Team will participate in a panel discussion entitled Understanding the Judicial and Practical Implications of PMPRB Developments and What it Means to the Industry.
For full event details click: http://www.strategyinstitute.com/110409_mas8/dsp.php
CDR Recent Recommendations: Forteo, Duodopa, Levemir, Lyrica and Pristiq
CDR made final recommendations on five products, Forteo, Duodopa, Levemir, Lyrica and Pristiq, during the last quarter (July to September). All of these are “do not list” decisions.
Forteo (teriparatide, submitted by Eli Lilly Canada Inc.) is indicated for the treatment of glucocorticoid induced osteoporosis. CEDAC recommends that teriparatide not be listed because it lacks significant clinical advantages over existing treatments (e.g., alendronate groups) and is more expensive than some comparators (including generics).
Duodopa, indicated for advanced Parkinson's disease, is a combination of levodopa and carbidopa in a gel formula submitted by Solvay Pharma Inc. The negative recommendation decision is not surprising since the daily cost of Duodopa is $166, which is significantly higher than the conventional oral drug therapies (e.g., generic levodopa/carbidopa cost less than $3 per day). Clinically, it has been issued a Notice of Compliance with Conditions from Health Canada, pending the results of studies to verify its clinical benefit.
Novo Nordisk Canada Inc. submitted Levemir (insulin detemir) for two indications: a) treatment of adult patients with Type 1 or 2 diabetes mellitus and, b) treatment of Type 1 diabetes mellitus in pediatric patients. The Committee had concerns about the outcome of clinical trials that may have been subject to potential reporting bias, and also believed that the cost-effectiveness was not demonstrated when compared with NPH (insulin detemir costs $7.32 per ml while NPH insulin costs $1.94 - $2.53). A reduced price would improve Levemir’s cost-effectiveness and increase the likelihood of a recommendation for positive listing.
Pfizer Canada Inc.’s product Lyrica (pregabalin) is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. It previously received a CEDAC recommendation of “do not list” on January 25, 2006. The resubmission is based on a new economic model with some adjustments on price. Because less expensive comparators already exist, and there is no new RCT evidence since the initial submission to demonstrate clinical effectiveness of Lyrica over its comparators, the Committee again recommends that Lyrica not be listed.
Wyeth Canada submitted Pristiq (desvenlafaxine succinate) for the treatment of major depressive disorder (MDD). The reasons for the Committee’s negative recommendation are lacking RCT comparison of Pristiq at Health Canada approved doses with its parent compound, and also the higher price when compared to generic comparators at recommended daily doses.
| CDR Activity as of October 3, 2009 |
| Number of CDR Submissions |
171 |
| Number of CDR Completed Submissions |
148 |
| Number of CDR Active Submissions |
12 |
| Number of CDR Submissions Withdrawn/Suspended |
11 |
| |
|
| Number of CEDAC Recommendations |
142 |
| Number of Positive CEDAC Recommendations |
67 |
| Number of Negative CEDAC Recommendations |
72 |
| Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
|
| Number of Priority Reviews Requested/Granted |
32/12 |
| Number of PreNOC Pilot Submissions/Positively Recommended |
1/1 |
| |
|
| Number of Unique Products Receiving Recommendations |
114 |
| Number of Unique Products Receiving Positive Recommendations |
59 |
| Number of Unique Products Receiving Negative Recommendations |
55 |
| |
|
| The Newest CEDAC Recommendations from the Latest Update |
Forteo (Negative) |
| Duodoba (Negative) |
| Levemir (Resubmission, Negative) |
| Levemir (New indication, Negative) |
| Lyrica (Negative) |
| Pristiq (Negative) |
| The Newest CDR Submissions from the Latest Update |
Azarga
(Glaucoma and Ocular hypertension) |
Simponi
(Arthritis (rheumatoid, psoriatic) and Ankylosing spondylitis (AS)) |
Cimzia
(Arthritis, rheumatoid) |
Soliris
(Paroxysmal nocturnal hemoglobinuria (PNH)) |
Multaq
(Atrial fibrillation) |
CDR Recent Recommendations: Vesicare, Stelara and Fosavance 70/5600
June 24, 2009:
Three products, Vesicare, Stelara and Fosavance 70/5600, have received positive final recommendations since the last CDR update.
Vesicare (solifenacin, manufactured by Astellas Pharma Canada Inc.) is indicated for the treatment of overactive bladder. The initial submission to the CDR on January 24, 2007 received a “do not list” recommendation. This resubmission was based on a confidential new price and new clinical trial information. The new clinical trials did not show sufficient evidence of outcome improvements. Likely then, a lower confidential price led to the positive listing recommendation.
Janssen-Ortho Inc.’s new biologic product Stelara (ustekinumab) is indicated for the treatment of chronic moderate to severe plaque psoriasis in adult patients. The rationale of the positive recommendation was based on statistically significant better clinical outcomes and a similar annual cost to comparators (e.g., Humira and Enbrel). The annual cost of ustekinumab is $25,200, while Enbrel is $25,134 and Humira is above $18,000.
Merck Frosst Canada Ltd.’s combination product Fosavance 70/5600 (alendronate sodium & cholecalciferol (vitamin d3) is indicated for the treatment of Osteoporosis in men and postmenopausal women. Since no clinical advantages over generic alendronate were offered, the confidential price submitted was an important consideration that led to CDR’s positive listing recommendation.
CDR Activity as of June 19, 2009 |
Number of CDR Submissions |
164 |
| Number of CDR Completed Submissions |
140 |
Number of CDR Active Submissions |
13 |
Number of CDR Submissions Withdrawn/Suspended |
11 |
| |
Number of CEDAC Recommendations |
136 |
Number of Positive CEDAC Recommendations |
67 |
Number of Negative CEDAC Recommendations |
66 |
Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
Number of Priority Reviews Requested/Granted |
32/12 |
Number of PreNOC Pilot Submissions/Positively Recommended |
1 / 1
|
| |
Number of Unique Products Receiving Recommendations |
112 |
Number of Unique Products Receiving Positive Recommendations |
59
|
Number of Unique Products Receiving Negative Recommendations |
53 |
| |
The Newest CEDAC Recommendations from the Latest Update |
Fosavance 70/5600(Positive)
|
Vesicare (Positive) |
Stelara
(Positive) |
| The Newest CDR Submissions from the Latest Update |
Lantus
(Request for Advice for Diabetes, Type 1 and 2) |
Omnitrope
(for Growth hormone deficiency in children and adults) |
Xeomin
(for Symptomatic management of blepharospasm, cervical dystonia, and post-stroke spasticity of the upper limb) |
CDR Recent Recommendations: Olmetec and Olmetec Plus
June 3, 2009:
Schering-Plough Canada Inc.’s anti-hypertensive products Olmetec and Olmetec Plus obtained positive CEDAC final recommendations at the end of May 2009.
Olmetec (olmesartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. Clinical trials showed similar results as other ARBs and the daily cost of Olmetec is less than other ARBs ($0.99 vs. $1.03 ~ $2.28).
Olmetec Plus (olmesartan medoxomil / hydrochlorothiazide) is a combination of an ARB and a thiazide diuretic indicated for the treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. The positive listing recommendation is also based on similar clinical outcomes and a less than or similar daily cost to other ARB/hydrochlorothiazide combination products ($0.99 vs. $1.03 ~ $1.25).
CDR Activity as of June 1, 2009 |
Number of CDR Submissions |
160 |
| Number of CDR Completed Submissions |
137 |
Number of CDR Active Submissions |
12 |
Number of CDR Submissions Withdrawn/Suspended |
11 |
| |
Number of CEDAC Recommendations |
133 |
Number of Positive CEDAC Recommendations |
64 |
Number of Negative CEDAC Recommendations |
66 |
Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
Number of Priority Reviews Requested/Granted |
32/12 |
Number of PreNOC Pilot Submissions/Positively Recommended |
1 / 1
|
| |
Number of Unique Products Receiving Recommendations |
110 |
Number of Unique Products Receiving Positive Recommendations |
56
|
Number of Unique Products Receiving Negative Recommendations |
54 |
| |
The Newest CEDAC Recommendations from the Latest Update |
Olmetec(Positive)
|
Olmetec Plus (Positive) |
| The Newest CDR Submissions from the Latest Update |
Inspira
(Post myocardial infarction)
|
CDR Recent Recommendations: Enablex, Orencia and Remicade
May 4, 2009:
Enablex and Orencia both obtained positive CEDAC final recommendations and Remicade received a negative recommendation during April 2009.
Novartis Pharmaceuticals Canada Inc.’s product Enablex (darifenacin hydrobromide) is for the treatment of overactive bladder. The initial submission for Enablex received CDR’s negative recommendation on October 19, 2006. The basis of the resubmission was a confidential new price submitted by the manufacturer. The new daily cost of Enablex is $1.46 and the original submission was $1.58. There also has been one new RCT since the initial submission, but was not considered as any improvement. The new lower price likely led to a positive final recommendation.
Orencia (abatacept), a biologic product of Bristol-Myers Squibb Canada was positively recommended by CDR for the treatment of juvenile idiopathic/juvenile rheumatoid arthritis. Orencia previously received a positive recommendation for the treatment of RA in adults on June 27, 2007.
Orencia was shown to be more effective than placebo in the clinical trial. The daily cost of Orencia ranges from $15.67 to $47.01, which is similar to the cost of etanercept (Enbrel) of $18.88 to $54.93. CEDAC made the positive listing recommendation however concerns remain on safety issues associated with long-term use in children.
CDR’s review of Remicade (infliximab) was initiated in response to a submission from the Advisory Committee on Pharmaceuticals (ACP) for the treatment of ulcerative colitis. Although clinical trials provide some evidence that Remicade is effective versus placebo, CEDAC felt that treatment with Remicade was not cost effective. The annual cost of Remicade 5mg/kg is $30,080 in the first year and $22,440 thereafter (for a 70kg patient). There will be an estimated incremental cost per QALY of $125,000 compared to standard care.
CDR Activity as of April 30, 2009 |
Number of CDR Submissions |
159 |
| Number of CDR Completed Submissions |
135 |
Number of CDR Active Submissions |
13 |
Number of CDR Submissions Withdrawn/Suspended |
11 |
| |
Number of CEDAC Recommendations |
131 |
Number of Positive CEDAC Recommendations |
62 |
Number of Negative CEDAC Recommendations |
66 |
Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
Number of Priority Reviews Requested/Granted |
32/12 |
Number of PreNOC Pilot Submissions/Positively Recommended |
1 / 1
|
| |
Number of Unique Products Receiving Recommendations |
108 |
Number of Unique Products Receiving Positive Recommendations |
54
|
Number of Unique Products Receiving Negative Recommendations |
54 |
| |
The Newest CEDAC Recommendations from the Latest Update |
Enablex(Positive)
|
Orencia (Positive) |
Remicade (Negative) |
| The Newest CDR Submissions from the Latest Update |
Prezista
(New Indication for HIV-treatment naive) |
Copaxone
(Indicated for Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis)
|
CDR Recent New Recommendations: Tysabri and Viread
March 23, 2009:
CEDAC made two new positive final recommendations for Tysabri and Viread on February 25, 2009 and March 18, 2009 respectively. Both drugs had been submitted to CDR more than once.
The MS (Multiple Sclerosis, relapsing-remitting) biologic drug Tysabri (natalizumab) is a product of Biogen Idec Canada Inc. The initial submission for Tysabri received CDR’s negative recommendation on April 26, 2007. There have been no new RCTs since the original submission. The basis of this resubmission was a new pharmacoeconomic evaluation and a 15% price reduction compared to the initial submission, which led to a positive final recommendation.
Viread (tenofovir disoproxil fumarate), a product of Gilead Sciences Canada Inc. was positively recommended by CDR for the treatment of adult patients with chronic hepatitis B infection. Viread previously received a positive recommendation for the indication of HIV-1 infection on March 15, 2006.
The committee’s decision was based on statistically significant improvement in RCTs and a cost-utility analysis, cost/QALY estimates. The daily cost of Viread is $16.74, which is less expensive than some of the other chronic hepatitis B comparators (e.g., Baraclude, Hepsera and Sebivo).
CDR Activity as of March 20, 2009 |
Number of CDR Submissions |
156 |
| Number of CDR Completed Submissions |
132 |
Number of CDR Active Submissions |
13 |
Number of CDR Submissions Withdrawn/Suspended |
11 |
| |
Number of CEDAC Recommendations |
128 |
Number of Positive CEDAC Recommendations |
60 |
Number of Negative CEDAC Recommendations |
65 |
Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
Number of Priority Reviews Requested/Granted |
32/12 |
Number of PreNOC Pilot Submissions/Positively Recommended |
1 / 1
|
| |
Number of Unique Products Receiving Recommendations |
107 |
Number of Unique Products Receiving Positive Recommendations |
53
|
Number of Unique Products Receiving Negative Recommendations |
54 |
| |
The Newest CEDAC Recommendations from the Latest Update |
Tysabri(Positive)
|
Viread (Positive) |
| The Newest CDR Submissions from the Latest Update |
Pristiq (MDD) |
Levemir
(Resubmission for Diabetes mellitus)
|
Azilect
(Request for Advice for Parkinson's disease)
|
CDR Published a New Recommendation on February 20, 2009: Apidra
February 24, 2009:
This past Friday CEDAC recommended Apidra to be listed in a similar manner to other rapid-acting insulin analogues.
Apidra (insulin glulisine) is produced by Sanofi-Aventis Canada Inc. and indicated for the treatment of adult patients with Type 1 or Type 2 Diabetes Mellitus.
This product is less costly than some of its comparators (e.g., insulin lispro and insulin aspart), but has similar clinical efficacy and safety which likely lead to the positive recommendation from CEDAC.
CDR Activity as of February 20, 2009 |
Number of CDR Submissions |
153 |
| Number of CDR Completed Submissions |
130 |
Number of CDR Active Submissions |
13 |
Number of CDR Submissions Withdrawn/Suspended |
10 |
| |
Number of CEDAC Recommendations |
126 |
Number of Positive CEDAC Recommendations |
58 |
Number of Negative CEDAC Recommendations |
65 |
Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
Number of Priority Reviews Requested/Granted |
32/12 |
Number of PreNOC Pilot Submissions/Positively Recommended |
1 / 1
|
| |
Number of Unique Products Receiving Recommendations |
107 |
Number of Unique Products Receiving Positive Recommendations |
52
|
Number of Unique Products Receiving Negative Recommendations |
55 |
| |
The Newest CEDAC Recommendations from the Latest Update |
Apidra(Positive)
|
| The Newest CDR Submissions from the Latest Update |
No |
CDR published four final recommendations on Jan 30, 2009: Pradax, Relistor, Thelin and Xyrem
February 4, 2009:
The four products all received do not list recommendations by CEDAC.
Boehringer Ingelheim (Canada) Inc.’s product Pradax (dabigatran) is indicated for venous thromboembolism prevention (VTE). Although the manufacturer’s cost utility analysis showed some cost savings associated with dabigatran use compared with enoxaparin (Lovenox), CEDAC felt these cost savings were not sufficient to offset the higher incidence of venous thrombosis observed in the REMOBILIZE trial. And dabigatran ($7.85) is more expensive than another comparator warfarin ($7.85 vs. $0.40 per day).
Relistor (methylnaltrexone) produced by Wyeth is indicated for the treatment of opioid-induced constipation. The cost effectiveness and clinic advantage of Relistor compared to other laxatives are uncertain according to CEDAC.
The resubmission of Encysive Canada Inc.’s product Thelin (sitaxsentan) still received a negative recommendation in spite of a price reduction. Not showing improved clinical outcomes and still being too costly comparing with some existing comparators for WHO class II & III PAH are the reasons for the negative final recommendation.
Xyrem (sodium oxybate) produced by Valeant Canada Ltd. is for treatment of narcolepsy. The committee felt that the cost effectiveness of Xyrem had not been demonstrated since the clinical effectiveness is uncertain.
CDR Activity as of January 30, 2009 |
Number of CDR Submissions |
152 |
| Number of CDR Completed Submissions |
129 |
Number of CDR Active Submissions |
14 |
Number of CDR Submissions Withdrawn/Suspended |
9 |
| |
Number of CEDAC Recommendations |
125 |
Number of Positive CEDAC Recommendations |
57 |
Number of Negative CEDAC Recommendations |
65 |
Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
Number of Priority Reviews Requested/Granted |
32/12 |
Number of PreNOC Pilot Submissions/Positively Recommended |
1 / 1
|
| |
Number of Unique Products Receiving Recommendations |
106 |
Number of Unique Products Receiving Positive Recommendations |
51 |
Number of Unique Products Receiving Negative Recommendations |
55 |
| |
The Newest CEDAC Recommendations from the Latest Update |
Pradax (Negative)
Relistor (Negative)
Thelin (Negative)
Xyrem (Negative) |
| The Newest CDR Submissions from the Latest Update
|
Fosavance 70/5600
(for Osteoporosis) |
Forteo (for glucocorticoid induced Osteoporosis) |
Duodopa (for Parkinson's disease) |
Vesicare (Resubmisison for overactive bladder) |
| Stelara
(for Psoriasis)
|
Provincial Formulary Updates
Posted December 18, 2009
Newfoundland
NLPDP Bulletin No. 88, December 16, 2009
Highlights
Revision to Bulletin #87 - Benefit List Update - Special Authorization to Open Benefit for All Plans under NLPDP and Special Authorization for Cystics.
Posted December 18, 2009
British Columbia
BC Pharmacare Newsletter, Edition #09-018, December 17, 2009
Highlights
New Drugs Categorized to Low Cost Alternative (LCA) and/or Reference Drug Program (RDP): Apo-Hydro 12.5mg Tab; Apo-Venlafaxine XR 37.7mg, 75mg, 150mg Tab; Mylan-Omeprazole 10mg, 20mg Cap; Ibuprofen 400mg Tab; Jamp Niacin 500mg Tab; Jamp Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Mint Ciprofloxacin 250mg, 500mg, 750mg Tab; Mint Lisinopril 5mg, 20mg Tab; Mint Pioglitasone 15mg, 30mg, 45mg Tab; Mint Pravastatin 10mg, 20mg, 40mg Tab; NG-Citalopram 20mg, 40mg Tab; Novo-Benzydamine 1.5mg/ml Sol; Phl-Citalopram 10mg, 20mg, 40mg Tab; Phl-Gabapentin 100mg, 300mg, 400mg Cap; Phl-Pioglitasone 15mg, 30mg, 45mg Cap; Pms-Terbinafine 250mg Tab; Ran-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Sandoz Azithromycin 100mg/5ml, 200mg/5ml Susp; New Drugs Categorized to LCA and/or RDP-Plan P (Palliative Care): Co-Fluconazole 150mg Cap; Ran-Fentanyl Matrix 12mcg/h, 25mcg/h, 50mcg/h, 75mcg/h, 100mcg/h Patch; Sandoz Fentanyl Matrix 12mcg/h, 25mcg/h, 50mcg/h, 75mcg/h, 100mcg/h Patch; Low Cost Alternative (LCA)/Reference Drug Program (RDP) Booklet Changes: Apo-Citalopram 20mg, 40mg Tab; Celexa 20mg, 40mg Tab; Citalopram-Odan 20mg, 40mg Tab; Co-Citalopram 20mg, 40mg Tab; Mylan-Citalopram 20mg, 40mg Tab; Jamp-Citalopram 20mg, 40mg Tab; Mint Citalopram 20mg, 40mg Tab; NG-Citalopram 20mg, 40mg Tab; Novo-Citalopram 20mg, 40mg Tab; Pms-Citalopram 20mg, 40mg Tab; Ran-Citalo 20mg, 40mg Tab; Ran-Citalopram 20mg, 40mg Tab; Ratio-Citalopram 20mg, 40mg Tab; Sandoz Citalopram 20mg, 40mg Tab; Depo-Provera Acetate 150mg/ml Inj Susp; Medroxyprogesterone Acetate 150mg Inj Susp; Airomir 100mcg Aer Inh; Apo-Salvent CHF Free 100mcg Aer Inj; Ratio-Salbutamol HFA 100mcg Aer Inh; Ventolin HFA 100mcg Aer Inh; Benefits: Phl-Amlodipine 2.5mg Tab; Jamp-Amlodipine 5mg, 10mg Tab; Palliative Care Drug Plan: Jamp Sennosides 8.6mg, 12mg Tab; Non-Benefits: Ascorbic Acid 500mg Tab; Calcium and Magnesium and Vitamin D 333mg-167mg-125IU Tab; Calcium Carbonate and Vitamin D 500mg-125IU Tab; Vitamin C 500mg Chew Tab; Vitamin D3 400IU, 1000IU Tab.
Posted December 17, 2009
New Brunswick
NBPDP Benefit Changes Bulletin #777, Dec 9, 2009
Highlights
Regular Benefits Additions: Atacand 32mg Tab; Ceftin 125mg/5ml Suspension; Cefoxitin for Injection 1G, 2G, 10G Vial Inj; Levaquin 250mg, 500mg, 750mg Tab; Novo-Levofloxacin 250mg, 500mg, 750mg Tab; Apo-Levofloxacin 250mg, 500mg, 750mg, Tab; Co-Levofloxacin 250mg, 500mg, 750mg Tab; Mylan-Levofloxacin 250mg, 500mg Tab; pms-Levofloxacin 250mg, 500mg, 750mg Tab; Sandoz-Levofloxacin 250mg, 500mg, 750mg Tab; Levaquin for Injection 5mg/ml Inj; Enablex 7.5mg, 15mg Tab; Trosec 20mg Tab; Vesicare 5mg, 10mg Tab; Special Authorization Additions: Protopic .1% Oint; Special Authorization – Revised Process: Trosec 20mg Tab; Enablex 7.5mg, 15mg Tab; Vesicare 5mg, 10mg Tab; Levaquin (and generics) 250mg, 500mg Tab; Avelox 400mg Tab; Drugs Reviewed and Not Listed: Adalat XL Plus 20mg, 30mg, 40mg+81mg ASA Tab.
Posted December 16, 2009
Prince Edward Island
PEI MAC Memo, December 7, 2009
Highlights
Products Added to the Interchangeable/MAC list: Co-Olanzapine ODT 5mg, 10mg, 15mg Tabs; Novo-Lansoprazole DR 15mg, 30mg Cap; Phl-Alendronate FC 70mg Tab; Phl-Amlodipine 5mg, 10mg Tab; Phl-Atenolol 25mg, 50mg, 100mg Tab; Phl-Azithromycon 250mg Tab; Phl-Baclofen 10mg, 20mg Tab; Phl-Carvedilol 3.125mg, 6.25mg, 12.5mg, 25mg Tab; Phl-Citalopram 10mg, 20mg, 40mg Tab; Phl-Clonazepam 0.5mg, 1mg, 2mg Tab; Phl-Cyclobenzaprine 10mg Tab; Phl-Fluoxetine 10mg, 20mg Cap; Phl-Gabapentin 100mg, 300mg, 400mg Cap; Phl-Mirtazapine 15mg, 30mg Tab; Phl-Ondansetron 4mg, 8mg Tab; Phl-Pantoprazole 40mg Tab; Phl-Paroxetine 20mg, 30mg Tab; Phl-Pioglitazone 15mg, 30mg, 45mg Tab; Phl-Pravastatin 10mg, 20mg, 40mg Tab; Phl-Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Phl-Sertraline 25mg, 50mg, 100mg Cap; Phl-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Phl-Topiramate 25mg, 100mg, 200mg Tab; Phl-Zopiclone 5mg, 7.5mg Tab; Ran-Fentanyl MTX Patches 12ug/hr, 24ug/hr, 50ug/hr, 75ug/hr, 100ug/hr; Changes to MAC Prices: Zithromax 250mg Tab; Apo-Azithromycin 250mg Tab; Co Azithromycin 250mg Tab; Pms-Azithromycin 250mg, Sandoz Azithromycin 250mg Tab; Novo-Azithromycin 250mg Tab; Ratio-Azithromycin 250mg Tab; Gen-Azithromycin 250mg Tab; Phl-Azithromycin 250mg Tab; Reactine 10mg Tab; Apo-Cetirizine 10mg Tab; Zyprexa 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Novo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Apo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Pms-Olanzapine 2.5mg, 5mg, 7.5mg 10mg, 15mg Tab; Co-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Zofran 8mg Tab; Pms-Ondansetron 8mg Tab; Novo-Ondansetron 8mg Tab; Sandoz Ondansetron 8mg Tab; Ratio-Ondansetron 8mg Tab; Phl-Ondansetron 8mg Tab; Apo-Ondansetron 8mg Tab; Co Ondansetron 8mg Tab; Gen-Ondansetron 8mg Tab; Mint-Ondansetron 8mg Tab; Ondansetron-Odan 8mg Tab; Ran-Ondansetron 8mg Tab; Jamp-Ondansetron 8mg Tab; Discontinued Products: Co-Glimepiride 1mg, 2mg, 4mg Tab; MOS Concentrate 20mg/ml; Pms-Mefenamic Acid 250mg Cap; Zaditen 1mg Tab.
Posted December 16, 2009
Newfoundland
NLPDP Bulletin No. 87, December 16, 2009
Highlights
Benefit change from Special Authorization to Open Benefit: Zithromax 250mg; Apo-Azithromycin 250mg; Gen-Azithromycin 250mg; Novo-Azithromycin 250mg; Pms-Azithromycin 250mg; Ratio-Azithromycin 250mg; Sandoz-Azithromycin 250mg; Co-Azithromycin 250mg; Zithromax 100mg/5ml Susp; Novo-Azithromycin 100mg/5ml; Pms-Azithromycin 100mg/5ml; Zithromycin 200mg/5ml; Novo-Azithromycin 200mg/5ml; Pms-Azithromycin 200mg/5ml; Norvasc 5mg, 10mg; Apo-Amlodipine 5mg, 10mg; Co-Amlodipine 5mg, 10mg; Mylan-Amlodipine 5mg, 10mg; Novo-Amlodipine 5mg, 10mg; Pms-Amlodipine 5mg, 10mg; Ran-Amlodipine 5mg, 10mg; Ratio-Amlodipine 5mg, 10mg; Sandoz Amlodipine 5mg, 10mg.
Posted December 14, 2009
Newfoundland
NLPDP Bulletin No. 86, December 10, 2009
Highlights
Price Change: Sinemet CR
Posted December 14, 2009
Quebec
Modification No. 1 to Edition 26, Effective December 16, 2009
Highlights
Additions: Co Olanzapine ODT 5mg, 10mg, 15mg, 20mg Tab O/Dis; Novo-Olanzapine OD 5mg, 10mg, 15mg, 20mg Tab O/Dis; Pms-Olanzapine ODT 5mg, 10mg, 15mg Tab O/Dis; Sandoz Olanzapine ODT 5mg, 10mg, 15mg, 20mg Tab O/Dis; Myozyme 50mg IV Pws; Price Changes: Novo-Olanzapine 5mg, 10mg, 15mg Tab; Pms-Olanzapine 5mg, 10mg, 15mg Tab; Sandoz Olanzapine 5mg, 10mg, 15mg Tab
Posted December 9, 2009
British Columbia
BCPharmacare Newsletter December 8, 2009. Edition 09-017
Highlights
Olanzapine – Specific Products no longer eligible for Pharmacare Coverage: Co Olanzapine ODT, Sandoz Olanzapine ODT 5mg Tab O/DIS; Co Olanzapine ODT, Sandoz Olanzapine ODT 10mg Tab O/DIS; Co Olanzapine ODT, Sandoz Olanzapine ODT 15mg Tab O/DIS; Co Olanzapine ODT, Sandoz Olanzapine ODT 20mg Tab O/DIS.
Posted December 2, 2009
Newfoundland
NLPDP Bulletin No. 80 November 26, 2009
Highlights
Special Authorization for All Plans and the Cystic Fibrosis Program: Sandoz Olanzapine ODT 5mg, 10mg, 15mg, 20mg Tab; Co Olanzapine ODT 5mg, 10mg, 15mg, 20mg Tab; Co Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Apo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Sandoz Azithromycin 100mg/5ml, 200mg/5ml Suspension; ratio-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Novo-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Mylan-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Ran-Fentanyl Matrix 12mcg, 25mcg, 50mcg, 75mcg, 100mcg Patch; Open Benefit for All Plans and Special Authorization for the Cystic Fibrosis Program: pms-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; pms-Omeprazole 20mg Tab; Jamp-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Jamp-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Novo-Lisinopril (Type Z) 5mg, 10mg, 20mg Tab; Novo-Lisinopril (Type P) 5mg, 10mg, 20mg Tab; Not Considered for Coverage under NLPDP: Co Olanzapine 20mg Tab; Apo-Olanzapine 20mg Tab.
Posted December 2, 2009
Newfoundland
NLPDP Bulletin No. 79 November 26, 2009
Highlights
New Categories: Sandoz Olanzapine ODT 5mg, 10mg, 15mg, 20mg Tab; Co Olanzapine ODT 5mg, 10mg, 15mg, 20mg Tab; Zyprexa Zydis 5mg, 10mg, 15mg, 20mg Tab; Co Olanzapine 20mg Tab; Apo-Olanzapine 20mg Tab; Zyprexa 20mg Tab; Additions to Existing Categories: Co Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Apo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Sandoz Azithromycin 100mg/5ml, 200mg/5ml Suspension; pms-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; pms-Omeprazole 20mg Tab; Jamp-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Jamp-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; ratio-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Novo-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Mylan-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Ran-Fentanyl Matrix 12mcg, 25mcg, 50mcg, 75mcg, 100mcg Patch; Novo-Lisinopril (Type Z) 5mg, 10mg, 20mg Tab; Novo-Lisinopril (Type P) 5mg, 10mg, 20mg Tab.
Posted December 1, 2009
Nova Scotia
NS Pharmacare Bulletin, Volume 09-10, November 2009
Highlights
New Products Added to the Nova Scotia Formulary: Novo-Quetiapine 150mg Tab; Olmetec 20mg, 40mg Tab; Olmetec Plus 20mg/12.5mg, 40mg/12.5mg; Sprycel 100mg Cap; Wellbutrin XL 150mg, 300mg Tab. New Exception Status Benefits: Enablex 7.5mg, 15mg Tab; Fosavance 70mg/5600IU; Stelara 45mg/0.5ml Inj; Vesicare 5mg, 10mg Tab; Orecia 250mg/vial Inj; Kaletra 100mg/25mg Pediatric Tabs. Change in Benefit Status for Bupropion: ratio-Bupropion SR 100mg Tab; Sandoz Bupropion SR 100mg Tab; pms- Bupropion SR 150mg Tab; ratio- Bupropion SR 150mg Tab; Sandoz Bupropion SR 150mg Tab; Wellbutrin SR 150mg Tab. Existing Categories: Novo-Etidronatecal Kit. Correction to MAC Pricing for Ramipril 15mg Cap: Apo-Ramipril 15mg Cap; Ratio-Ramipril 15mg Cap; Altace 15mg Cap. Change in MAC Pricing: Airomir 100mcg/dose oral inh; Apo-Salvent CFC Free 100mcg/dose oral inh; ratio-Salbutamol HFA 100mcg/dose oral inh; Ventolin HFA 100mcg/dose oral inh.
Posted Date November 27, 2009
British Columbia
BC Pharmacare Newsletter, Edition 09-016, November 18, 2009
Highlights
H1N1 Flu Virus Updates: Product Identification Numbers-Provincial Pandemic Supply: Oseltamivir 30mg, 45mg, 75mg Cap, 15mg/ml – 30ml, 40ml, 50ml, 60ml Compounded Suspension; Zanamivir 5mg disk with device; Low Cost Alternative (LCA)/Reference Drug Program (RDP) Booklet – Changes: Fosavance 70mg/5600IU Tab; Apo-Alendronate 70mg, 10mg Tab; Co Alendronate 70mg Tab; Fosamax 70mg, 10mg Tab; Mylan-Alendronate 70mg, 10mg Tab; Novo-Alendronate 70mg, 10mg Tab; Sandoz-Alendronate 70mg, 10mg Tab; Pms-Alendronate 70mg Tab; Pms-Alendronate-FC 70mg Tab; Ratio Alendronate 70mg Tab; New Low Cost Alternative (LCA) Categories: Co Olanzapine 20mg Tab; Zyprexa 20mg Tab; New Benefits – Limited Drug Coverage Program: Diovan-HCT 320/12.5mg, 320/25mg Tab; Olmetec 20mg, 40mg Tab; Olmetec Plus 20/12.5mg, 40/12.5mg, 40/25mg Tab; Viread 300mg Tab; Fosavance 70mg/5600 IU Tab; Exjade 125mg, 250mg, 500mg Tab; Enbrel 25mg Vial, 50mg/ml Prefilled Syringe; Humira 40mg/0.8ml Kit; Remicade 100mg Vial; Stelara 45mg/0.5ml Sol; Multi-Source Generic Pricing: Co Olanzapine ODT 5mg, 10mg, 15mg, 20mg Oral Dis; Pms-Olanzapine ODT 5mg, 10mg, 15mg, 20mg Oral Dis Tab; Sandoz Olanzapine ODT 5mg, 10mg, 15mg, 20mg Oral Dis Tab; Zyprexa Zydis 5mg, 10mg, 15mg, 20mg Oral Dis Tab; Pms-Amlodipine 2.5mg Tab; Sandoz Amlodipine 2.5mg Tab; Jamp-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Non-Benefits: Apo-Levofloxacin 250mg, 500mg, 750mg Tab; Bicalutamide (Accord) 50mg Tab; Cefepime for Injection 1g/vial, 2g/vial; Co Levofloxacin 250mg, 500mg, 750mg Tab; Jamp ASA 80mg Tab; Novo-Levofloxacin 250mg, 500mg, 750mg Tab; Omnaris 50ug/spray nasal spray; Relistor 12mg/0.6ml Vial; Sandoz Levofloxacin 250mg, 500mg, 750mg Tab.
Posted November 23, 2009
Alberta
Additions to the AHWDBL, effective Nov 15, 2009
Highlights
New Interchangeable Drug Products Available by Special Authorization: Sandoz Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap.
Posted November 18, 2009
Ontario
ODB Formulary Update N1, Effective Nov 19, 2009
Highlights
Delisted: Mint-Pravastatin 10mg, 20mg, 40mg Tabs.
Posted Date November 16, 2009
Quebec
Correction No 1 a la Liste de medicaments, effective Oct 21, 2009
Highlights
New products: Cystapen 5000000U pd inj; Riva-Fluoxetine 20mg Cap. Products modified: 23 included - please see bulletin for particulars.
Posted Date November 16, 2009
British Columbia
BC Pharmacare Newsletter, Edition 09-015, October 30, 2009
Highlights
H1N1 Flu Virus Information - Update #1 Antivirals and Vaccinatons
Posted November 12, 2009
Newfoundland
NLPDP Bulletin No. 74, Nov 6, 2009
Highlights
Special Authorization for All Plans and the Cystic Fibrosis Program: Gen-Amlodipine 5mg, 10mg Tab; Pms-Amlodipine 5mg, 10mg Tab; Sandoz Amlodipine 5mg, 10mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Co Amlodipine 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; Apo-Amlodipine 5mg, 10mg Tab; Ran-Amlodipine 5mg, 10mg Tab; Norvasc 5mg, 10mg Tab; Sandoz Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Pms-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap; Citalopram-Odan 20mg Tab; Sandoz Levofloxacin 250mg, 500mg Tab; Co Levofloxacin 250mg, 500mg Tab; Pms-Levofloxacin 250mg, 500mg Tab; Gen-Levofloxacin 250mg, 500mg Tab; Apo-Levofloxacin 250mg, 500mg Tab; Sandoz Fentanyl MTX 12mcg, 25mcg, 50mcg, 75mcg, 100mcg Patch; Co Ondansetron 4mg, 8mg Tab; Ondansetron-Odan 4mg, 8mg Tab; Open Benefit for All Plans and Special Authorization for the Cystic Fibrosis Program: Apo-Ramipril 15mg Cap; Ratio-Ramipril 15mg Cap; Altace 15mg Cap; Co Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Pms-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Requip 0.25mg, 1mg, 2mg, 5mg Tab; Apo-Levocarb CR 25mg/100mg Tab; Sinemet CR 25mg/100mg Tab; Ran-Simvastatin 5mg, 1-0mg, 20mg, 40mg, 80mg Tab; Apo-Venlafaxine XR 37.5mg, 75mg, 150mg Cap; Co Fluconazole 150mg Cap; Citalopram-Odan 40mg Tab; Pms-Terbinafine 250mg Tab; Gen-Omeprazole 10mg, 20mg Cap DR; Sandoz Rabeprazole EC 10mg, 20mg Tab; Not Considered for Coverage under NLPDP: Novo-Levofloxacin 750mg Tab; Apo-Levofloxacin 750mg Tab; Sandoz Levofloxacin 750mg Tab; Co Levofloxacin 750mg Tab; Pms-Levofloxacin 750mg Tab; Levaquin 750mg Tab.
Posted November 12, 2009
Newfoundland
NLPDP Bulletin No. 75, November 6, 2009
Highlights
New Categories: Gen-Amlodipine 5mg, 10mg Tab; Pms-Amlodipine 5mg, 10mg Tab; Sandoz Amlodipine 5mg, 10mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Co Amlodipine 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; Apo-Amlodipine 5mg, 10mg Tab; Ran-Amlodipine 5mg, 10mg Tab; Norvasc 5mg, 10mg Tab; Apo-Ramipril 15mg Cap; Ratio-Ramipril 15mg Cap; Altace 15mg Cap; Sandoz Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Pms-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap; Co Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Pms-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Requip 0.25mg, 1mg, 2mg, 5mg Tab; Novo-Levofloxacin 750mg Tab; Apo-Levofloxacin 750mg Tab; Sandoz Levofloxacin 750mg Tab; Co Levofloxacin 750mg Tab; Pms-Levofloxacin 750mg Tab; Levaquin 750mg Tab; Apo-Levocarb CR 25mg/100mg Tab; Sinemet CR 25mg/100mg Tab; Addition to an Existing Category: Sandoz Levofloxacin 250mg, 500mg Tab; Co Levofloxacin 250mg, 500mg Tab; Pms-Levofloxacin 250mg, 500mg Tab; Gen-Levofloxacin 250mg, 500mg Tab; Apo-Levofloxacin 250mg, 500mg Tab; Sandoz Fentanyl MTX 12mcg, 25mcg, 50mcg, 75mcg, 100mcg Patch; Co Ondansetron 4mg, 8mg Tab; Ondansetron-Odan 4mg, 8mg Tab; Ran-Simvastatin 5mg, 1-0mg, 20mg, 40mg, 80mg Tab; Apo-Venlafaxine XR 37.5mg, 75mg, 150mg Cap; Gen-Omeprazole 10mg, 20mg Cap DR; Co Fluconazole 150mg Cap; Citalopram-Odan 20mg, 40mg Tab; Sandoz Rabeprazole EC 10mg, 20mg Tab; Pms-Terbinafine 250mg Tab.
Posted Date, November 11, 2009
Ontario
ODB, Edition 41, Update N, Effective Nov 19, 2009
Highlights
New Multi-Source Drugs: Mint-Pravastatin 10mg, 20mg, 40mg Tab; Phl-Alendronate-FC 70mg Tab; Phl-Citalopram 20mg, 40mg Tab; Phl-Gabapentin 100mg, 300mg, 400mg Cap; Phl-Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Phl-Sertraline 25mg, 50mg, 100mg Cap; Phl-Topiramate 25mg, 100mg, 200mg Tab; Pms-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Ratio-Rivastigmine 4.5mg Cap; Sandoz Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Manufacturer Requested Discontinued Drugs: Apo-Digoxin 0.125mg, 0.25mg Tab; Gen-Alendronate 5mg Tab; Gen-Diltiazem CD 120mg, 180mg, 240mg, 300mg LA Cap; Gen-Medroxy 2.5mg, 10mg Tab; Isotamine 300mg Tab; Phenazo 100mg Tab; Ratio-Salbutamol HFA 100mcg/metered dose; Delisted Drugs: Apo-Lithium Carbonate SR 300mg ER Tab; Drug Benefit Prices: Apo-Lansoprazole 15mg, 30mg DR Cap; Apo-Salvent CFC Free 100mcg/metered dose; Off Formulary Interchangeable Products: Mint-Pioglitazone 15mg, 30mg, 45mg Tab; Mylan-Omeprazole 10mg DR Cap; Phl-Fluoxetine 10mg Cap; Phl-Pioglitazone 45mg Tab; Not A Benefit Drugs (Removed From Listing): Allerdryl 50mg Cap; Status Changes from Discontinued to Active: Enemol 160mg & 60mg/ml Rect Sol; Pms-Potassium Chloride 1.33mEq/ml O/L.
Posted Date, November 11, 2009
Ontario
ODB, Edition 41, Update M, Effective Nov. 13, 2009
Highlights
New Single Source Drugs: DuoTrav 0.5% & 0.004% Oph Sol; Micardis Plus 80mg & 25mg Tab; New Multi-Source Drugs: Mint-Ciprofloxacin 250mg, 500mg, 750mg Tab; Mylan-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Novo-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Phl-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Pms-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Ran-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Ratio-Rivastigmine 1.5mg, 3mg, 6mg Cap; Ventolin HFA 100mcg/Metered Dose Inh; Delisted Drugs: Novo-Cefaclor 250mg, 500mg Cap; Off Formulary Interchangeable Products: Extra Strength Allergy Relief 10mg Tab; Sandoz Levofloxacin 750mg Tab; Discontinued Drugs: Apo-Digoxin 0.0625mg Tab; Not a Benefit Drugs: Allerdryl 25mg Cap; Empracet-60 300mg & 60mg Tab; Metamucil Sugar Free Oral Pd; Status Changes from Not a Benefit to Limited Use: Apo-Brimonidine P 0.15% Oph Sol; New Nutrition Products: EO28 Splash (Grape Flavoured) 1kcal/ml Liq; EO28 Splash (Orange-Pineapple Flavoured) 1kcal/ml Liq; Drug Benefit Prices: Apo-Raloxifene 60mg Tab; Asacol 400mg, 800mg Tab; MetroLotion 0.75% Top Lot; Pms-Quetiapine 200mg, 300mg Tab; Sandoz Levofloxacin 250mg, 500mg Tab; Thyrogen 0.9mg/ml Inj Pd; Viread 300mg Tab; Manufacturer Requested Discontinued Drugs: 64 products – See bulletin for full list.
Posted November 9, 2009
New Brunswick
Benefit Changes to NBPDP, Bulletin # 775, Nov 6, 2009
Highlights
Special Authorization Additions: Fosavance 70mg/140mcg Tab; Vesicare 5mg, 10mg Tab; Stelara 45mg/0.5ml vial for subcutaneous injection; Lucentis 2.3mg/0.23ml vial for intravitreal injection.
Posted November 9, 2009
Prince Edward Island
PEI MAC Memo, November 5, 2009
Highlights
New Interchangeable/MAC Categories: Zyprexa Zydis 5mg, 10mg, 15mg Tab O/Dis; Pms-Olanzapine ODT 5mg, 10mg 15mg Tab O/Dis; Co-Olanzapine 5mg, 10mg, 15mg Tab O/Dis; Products Added to the Interchangeable/MAC List: Apo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Co-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Co-Olanzapine ODT 5mg, 10mg, 15mg Tab; Pms-Olanzapine 5mg, 10mg, 15mg Tab; Jamp-Amlodipine 5mg, 10mg Tab; Jamp-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Mylan-Omeprazole 20mg Cap DR; Changes to MAC Prices: Losec 20mg Tab DR; Ratio-Omeprazole 20mg Tab DR; Mylan-Omeprazole 20mg Tab DR; Zyprexa 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Novo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg 15mg Tab; Apo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Pms-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Co-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Airomir HFA 100mcg/dose Inh; Ventolin HFA 100mcg/dose Inh; Ratio-Salbutamol 100mcg/dose Inh; Apo-Salvent CFC Free 100mcg/dose Inh; Deleted Interchangeable/MAC Categories: Amitriptyline 25mg, 50mg Tab; Discontinued Products: Novo-Triptyn 25mg, 50mg Tab; New PDIN added: Miles Solution.
Posted November 4, 2009
British Columbia
BC Pharmacare Newsletter, Edition #09-014, Oct 30, 2009
Highlights
Updated Product Information Numbers: For Mastectomy products; New Drugs Categorized to LCA and/or RDP: Apo-Oxycodone/Acet 5mg/325mg Tab; Co-Ondansetron 4mg, 8mg Tab; Novo-Azithromycin 100mg/5ml, 200mg/5ml Susp; Novo-Etidronatecal 400/500mg Tab; Sandoz Methylphenidate SR 20mg Tab; Loperamide 2mg Cap; New LCA Categories: Cefazolin for Injection 1g, 10g Vial; Depo-Provera 150mg/ml Susp; Medroxyprogesterone Acetate Injectable Suspension 150mg/ml Susp; Altace 15mg Cap; Apo-Ramipril 15mg Cap; Ratio-Ramipril 15mg Cap; Benefits – Drugs: Mezavant 1.2g Tab; Seroquel XR 150mg Tab; Benefits – Insulin Pumps: Animas Onetouch Ping Glucose Management System; Limited Coverage Program: DDAVP Melt 240mcg Tab O/Dis.
Posted November 3, 2009
New Brunswick
NBPDP Formulary Sept 2009
Highlights
NBPDP Full Formulary Release
Posted November 3, 2009
Saskatchewan
Saskatchewan Fomulary Bulletin #120, Oct 2009
Highlights
New Full Formulary Listings Effective August 1, 2009: Olmetec 20mg, 40mg Tab; Olmetec Plus 20mg/12.5mg, 40mg/12.5mg, 40mg/25mg Tab; Micardis Plus 80mg/25mg Tab; New Full Formulary Listings Effective October 1, 2009: NorLevo 0.75mg Tab; OxyContin 15mg, 30mg, 60mg Tab CR; Coversyl Plus HD 8mg/2.5mg Tab; Seroquel XR 150mg Tab ER; New Exception Drug Status Listings Effective August 1, 2009: Fosavance 70mg/5600IU Tab; New Exception Drug Status Listings Effective October 1, 2009: Prezista 600mg Tab; Vesicare 5mg, 10mg Tab; Stelara 45mg/0.5ml Inj Sol; Revised Exception Drug Status Criteria Effective August 1, 2009: Orencia 250mg/vial Pws; Revised Exception Drug Status Criteria Effective October 1, 2009: Botox 100IU/vial Inj; Fragmin 2,500IU/ml (0.2ml), 25,000IU/ml (0.2ml, 0.3ml, 0.4ml, 0.5ml, 0.6ml, 0.72ml) Syringe, 10,000IU/ml (1ml), 25,000IU/ml (3.8ml) Inj Sol; Fraxiparine 9,500IU/ml (0.3ml, 0.4ml, 0.6ml, 0.8ml, 1.0ml) Syringe; Fraxiparine Forte 19,000IU/ml (0.6ml, 0.8ml, 1ml) Syringe; Innohep 10,000IU/ml(0.35ml, 0.45ml), 20,000IU/ml (0.5ml, 0.7ml, 0.9ml) Syringe, 10,000IU/ml (2ml), 20,000IU/ml(2ml) Inj Sol; Change from Exception Drug Status to Full Formulary Listing Effective August 1, 2009: Monocor 5mg, 10mg Tab; Apo-Bisoprolol 5mg, 10mg Tab; Novo-Bisoprolol 5mg, 10mg Tab; Pms-Bisoprolol 5mg, 10mg Tab; Sandoz Bisoprolol 5mg, 10mg Tab; New Interchangeable Full Formulary or EDS Listings Effective July 1, 2009: Apo-Levofloxacin 250mg, 500mg, 750mg Tab; Co Levofloxacin 250mg, 500mg, 750mg Tab; Mylan-Levofloxacin 250mg, 500mg Tab; Pms-Levofloxacin 250mg, 500mg, 750mg Tab; Novo-Levofloxacin 750mg Tab; Sandoz Levofloxacin 250mg, 500mg, 750mg Tab; New Interchangeable Full Formulary or EDS Listings Effective August 1, 2009: Sandoz Fentanyl MTX 12ug/hr, 25ug/hr, 50ug/hr, 75ug/hr, 100ug/hr Trans Patch; Apo-Hydro 12.5mg Tab; Novo-Raloxifene 60mg Tab; Pms-Terbinafine 250mg Tab; New Interchangeable Full Formulary or EDS Listings Effective August 15, 2009: Sandoz Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Co Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; New Interchangeable Full Formulary or EDS Listings Effective September 1, 2009: Mint-Ciprofloxacin 250mg, 500mg, 750mg; Co Fluconazole 150mg Cap; Mint-Lisinopril 5mg, 10mg, 20mg Tab; Mylan-Omeprazole 10mg, 20mg Cap; Mint-Pioglitazone 15mg, 30mg, 45mg Tab; Mint-Pravastatin 10mg, 20mg, 40mg Tab; Pms-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Simvistatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; New Interchangeable Full Formulary or EDS Listings Effective October 1, 2009: Apo-Amlodipine 5mg, 10mg Tab; Co Amlodipine 5mg, 10mg Tab; GD-Amlodipine 5mg, 10mg Tab; Mylan-Amlodipine 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; Pms-Amlodipine 5mg, 10mg Tab; Ran-Amlodipine 5mg, 10mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Sandoz Amlodipine 5mg, 10mg Tab; Duragesic MAT 25ug/hr, 50ug/hr, 75ug/hr, 100ug/hr Trans Patch; Mylan-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Novo-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Ratio-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap.
Posted October 28, 2009
Nova Scotia
NS Pharmacare Bulletin, Volume 09-09, October 2009
Highlights
Correction to Nova Scotia Formulary: Sandoz Lisinopril 5mg, 10mg, 20mg Tab; New Categories: Apo-Hydro 12.5 mg Tab; pms-Hydrochlorothiazide 12.5mg Tab; Mylan-Omeprazole 10mg Cap; Losec 10mg Tab; Mylan-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; pms-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Sandoz Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap; Co Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; ReQuip 0.25mg, 1mg, 2mg, 5mg Tab; Existing Categories: Sandoz Fentanyl MTX 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Patch; Co Fluconazole 150mg Cap; Mylan-Omeprazole 10mg, 20mg Cap; Sandoz Omeprazole 10mg Cap; Losec 10mg Cap; Co Ondansetron 4mg, 8mg Tab; pms-Terbinafine 250mg Tab; Non-Insured: Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Fragmin-Pins for Pre-filled Syringe Sizes: Fragmin 5000U/0.2ml, 7500U/0.3ml, 10000U/0.4ml, 12500U/0.5ml, 15000U/0.6ml, 18000U/0.72ml Prefilled Syringes.
Posted October 28, 2009
New Brunswick
NBPDP Bulletin #774, Oct 27, 2009
Highlights
Special Authorization Requests from NB Pharmacists
Now Considered by NBPDP
Posted October, 2009
NIHB
NIHB Updates to the Drug Benefit List - Summer 2009
Highlights
Additions to the Drug Benefit List: Open Benefits: Single-Source Drug Products: Aerochamber AC Boyz, Girlz; Apidra 100Unit/ml Inj, Solostar Prefilled Pen; Citro Mag 15mg/300ml Inj; Euro D 800IU Cap; Fragmin 7500U/0.3ml Inj; Micardis plus 25mg/80mg Tab; Norlevo 0.75mg Tab; Omniflex Diaphragm 75; Stalevo 100mg/25mg/200mg, 150mg/37.5mg/200mg, 50mg/12.5mg/200mg Tab; Vitamin B6 25mg Tab; Vitamin E 400IU Nat Source Cap; Yaz Tab; Multi-Source Drug Products: Acetominophene 160mg/5ml Syrup; Apo-Amlodipine 5mg, 10mg Tab; Apo-Bicalutamide 50mg Tab; Apo-Hydro 12.5mg Tab; Apo-Ramipril 15mg Cap; Calcium Carb/Etidronate Disodium; Co Amlodipine 5mg, 10mg Tab; Co Fluconazole 100mg Tab, 150mg Cap; Co Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Co-Ondansetron 4mg, 8mg Tab; Co-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Euro-Docusate 100mg Cap; Euro-Folic 5mg Tab; Gen-Amlodipine 5mg, 10mg Tab; Gen-Omeprazole 10mg Cap LA; Ibuprofen ES 400mg Liq Cap; Jamp Ibuprofen 400mg Cap; Jamp-Diphenhydramine 12.5mg/5m; Jamp-Magnesium Gluce 100mg/ml; Jamp-Magnesium Gluconate 500mg; Jamp-Multivitamin A/D/C Drops; Jamp-Sennosides 8.6mg, 12mg Tab; Jamp-Vitamin B1 50mg Tab; Mint-Ciprofloxacin 250mg, 500mg, 750mg Tab; Mint-Pravastatin 10mg, 20mg, 40mg Tab; Mylan-Ondansetron 4mg Tab; Novo-Amlodipine 5mg, 10mg Tab; Novo-Ferrogluc 300mg Tab; Pdl-Glyburide 5mg Tab; Phl-Amlodipine 5mg, 10mg Tab; Phl-Gabapentin 100mg, 300mg, 400mg Tab; Pms-Amlodipine 5mg, 10mg Tab; Pms-Dimenhydrinate Syrup; Pms-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Pms-Terbinafine 250mg Tab; Procet-30 Tab; Ran-Amlodipine 5mg, 10mg Tab; Ran-Simvistatin 0.25mg, 10mg, 20mg, 40mg, 50mg, 80mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Ratio-Ramipril 15mg Cap; Sandoz-Amlodipine 5mg, 10mg Tab; Sandoz-Methylphenidate SR 20mg Tab; Sig-Enalapril 2mg, 4mg, 8mg, 16mg Tab; Vitamin D 400IU, 800IU Cap; Zym-ASA 80mg Tab; Zym-ASA EC 80mg Tab; New Limited Use Benefits: Single-Source Drug Products: Campral 333mg DR Tab; Wellbutrin XL 150mg, 300mg Tab; Enablex 7.5mg, 15mg SR Tab; Cymbalta 30mg, 60mg DR Cap; Intelence 100mg Tab; Celsentri 150mg, 300mg Tab; Oxycontin 15mg, 30mg, 60mg CR Tab; Tecta 40mg Tab; Zeldox 20mg, 40mg, 60mg, 80mg Cap; Phl-Alendronate-FC 70mg Tab; Novo-Benzydamine 1.5mg/ml MWH; Apo-Lansoprazole 15mg DR Cap, 30mg Cap LA; Pantoprazole 40mg DR Tab; Accel Pioglitazone 15mg, 30mg, 45mg Tab; Mylan-Pioglitazone 15mg, 30mg, 45mg Tab; Apo-Raloxifene 60mg Tab; Novo-Raloxifene 60mg Tab; Mylan-Tamsulosin 0.4mg Cap; Indications added to the NIHB Drug Benefit List: Viread 245mg Tab; Changes in Benefit Status: Allegra 60mg Tab; Not Added to Formulary: 27 Products, See Bulletin for Details; Drugs Discontinued by the Manufacturer: Betaloc 50mg, 100mg, 200mg Tab; Covera-HS 180mg, 240mg Tab; Estracomb Patch; M.O.S. 40mg Tab; Rythmodan LA 250mg Tab;
Posted October, 2009
New Brunswick
New Brunswick Formulary, Volume 51, Update No 3, Oct 14, 2009
Highlights
Additions: Novo-Benzydamine 0.15% O/L; Maxipime 2g/vial Inj PWS; Cefepime for Injection 2g/vial Inj PWS; Sandoz-Fentanyl 12mcg/hr, 25mcg/hr, 37mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Transdermal System; Duragesic 12mcg/hr, 25mcg/hr, 37mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Transdermal System; Co-Fluconazole 150mg Cap; pms-Hydrochlorothiazide 12.5mg Tab; Apo-Hydro 12.5mg Tab; Novo-Levofloxacin 750mg Tab; Mylan-Omeprazole 20mg Orl Cap; Co-Ondansetron 4mg, 8mg Tab; Accel-Pioglitazone 15mg, 30mg, 45mg Tab; Ratio-Ramipril 15mg Cap; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap; Novo-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; pms-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; ratio-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Sandoz-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Requip 0.25mg, 1mg, 2mg, 5mg Tab; Co-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; pms-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Pms-Terbinafine 250mg Tab.
Posted October, 2009
New Brunswick
Benefit Changes to NBPDP, Bulletin #772, Oct 14, 2009
Highlights
NBPDP Benefit Additions: Novo-Benzydamine 0.15% O/L; Cefepime for Injection 2g/vial Inj PWS; Sandoz-Fentanyl 12mcg/hr, 25mcg/hr, 37mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Transdermal System; Duragesic 12mcg/hr, 25mcg/hr, 37mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Transdermal System; Co-Fluconazole 150mg Cap; Apo-Hydro 12.5mg Tab; Mylan-Omeprazole 20mg Orl Cap; Co-Ondansetron 4mg, 8mg Tab; Accel-Pioglitazone 15mg, 30mg, 45mg Tab; Ratio-Ramipril 15mg Cap; Novo-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; pms-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; ratio-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Sandoz-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Co-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; pms-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Pms-Terbinafine 250mg Tab. Non-Listed Products Subject to Map: Novo-Levofloxacin 750mg Tab.
Posted October, 2009
Prince Edward Island
PEI MAC Memo - October 13, 2009
Highlights
Products Added to Interchangeable/MAC List: GD-Amlodipine Besylate 5mg, 10mg Tab; Novo-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Ratio-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Sandoz-Azithromycin 100mg/5ml, 200mg/5ml; Discontinued Products: Betaloc 100mg Tab, 200mg Durules; M.O.S 1mg/ml Syrup, 10mg/ml Sol; PMS-Desipramine 10mg Tab; Ratio-Clindamycin 150mg, 300mg Cap; Vibra Tabs; Drug Deleted in Error in September MAC List: Apo-Temazepam 15mg.
Posted October 6, 2009
Alberta
AHWDBL Quarterly Update, Oct 1, 2009
Highlights
Drug Additions: PMS-Bupropion SR, Ratio-Bupropion SR, Sandoz Bupropion 100mg Tab SR; Apo-Cilazapril/HCTZ, Novo-Cilazapril/HCTZ, Inhibace Plus 5mg/12.5mg Tab; Co Etidrocal, Gen-Eti-Cal-Carepac, Novo-Etidronatecal, Didrocal 400mg/500mg Tab; Apo-Granisetron, Kytril 1mg Tab; Xalacom 0.005%/0.5% OPH SOL; Olmetec 20mg, 40mg Tab; Olmetec Plus 20mg/12.5mg, 20mg/12.5mg, 40mg/25mg Tab; Apo-Omeprazole, PMS-Omeprazole, Ratio-Omeprazole, Sandoz Omeprazole, Losec (Cap), Losec (Tab) 20mg Tab (SR); Oxycontin 15MG, 30MG, 60MG Tab SR; Apo-Oxycodone, Endocet, Novo-Oxycodone Acet, PMS-Oxycodone-Acetaminophen, Ratio-Oxycocet, Percocet 5mg/325mg Tab; Apo-Pramipexole, Co Pramipexole, Novo-Pramipexole, PMS-Pramipexole, Sandoz Pramipexole, Mirapex 0.25mg Tab; Apo-Pramipexole, Co Pramipexole, Novo-Pramipexole, PMS-Pramipexole, Sandoz Pramipexole, Mirapex 1mg Tab; Apo-Pramipexole, Co Pramipexole, Novo-Pramipexole, PMS-Pramipexole, Sandoz Pramipexole, Mirapex 1.5mg Tab. Special Authorization: Orencia 250mg/vial Injection; Humira 40mg/syr Injection; Fosavance 70mg/5600U Tab; Kineret 100mg/syr Injection; Enablex 7.5mg, 15mg Tab ER; Cymbalta 30mg, 60mg Cap DR, Avodart 0.5mg Cap; Enbrel 25mg/vial, 50mg/syr Injection; Novo-Fentanyl, Ran-Fentanyl, Ratio-Fentanyl, Duragesic 25mcg/hr Trans Patch; Novo-Fentanyl, Ran-Fentanyl, Ratio-Fentanyl, Duragesic 50mcg/hr Trans Patch; Novo-Fentanyl, Ran-Fentanyl, Ratio-Fentanyl, Duragesic 75mcg/hr Trans Patch; Novo-Fentanyl, Ran-Fentanyl, Ratio-Fentanyl, Duragesic 100mcg/hr Trans Patch; Proscar 5mg Tab; Remicade 100mg/vial Injection; Somatuline Autogel 60mg/syr, 90mg/syr, 120mg/syr Injection; Octreotide Acetate Omega, Sandostatin 50mcg/ml Injection; Octreotide Acetate Omega, Octreotide, Sandostatin 100mcg/ml Injection; Octreotide Acetate Omega, Octreotide, Sandostatin 200mcg/ml Injection; Octreotide Acetate Omega, Octreotide, Sandostatin 500mcg/ml Injection; Sandostatin LAR 10mg/vial, 20mg/vial, 30mg/vial Injection; Apo-Raloxifene, Novo-Raloxifene, Evista 60mg Tab; Rilutek 50mg Tab; Risperdal Consta 25mg/vial, 37.5mg/vial, 50mg/vial Injection; Rituxan 10mg/ml Injection; Stelara 45mg/vial Injection. Multiple Sclerosis Drug Coverage: Rebif (1.5ml Cartridge) 44mcg/ml, 88mcg/ml Injection Cartridge.
Posted October 6, 2009
Alberta
AEIDBS Quarterly Update, Oct 1, 2009
Highlights
Drug Additions: Resource Dairy Thick, Boost 1.0 Standard, Isosource HN, Resource Thickened Juice, Boost 1.5 Plus Calories, Glucerna, Nutren Junior, Nutren Junior Fibre W Prebiotic, Resource Diabetic, Ensure, Ensure Plus, Ensure Prebiotics, Ensure with Fibre, Boost, Boost Plus Calories, Isosource HN with Fibre, Isosource 1.5 Cal, Nutren 1.5, Compleat, Suplena, Resource 2.0, Novasource Renal, Nepro, Pediasure, Pediasure with Fibre, Resource Just for Kids 1.5Cal with Fibre, Jevity 1 Cal, Nutren 2.0, Pulmocare. Special Authorization: Orencia 250mg/vial Injection; Humira 40mg/syr Injection; Fosavance 70mg/5600U Tab; Kineret 100mg/syr Injection; Enablex 7.5mg, 15mg Tab ER; Cymbalta 30mg, 60mg Cap DR; Avodart 0.5mg Cap; Enbrel 25mg/vial, 50mg/syr Injection; Novo-Fentanyl, Ran-Fentanyl, Ratio-Fentanyl, Duragesic 25mcg/hr Trans Patch; Novo-Fentanyl, Ran-Fentanyl, Ratio-Fentanyl, Duragesic 50mcg/hr Trans Patch; Novo-Fentanyl, Ran-Fentanyl, Ratio-Fentanyl, Duragesic 75mcg/hr Trans Patch; Novo-Fentanyl, Ran-Fentanyl, Ratio-Fentanyl, Duragesic 100mcg/hr Trans Patch; Proscar 5mg Tab; Remicade 100mg/vial Injection; Somatuline Autogel 60mg/syr, 90mg/syr, 120mg/syr Injection; Octreotide Acetate Omega, Sandostatin 50mcg/ml Injection; Octreotide Acetate Omega, Octreotide, Sandostatin 100mcg/ml Injection; Octreotide Acetate Omega, Octreotide, Sandostatin 200mcg/ml Injection; Octreotide Acetate Omega, Octreotide, Sandostatin 500mcg/ml Injection; Sandostatin LAR 10mg/vial, 20mg/vial, 30mg/vial Injection; Apo-Raloxifene, Novo-Raloxifene, Evista 60mg Tab; Rilutek 50mg Tab; Risperdal Consta 25mg/vial, 37.5mg/vial, 50mg/vial Injection; Rituxan 10mg/ml Injection; Stelara 45mg/vial Injection. Special Authorization Nutritional Products: Ensure High Protein, Osmolite HN, Boost Fruit Falovored Beverage, Boost High Protein, Isosource VHN, Compleat Pediatric, Pediasure Plus With Fibre, Perative, Jevity 1.2 Cal, Jevity 1.5 Cal, Twocal HN, Optimental, Peptamen, Peptamen Junior, Peptamen With Prebiotic, E028 Splash, MCT Oil, Peptamen 1.5, Peptamen AF 1.2, Nutrihep. Multiple Sclerosis Drug Coverage: Rebif (1.5ml Cartridge) 44mcg/ml, 88mcg/ml Injection Cartridge.
Posted October 6, 2009
Alberta
DBL Report, Issue #54, October 2009
Highlights
Highlights of Products Added: Cymbalta 30mg, 60mg Cap DR; Enablex 7.5mg, 15mg Tab ER; Fosavance 70mg/5600U Tab; Olmetec 20mg/40mg Tab; Olmetec Plus 20mg/12.5mg, 40mg/12.5mg, 40mg/25mg Tab. De-Listing of Premarin Tablets: Premarin 0.3mg, 0.625mg, 1.25mg Tab. Highlights of Interchangeable Products Added: Amlodipine 5mg, 10mg Tab; Levofloxacin 250mg, 500mg, 750mg Tab. Special Authorization Criteria Change For Avodart and Proscar: Avodart 0.5mg Cap; Proscar 5mg Tab.
Posted October 5, 2009
Nova Scotia
NS Pharmacare Bulletin Vol #09-08, September 2009
Highlights
New Interchangeable Products Added to the Novo Scotia Formulary: New Categories: Apo-Amlodipine 5mg, 10mg Tab; Co Amlodipine 5mg, 10mg Tab; GD-Amlodipine 5mg, 10mg Tab; Gen-Amlodipine 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; Pms-Amlodipine 5mg, 10mg Tab; Ran-Amlodipine 5mg, 10mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Sandoz Amlodipine 5mg, 10mg Tab; Norvasc 5mg, 10mg Tab; Existing Categories: Novo-Levofloxacin 750mg Tab; Change to MAC Pricing: Prednisolone Acetate 1% Oph Susp.
Posted October 1, 2009
Newfoundland
NLPDP - Behind the Scenes - Fall 2009
Highlights
Newfoundland and Labrador Interchangeable Formulary New Category: Raloxifene Hydrochloride; Changes to the NLPDP Benefit Listing; New Open Benefits for Foundation, 65Plus, Access and Assurance Plans: PMS-Oxycodone 5mg, 10mg, 20mg; Oxy-IR 5mg, 10mg, 20mg; Olmetec 20mg, 40mg; Olmetec Plus 20mg/12.5mg, 40mg/12.5mg, 40mg/25mg; Atacand 32mg; Special Authorizaton: Stelara 25mg/0.5ml Inj-SC Sol; Fosavance 70/5600; Enablex 7.5mg, 15mg Tab; Apidra 100U/ml Vial, Cartridge; Common Drug Reviewed: Fosavance 70/2800 IU; Atlantic Common Drug Review: Adalat XL Plus 20mg/81mg, 30mg/81mg, 60mg/81mg.
Posted October 1, 2009
Newfoundland
NLPDP Bulletin No 60 - September 29, 2009
Highlights
Discontinued Products: Apo-Labetalol 100mg, 200mg Tab; Price Change and No Longer Interchangeable: Trandate 100mg, 200mg Tab.
Posted October 1, 2009
Newfoundland
NLPDP Bulletin No 59 - Sept 25, 2009
Highlights
Correction to Bulletin #57: Medroxyprogesterone Acetate 150mg/ml; Depo-Provera Injection
Posted October 1, 2009
Newfoundland
NLPDP Bulletin No 57 - Sept 23, 2009
Highlights
NIDPF Category: Medroxyprogesterone Acetate 150 mg/ml, Depo-Provera Injection
Posted October 1, 2009
Newfoundland
NLPDP Bulletin No. 56 - Sept 18, 2009
Highlights
NLPDP Quantity Coverage of Antiviral Medications
Posted October 1, 2009
Newfoundland
NLPDP Bulletin No. 61, Sept 30, 2009
Highlights
Highlights to follow shortly.
Posted October 1, 2009
Quebec
Quebec Capsule CdM - October 1, 2009
Highlights
Additions: Forteo 250mcg/ml Inj-SC Sol; Inspra 25mg, 50mg Tab; Prezista 400mg Tab; Stelara 45mg/0.5ml Inj-SC Sol; Yaz 0.02mg & 3mg Tab; Status Change: Apo-Flavoxate 200mg Tab; Premarin 0.3mg, 0.625mg, 1.25mg Tab; Premplus 0.625mg & 2.5mg, 0.625mg & 5mg Tab; Declined due to Economic and Pharmoeconomic Reasons: Actonel 150mg Tab; Declined: Soliris 300mg IV Sol; Refused due to Therapeutic Value: Avastin 25mg/ml IV Sol; Criteria Changes: Actos, Avandia, Avandemet and Generics; Adderall XR 5mg, 10mg, 15mg, 20mg, 25mg, 30mg Cap ER; Aranesp, Eprex; Tracleer, Flolan, Remodulan; Tysabri 300mg/15ml IV Sol; Xarelto 10mg Tab;
Posted September 29, 2009
New Brunswick
NBPDP Bulletin #768, Sept 24, 2009
Highlights
Antiviral Coverage for Influenza-Like-Illness (ILI) for NBPDP Beneficiaries
Posted September 28, 2009
New Brunswick
Benefit Changes To NBPDP, Bulletin #767, Sept 28, 2009
Highlights
Special Authorization Additions: Sprycel 20mg, 50mg, 70mg Tab; Nexavar 200mg Tab; Xeloda 150mg & 500mg Tab; Special Authorization Revised Criteria: Tarceva 100mg & 150mg Tab; Nexavar 200mg Tab; Sprycel 20mg, 50mg, 70mg Tab.
Posted September 28, 2009
Prince Edward Island
PEI MAC Memo, Sept 8, 2009
Highlights
New Interchangeable/MAC Categories: Dalacin T; Taro-Clindamycin; Plendil 2.5mg Tab SR; Renedil 2.5mg Tab SR; Remeron RD 15mg, 30mg, 45mg Orally Disintegrating Tab; Novo-Mirtazapine OD 15mg, 30mg, 45mg Orally Disintegrating Tab; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap; PMS-Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Sandoz Rivastigmine 1.5mg, 3mg, 4.5mg, 6mg Cap; Products Added to the Interchangeable/MAC List: Betaloc Durules 200mg Tab SR; Gen-Omeprazole 20mg Cap; Novo-Docusate 100mg Cap; PMS-Oxycodone-Acet 5mg & 325mg Tab; Ran-Citalopram 20mg, 40mg Tab; Changes to MAC Prices: Apo-Bromazepam 1.5mg Tab; Gen-Bromazepam 1.5mg Tab; Apo-Capto 12.5mg Tab; Nu-Capto 12.5mg Tab; Novo-Captoril 12.5mg Tab; Gen-Captopril 12.5mg Tab; PMS-Captopril 12.5mg Tab; Cipro 250mg Tab; Novo-Ciprofloxacin 250mg Tab; Apo-Ciproflox 250mg Tab; Gen-Ciprofloxacin 250mg Tab; Ratio-Ciprofloxacin 250mg Tab; Co Ciprofloxacin 250mg Tab; PMS-Ciprofloxacin 250mg Tab; Sandoz Ciprofloxacin 250mg Tab; Taro-Ciprofloxacin 250mg Tab; Ran-Ciprofloxacin 250mg Tab; Mint-Ciprofloxacin 250mg Tab; Apo-Nabumetone 500mg Tab; Novo-Nabumetone 500mg Tab; Gen-Nabumetone 500mg Tab; Pred-Forte 1% Oph Susp; Ratio-Prednisolone 1% Oph Susp; Sandoz Prednisolone 1% Oph Susp; Diopred 1% Oph Susp; Novo-Ticlopidine 250mg Tab; Nu-Ticlopidine 250mg Tab; Apo-Ticlopidine 250mg Tab; Gen-Ticlopidine 250mg Tab; PMS-Ticlopidine 250mg Tab; Sandoz Ticlopidine 250mg Tab; Apo-Timop 0.25% Oph Sol; Gen-Timolol 0.25% Oph Sol; PMS-Timolol 0.25% Oph Sol; Sandoz Timolol 0.25% Oph Sol; Deleted Interchangeable/MAC Categories: Novo-Propamide 250mg Tab; Apo-Chlorpropamide 250mg Tab; Novo-Cimetine 800mg Tab; Apo-Cimetidine 800mg Tab; Dexasone 0.75mg Tab; PMS-Dexamethasone 0.75mg Tab, 0.1% Oph/Otic Sol; Ratio-Dexamethasone 0.75mg Tab; Sandoz Dexamethasone 0.1% Oph/Otic Sol; Gravol 10mg/ml IV Inj Sol; Dimenhydrinate 10mg/ml IV Inj Sol; Ratio-Fulnisolide 0.025% Nas Spr; Rhinaris-F 0.025% Nas Spr; Rhinalar 0.025% Nas Spr; Apo-Flunisolide 0.025% Nas Spr; Apo-Haloperidol 2mg/ml O/Sol; PMS-Haloperidol 2mg/ml O/Sol; Trandate 100mg, 200mg Tab; Apo-Labetalol 100mg, 200mg Tab; Apo-Naproxen 125mg Tab; Nu-Naprox 125mg Tab; Macrodantin 100mg Cap; Novo-Furatoin 100mg Cap; Permax 0.05mg, 0.25mg, 1mg Tab; Apo-Pergolide 0.05mg, 0.25mg, 1mg Tab; Oracort 0.1% Oral Top Oint; Kenalog-Orabase 0.1% Oral Top Oint; Discontinued Products: Apo-Ketotifen 0.2mg/ml Syr; Apo-Salvent Ipravent 1.0mg & 0.2mg /ml Neb; Endantadine 100mg Cap; Lectopam 1.5mg Tab; Lin-Buspirone 10mg Tab; Lin-Fosinopril 10mg, 20mg Tab; M.O.S. 5mg/ml Sol; Novo-Bupriopion SR 150mg Tab SR; Novo-Diflunisal 500mg Tab; Nu-Alprazolam 0.25mg, 0.5mg Tab; Nu-Bromazepam 1.5mg, 3mg, 6mg Tab; Nu-Ketotifen 0.2mg/ml Syr; Nu-Salbutamol 1mg/ml, 2mg/ml Neb; Nu-Temazepam 15mg, 30mg Cap; PMS-Cimetidine 300mg, 400mg, 600 Tab; PMS-Flavoxate 200mg Tab; PMS-Tiaprofenic Acid 200mg Tab; Ratio-Alprazolam 0.25mg, 0.5mg Tab; Ratio-Desipramine 25mg, 50mg Tab; Ratio-MPA 2.5mg, 5mg, 10mg Tab; Relafen 500mg Tab; Sandoz Nabumetone 500mg Tab; Ticlid 250mg Tab; Timoptic 0.25% Oph Sol; Changes to PDINs: Acetylsalicylic Acid 325mg Tab (Uncoated); Ascorbic Acid 500mg Tab; Calcium Carbonate 250mg Tab; Use of PDINs: Acetaminophen 32mg/ml Elix, 80mg/ml Drops, 325mg, 500mg Tab; Acetylsalicylic Acid 325mg Tab (Uncoated); Ascorbic Acid 500mg Tab; Calamine Lotion; Calcium Carbonate 250mg, 500mg Tab; Folic Acid 1mg Tab; Niacin 100mg, 500mg Tab; Vitamin E 200U, 400U Cap; Vitamin D 1000U Tab.
Posted September 24, 2009
British Columbia
BC Pharmacare Newsletter, Edition #09-013, Sept 23, 2009
Highlights
LCA/RDP Booklet Changes: Apo-Gliclazide 80mg Tab; Diamicron 80mg Tab; Mylan-Gliclazide 80mg Tab; Glicazide 80mg Tab; Novo-Gliclazide 80mg Tab; Pms-Gliclazide 80mg Tab; Sandoz-Gliclazide 80mg Tab; Apo-Risperidone 1mg/ml O/Sol, 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Pms-Risperidone 1mg/ml O/Sol, 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Risperdal 1mg/ml O/Sol, 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Co-Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Mylan-Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Novo-Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Ran-Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Ratio-Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; Sandoz-Risperidone 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg Tab; New LCA Categories: Apo-Gliclazide MR 30mg Tab; Diamicron MR 30mg Tab; Benefits: GD-Amlodipine 5mg, 10mg Tab;
Posted September 24, 2009
British Columbia
BC Pharmacare Newsletter, Edition 09-012, Sept 23, 2009
Highlights
H1N1 Flu Virus — Antiviral Treatment & Distribution Plans
Posted September 23, 2009
Ontario
ODB Edition #41, Update L, September 30, 2009
Highlights
New Single Source Drugs: Omnaris 50mcg/Actuation Metered Dose Nas Sp-120 Dose Pk; Testim 1% Top Gel-5g Pk; Yaz 3.0mg & 0.02mg Tab-28 Pk; New Multi-Source Drugs: Apo-Amlodipine 5mg, 10mg Tab; Apo-Levofloxacin 250mg, 500mg Tab; Apo-Oxycodone/Acet 5mg & 325mg Tab; Co Amlodipine 5mg, 10mg Tab; Co Fluconazole-150 150mg Cap; Co Levofloxacin 250mg, 500mg Tab; Co Odansetron 4mg, 8mg Tab; Co Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Gd-Amlodipine 5mg, 10mg Tab; Gen-Amlodipine 5mg, 10mg Tab; Gen-Levofloxacin 250mg, 500mg Tab; Medroxyprogesterone Acetate Injection Suspension USP 150mg/ml Inj; Mylan-Omeprazole DR Cap 20mg; Novo-Amlodipine 5mg, 10mg Tab; Novo-Fentanyl 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Novo-Raloxifene 60mg Tab; Phl-Amlodipine 5mg, 10mg Tab; Pms-Amlodipine 5mg, 10mg Tab; Pms-Levofloxacin 250mg, 500mg Tab; Pms-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Amlodipine 5mg, 10mg Tab; Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Ratio-Tamsulosin 0.4mg Cap; Sandoz Amlodipine 5mg, 10mg Tab; Sandoz Levofloxacin 250mg, 500mg Tab; Manufacturer Requested Discontinued Drugs: Apo-Labetalol 100mg, 200mg Tab; Betaloc 50mg, 100mg; M.O.S Conc 50 50mg/ml O/L; M.O.S.-40 40mg Tab; Novo-Buproprion SR 150mg Tab; Novo-Fluconazole-150 150mg Cap; Novo-Hylazin 25mg Tab; Pms-Terbinafine 250mg Tab; Ratio-Beclomethasone AQ 50mcg Nas Sp-200 Dose Pk; Drug Benefit Prices: Novo-Metoprol (Uncoated) 50mg, 100mg Tab; Novo-Quetiapine 200mg, 300mg Tab; Ratio-Prednisolone 1% Oph Susp; Ratio-Tamsulosin 0.4mg Cap; New Manufacturer Names: Actos 15mg, 30mg, 45mg Tab; Off Formulary Interchangeable Products: Accel Pioglitazone 15mg, 30mg, 45mg Tab; Apo-Levofloxacin 750mg Tab; Co Levofloxacin 750mg Tab; Novo-Levofloxacin 750mg Tab; Pms-Levofloxacin 750mg Tab; Pms-Terbinafine 250mg Tab; Discontinued Drugs (Removed from Payment & Listing): Dipentum 250mg Cap; Pms-Digoxin 0.0625mg, 0.125mg, 0.25mg Tab; New Package Sizes: Lucentis 10mg/ml Inj Sol-0.23ml Vial Pk; Trade Name Changes: Zym-Metformin 500mg Tab.
Posted September 17, 2009
Newfoundland
NLPDP Bulletin #53, September 15, 2009
Highlights
Added as Special Authorization: Vesicare 5mg, 10mg Tab.
Posted September 17, 2009
Newfoundland
NLPDP Bulletin #54, Sept 15, 2009
Highlights
Additions: Tamiflu 30mg, 45mg Cap; Relenza Inhalation Rotadisk 1 box (20 doses). Status Changes: Tamiflu 75mg Cap, 12mg/ml Powder for Suspension.
Posted September 27, 2009
Alberta
AEIDBS Quarterly Update July 1, 2009
Highlights
New Drug Products Available by Special Authorization: Nutramigen A+ O/Liq, O/Pwd; Drug Products with Changes to Criteria for Coverage: Aricept 5mg, 10mg Tab; Exelon 1.5mg, 3mg, 4.5mg, 6mg, Cap, 2mg/ml O/Sol; Reminyl ER 8mg, 16mg, 24mg Cap ER; Deleted Listings: Duovent UDV 0.125 mg/ml / 0.3125mg/ml Inh Sol; Additional Brands or Strengths of Drug Products Already Available by Optional Special Authorization: Mint-Ciprofloxacin 250mg, 500mg, 750mg Tab; New Drug Products Available Under the Multiple Sclerosis Drug Coverage Program: Tysabri 20mg/ml Inj; Special Authorization Additions: Apo-Alendronate 10mg, 70mg Tab; Co Alendronate 40mg, 70mg Tab; Gen-Alendronate 10mg, 70mg Tab; Novo-Alendronate 10mg, 70mg Tab; PMS-Alendronate-FC 70mg Tab; Ratio-Alendronate 70mg Tab; Sandoz Alendronate 10mg, 70mg Tab; Fosamax 10mg, 40mg, 70mg Tab; Apo-Alfuzosin 10mg Tab SR; Sandoz Alfuzosin 10mg Tab SR; Xatral 10mg Tab SR; Axert 6.25mg, 12.5mg Tab; Co Azithromycin 600mg Tab; PMS-Azithromycin 600mg Tab; Zithromax 600mg Tab; Benoxyl 10%, 20% Lot; Panoxyl 10%, 20% Gel, 10% Bar; Entocort 3mg Cap CR; Suprefact Intranasal 1mg/ml Nas Sol; Suprefact 1mg/ml Inj; Suprefact Depot 6.3mg Inj Imp; Co Cabergoline 0.5mg Tab; Dostinex 0.5mg Tab; Celebrex 100mg, 200mg Cap; Benzaclin 1%, 5% Top Gel; Clindoxyl 1%, 5% Top Gel; Neoral 10mg, 25mg, 50mg, 100mg Cap, 100mg/ml O/Sol; Sandoz Cyclosporine 25mg, 50mg, 100mg Cap; Apo-Cyclosporine 100mg/ml O/Sol; Androcur 50mg Tab; Androcur Depot 100mg/ml Inj; Apo-Cyproterone 50mg Tab; Gen-Cyproterone 50mg Tab; Exjade 125mg, 250mg, 500mg Dispersible Tab for Susp; Apo-Diltiaz SR 60mg, 90mg, 120mg Cap SR; Aricept 5mg, 10mg Tab; Stievamycin Mild, Reg, Forte 0.01%, 0.025%, 0.05% Top Gel; Ezetrol 10mg Tab; Ratio-Fentanyl 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Ran-Fentanyl 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Duragesic 12, 25, 50, 75, 100 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Fentanyl Citrate 0.05mg/ml Inj; Apo-Flutamide 250mg Tab; Euflex 250mg Tab; Novo-Flutamide 250mg Tab; PMS-Flutamide 250mg Tab; Reminyl ER 8mg, 16mg, 24mg Cap ER; Zoladex 3.6mg/Syr Inj Syr; Zoladex LA 10.8mg/Syr Inj Syr; Aldara 50mcg/g Top Crm; Similac Alimentum with Iron O/Liq; Nutramigen O/Liq, O/Pwd; Nutramigen A+ O/Liq, O/Pwd; Neocate O/Pwd; PMS-Ipratropium 125mcg/ml, 250mcg/ml (1ml, 2ml) Inh Unit Dose Sol; Ratio-Ipratropium UDV 125mcg/ml, 250mcg/ml Inh Unit Dose Sol; Gen-Ipratropium Sterinebs 250mcg/ml Inh Unit Dose Sol; Somatuline Autogel 60mg/Syr, 90mg/Syr, 120mg/Syr Inj Syringe; Lupron Depot 3.75mg/Vial, 5mg/Vial, 7.5mg/Vial, 11.25mg/Vial, 22.5mg/Vial Inj; Carnitor 330mg Tab, 100mg/ml O/Sol, 200mg/ml Inj; Megace OS 40mg/ml O/Susp; Megace 160mg Tab; Apo-Megestrol 40mg, 160mg Tab; Nu-Megestrol 40mg, 160mg Tab; Medrol Acne 2.5mg/ml, 50mg/ml, 100mg/ml Top Lot; Neo-Medrol Acne 2.5mg/ml, 2.5mg/ml, 100mg/ml, 50mg/ml Top Lot; Apo-Modafil 100mg Tab; Alertec 100mg Tab; Singulair 10mg Tab; 5mg Chew Tab; Amerge 1mg, 2.5mg Tab; Octreotide Acetate Omega 50mcg/ml, 100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Sandostatin 50mcg/ml, 100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Octreotide100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Sandostatin LAR 10mg/Vial, 20mg/Vial, 30mg/Vial Inj; Papaverine Hcl 32.5mg/ml Inj; Norprolac 0.075mg 0.15mg Tab; Evista 60mg Tab; Mycobutin 150mg Cap; Actonel 5mg, 30mg, 35mg Tab; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap, 2mg/ml O/Sol; Maxalt 5mg, 10mg Tab; Maxalt Rpd 5mg, 10mg O/Wafer; Humatrope 6mg/Vial, 12mg/Vial Inj; Saizen 3.3mg/Vial, 5mg/Vial, 8.8mg/Vial Inj; Sulfacet-R 5%, 10% Top Lot; Imitrex 5mg/Dose, 20mg/Dose Unit Dose Nas Spr; Apo-Sumatriptan 50mg, 100mg Tab; Co Sumatriptan 50mg, 100mg Tab; Gen-Sumatriptan 50mg, 100mg Tab; Novo-Sumatriptan 100mg; Novo-Sumatriptan DF 50mg, 100mg Tab; PMS-Sumatriptan 50mg, 100mg Tab; Ratio-Sumatriptan 50mg, 100mg Tab; Sandoz Sumatriptan 50mg, 100mg Tab; Imitrex DF 50mg, 100mg Tab; Imitrex 6mg/Syringe; Apo-Calcitonin 200IU/Dose Metered Dose Nas Spr; Sandoz Calcitonin NS 200IU/Dose Metered Dose Nasal Spr; Miacalcin 200IU/Dose Metered Dose Spr; Protopic 0.1%, 0.3% Top Oint; Androderm 2.5mg/day, 5mg/day Trans Patch; Andriol 40mg Cap; Nitoman 25mg Tab; Apo-Tizanidine 4mg Tab; Gen-Tizanidine 4mg Tab; Zanaflex 4mg Tab; Detrol LA 2mg, 4mg Cap ER; Stieva-A, Stieva-A Forte 0.01%, 0.025%, 0.05%, 0.1% Top Crm, 0.025% Top Sol; Retin-A 0.05%, 0.1% Top Crm, 0.01%, 0.025% Top Gel; Vitamin A Acid 0.01%, 0.025%, 0.05% Top Gel; Trosec 20mg Tab; Accolate 20mg Tab; Zometa Concentrate 0.8mg/ml Inj; Zomig 2.5mg Tab, 5mg/Dose Unit Dose Nas Spr; Zomig Rapimelt 2.5mg Dispersible Tab; Optional Special Authorization Additions: Apo-Ciproflox 250mg, 500mg, 750mg Tab; Co Ciprofloxacin 250mg, 500mg, 750mg Tab; Gen-Ciprofloxacin 250mg, 500mg, 750mg Tab; Novo-Ciprofloxacin 250mg, 500mg, 750mg Tab; PMS-Ciprofloxacin 250mg, 500mg, 750mg Tab; Ran-Ciproflox 250mg, 500mg, 750mg Tab; Ran-Ciprofloxacin 250mg, 500mg, 750mg Tab; Ratio-Ciprofloxacin 250mg, 500mg, 750mg Tab; Sandoz Ciprofloxacin 250mg, 500mg, 750mg Tab; Taro-Ciprofloxacin 250mg, 500mg Tab; Cipro 250mg, 500mg, 750mg Tab;
Posted September 27, 2009
Alberta
Alberta DBL Quarterly Update July 1, 2009
Highlights
Additions: Altace 1.25mg Cap; Apo-Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Apo-Levocarb CR 100/25mg Tab SR; Apo-Lisinopril 5mg, 10mg, 20mg Tab; Apo-Pravastatin 10mg, 20mg, 40mg Tab; Apo-Ramipril 1.25mg Cap; Co Lisinopril 5mg, 10mg, 20mg Tab; Co Pravastatin 10mg, 20mg, 40mg Tab; Co Ramipril 1.25mg Cap; Gen-Lisinopril 5mg, 10mg, 20mg Tab; Gen-Pravastatin 10mg, 20mg, 40mg Tab; Gen-Ramipril 1.25mg Cap; Medroxyprogesterone Acetate 150mg/ml Inj; Micardis Plus 80mg/25mg Tab; Mint-Lisinopril 5mg, 10mg, 20mg Tab; Mint-Pravastatin 10mg, 20mg, 40mg Tab; Novo-Azithromycin 20mg/ml, 40mg/ml O/Susp; Novo-Diltiazem HCL 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Novo-Lisinopril Type P 5mg, 10mg, 20mg Tab; Novo-Lisinopril Type Z 5mg Tab; Novo-Lisinopril 10mg, 20mg, Tab; Novo-Pravastatin 10mg, 20mg, 40mg Tab; Nu-Pravastatin 10mg, 20mg, 40mg Tab; Pravachol 10mg, 20mg, 40mg Tab; PMS-Azithromycin 20mg/ml, 40mg/ml O/Susp; PMS-Lisinopril 5mg, 10mg, 20mg Tab; PMS-Oxycodone 5mg, 10mg, 20mg Tab; PMS-Pravastatin 10mg, 20mg, 40mg Tab; Prinivil 5mg, 10mg, 20mg Tab; Ran-Lisinopril 5mg, 10mg, 20mg Tab; Ramipril 1.25mg Cap; Ran-Pravastatin 10mg, 20mg, 40mg Tab; Ran-Ramipril 1.25mg Cap; Ratio-Pravastatin 10mg, 20mg, 40mg Tab; Ratio-Lisinopril P 5mg, 10mg, 20mg Tab; Ratio-Lisinopril Z 5mg, 10mg, 20mg Tab; Ratio-Ramipril 1.25mg Cap; Sandoz Diltiazem T 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Sandoz Lisinopril 5mg, 10mg, 20mg Tab; Sandoz Methylphenidate 20mg Tab ER; Sandoz Pravastatin 10mg, 20mg, 40mg Tab; Sandoz Ramipril 1.25mg Tab; Sinemet CR 100/25 100mg/25mg Tab SR; Supeudol 5mg, 10mg, 20mg Tab; Tiazac 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Xamiol 50mcg/g Top Gel; Zestril 5mg, 10mg, 20mg Tab; Zithromax 20mg/ml, 40mg/ml O/Susp; Change in Status from Special Authorization to Unrestricted: Amatine 2.5mg, 5mg Tab; Apo-Midodrine 2.5mg, 5mg Tab; Co Etidronate 200mg Tab; Cosopt Preservative-Free 2%/0.5% Oph Sol; Didronel 200mg Tab; Flovent HFA 50mcg/Dose Metered Dose Aer; Gen-Etidronate 200mg Tab; Mepron 150mg/ml O/Susp; Trusopt (Preservative-Free) 2% Oph Sol; Deleted Listings: Norflex 30mg/ml Inj; Discontinued Listings: Estracomb 50mcg/day / 250mcg/day / 50mcg/day Trans Patch; Fenomax 160mg Cap; Levate 75mg Tab; Nu-Prochlor 5mg, 10mg Tab; Sandoz Risperidone 0.25mg Tab; Restricted Benefits: Viread 300mg Tab; Change in Status from Unrestricted to Restricted: Apo-Cyclobenzaprine 10mg Tab; Dom-Cyclobenzaprine 10mg Tab; Gen-Cyclobenzaprine 10mg Tab; Novo-Cycloprine 10mg Tab; Nu-Cycloprine 10mg Tab; PMS-Cyclobenzaprine 10mg Tab; Ratio-Cyclobenzaprine 10mg Tab; Change in Status from Special Authorization to Restricted: Apo-Leflunomide 10mg, 20mg Tab; Arava 10mg, 20mg Tab; Novo-Leflunomide 10mg, 20mg Tab; Sandoz-Leflunomide 10mg, 20mg Tab; Special Authorization: Drug Products with Changes to Criteria for Coverage: Aricept 5mg, 10mg Tab; Exelon 1.5mg, 3mg, 4.5mg, 6mg, Cap, 2mg/ml O/Sol; Reminyl ER 8mg, 16mg, 24mg Cap ER; Deleted Listings: Duovent UDV 0.125mg/ml / 0.3125mg/ml Inh Sol; Optional Special Authorization: Additional Brands or Strengths of Drug Products Already Available by Optional Special Authorization: Mint-Ciprofloxacin 250mg, 500mg, 750mg Tab; New Drug Products Available Under the Multiple Sclerosis Drug Coverage Program: Tysabri 20mg/ml Inj; Special Authorization Additions: Apo-Alendronate 10mg, 70mg Tab; Co Alendronate 40mg, 70mg Tab; Gen-Alendronate 10mg, 70mg Tab; Novo-Alendronate 10mg, 70mg Tab; PMS-Alendronate-FC 70mg Tab; Ratio-Alendronate 70mg Tab; Sandoz Alendronate 10mg, 70mg Tab; Fosamax 10mg, 40mg, 70mg Tab; Apo-Alfuzosin 10mg Tab SR; Sandoz Alfuzosin 10mg Tab SR; Xatral 10mg Tab SR; Axert 6.25mg, 12.5mg Tab; Co Azithromycin 600mg Tab; PMS-Azithromycin 600mg Tab; Zithromax 600mg Tab; Benoxyl 10%, 20% Lot; Panoxyl 10%, 20% Gel, 10% Bar; Entocort 3mg Cap CR; Suprefact Intranasal 1mg/ml Nas Sol; Suprefact 1mg/ml Inj; Suprefact Depot 6.3mg Inj Imp; Co Cabergoline 0.5mg Tab; Dostinex 0.5mg Tab; Celebrex 100mg, 200mg Cap; Benzaclin 1%, 5% Top Gel; Clindoxyl 1%, 5% Top Gel; Neoral 10mg, 25mg, 50mg, 100mg Cap, 100mg/ml O/Sol; Sandoz Cyclosporine 25mg, 50mg, 100mg Cap; Apo-Cyclosporine 100mg/ml O/Sol; Androcur 50mg Tab; Androcur Depot 100mg/ml Inj; Apo-Cyproterone 50mg Tab; Gen-Cyproterone 50mg Tab; Exjade 125mg, 250mg, 500mg Dispersible Tab for Susp; Apo-Diltiaz SR 60mg, 90mg, 120mg Cap SR; Aricept 5mg, 10mg Tab; Stievamycin Mild, Reg, Forte 0.01%, 0.025%, 0.05% Top Gel; Ezetrol 10mg Tab; Ratio-Fentanyl 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Ran-Fentanyl 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Duragesic 12, 25, 50, 75, 100 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Fentanyl Citrate 0.05mg/ml Inj; Apo-Flutamide 250mg Tab; Euflex 250mg Tab; Novo-Flutamide 250mg Tab; PMS-Flutamide 250mg Tab; Reminyl ER 8mg, 16mg, 24mg Cap ER; Zoladex 3.6mg/Syr Inj Syr; Zoladex LA 10.8mg/Syr Inj Syr; Aldara 50mcg/g Top Crm; PMS-Ipratropium 125mcg/ml, 250mcg/ml (1ml, 2ml) Inh Unit Dose Sol; Ratio-Ipratropium UDV 125mcg/ml, 250mcg/ml Inh Unit Dose Sol; Gen-Ipratropium Sterinebs 250mcg/ml Inh Unit Dose Sol; Somatuline Autogel 60mg/Syr, 90mg/Syr, 120mg/Syr Inj Syringe; Lupron Depot 3.75mg/Vial, 5mg/Vial, 7.5mg/Vial, 11.25mg/Vial, 22.5mg/Vial Inj; Carnitor 330mg Tab, 100mg/ml O/Sol, 200mg/ml Inj; Megace OS 40mg/ml O/Susp; Megace 160mg Tab; Apo-Megestrol 40mg, 160mg Tab; Nu-Megestrol 40mg, 160mg Tab; Medrol Acne 2.5mg/ml, 50mg/ml, 100mg/ml Top Lot; Neo-Medrol Acne 2.5mg/ml, 2.5mg/ml, 100mg/ml, 50mg/ml Top Lot; Apo-Modafil 100mg Tab; Alertec 100mg Tab; Singulair 10mg Tab; 5mg Chew Tab; Amerge 1mg, 2.5mg Tab; Octreotide Acetate Omega 50mcg/ml, 100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Sandostatin 50mcg/ml, 100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Octreotide100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Sandostatin LAR 10mg/Vial, 20mg/Vial, 30mg/Vial Inj; Papaverine Hcl 32.5mg/ml Inj; Norprolac 0.075mg 0.15mg Tab; Evista 60mg Tab; Mycobutin 150mg Cap; Actonel 5mg, 30mg, 35mg Tab; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap, 2mg/ml O/Sol; Maxalt 5mg, 10mg Tab; Maxalt Rpd 5mg, 10mg O/Wafer; Humatrope 6mg/Vial, 12mg/Vial Inj; Saizen 3.3mg/Vial, 5mg/Vial, 8.8mg/Vial Inj; Sulfacet-R 5%, 10% Top Lot; Imitrex 5mg/Dose, 20mg/Dose Unit Dose Nas Spr; Apo-Sumatriptan 50mg, 100mg Tab; Co Sumatriptan 50mg, 100mg Tab; Gen-Sumatriptan 50mg, 100mg Tab; Novo-Sumatriptan 100mg; Novo-Sumatriptan DF 50mg, 100mg Tab; PMS-Sumatriptan 50mg, 100mg Tab; Ratio-Sumatriptan 50mg, 100mg Tab; Sandoz Sumatriptan 50mg, 100mg Tab; Imitrex DF 50mg, 100mg Tab; Imitrex 6mg/Syringe; Apo-Calcitonin 200IU/Dose Metered Dose Nas Spr; Sandoz Calcitonin NS 200IU/Dose Metered Dose Nasal Spr; Miacalcin 200IU/Dose Metered Dose Spr; Protopic 0.1%, 0.3% Top Oint; Androderm 2.5mg/day, 5mg/day Trans Patch; Andriol 40mg Cap; Nitoman 25mg Tab; Apo-Tizanidine 4mg Tab; Gen-Tizanidine 4mg Tab; Zanaflex 4mg Tab; Detrol LA 2mg, 4mg Cap ER; Stieva-A, Stieva-A Forte 0.01%, 0.025%, 0.05%, 0.1% Top Crm, 0.025% Top Sol; Retin-A 0.05%, 0.1% Top Crm, 0.01%, 0.025% Top Gel; Vitamin A Acid 0.01%, 0.025%, 0.05% Top Gel; Trosec 20mg Tab; Accolate 20mg Tab; Zometa Concentrate 0.8mg/ml Inj; Zomig 2.5mg Tab, 5mg/Dose Unit Dose Nas Spr; Zomig Rapimelt 2.5mg Dispersible Tab; Optional Special Authorization Additions: Apo-Ciproflox 250mg, 500mg, 750mg Tab; Co Ciprofloxacin 250mg, 500mg, 750mg Tab; Gen-Ciprofloxacin 250mg, 500mg, 750mg Tab; Novo-Ciprofloxacin 250mg, 500mg, 750mg Tab; PMS-Ciprofloxacin 250mg, 500mg, 750mg Tab; Ran-Ciproflox 250mg, 500mg, 750mg Tab; Ran-Ciprofloxacin 250mg, 500mg, 750mg Tab; Ratio-Ciprofloxacin 250mg, 500mg, 750mg Tab; Sandoz Ciprofloxacin 250mg, 500mg, 750mg Tab; Taro-Ciprofloxacin 250mg, 500mg Tab; Cipro 250mg, 500mg, 750mg Tab; Multiple Sclerosis Drug Coverage Additions: Tysabri 20mg/ml Inj;
Posted September 9, 2009
Alberta
AHWDBL Additions, Sept 1, 2009
Highlights
New Restricted Benefit: Lucentis 2.3mg/ml vial inj
Posted September 9, 2009
Nova Scotia
NS Pharmacare Bulletin Vol #09-07, August 2009
Highlights
Change in Special MAC Pricing: Famotidine 20mg, 40mg Tab; Nizatidine 150mg, 300mg Tab; eminder: Delisted Premarin Products; 35 New Ostomy Products: See bulletin for details; Discontinued Products: Apo-Ipravent Nasal Spray 0.03%; Apo-Loxapine 5mg, 10mg, 25mg, 50mg Tab; Apo-Phenylbutazone 100mg Tab; Betadine Vaginal Douche 10%; Capoten 12.5mg Tab; Cicatrin Powder; Covera-HS 180mg, 240mg Tab; Cytoxan 50mg Tab; Didronel 200mg Tab; Duricef 500mg Tab; Imitrex DF 25mg Tab; Isotamine Syr Pediatric 50mg/5ml; K Lyte CL Pwr 238.46153mg; K-Exit Poudre 100%; Megace 160mg Tab; Nu-Loxapine 5mg, 10mg, 25mg, 50mg Tab; Nu-Salbutamol 2mg/ml PI Amp; Percodan 325/5mg Tab; pms-Digoxin 0.0625mg, 0.125mg, 0.25mg Tab; pms-Methotrimeprazine 5mg Tab; Propaderm Crm 0.025%; Retin-A Crm 0.01%, 0.025%; Sansert 2mg Tab; Starlix 180mg Tab; Symmetrel 10mg/ml Syr; Testosterone Cyprionate 100mg/ml Inj; Ultravate Crm 0.05%; Ultravate Oint 0.05%; Ventolin 0.4mg/ml Oral Liq; Viokase Pwr;
Posted September 4, 2009
New Brunswick
NBPDP Benefit Changes Bulletin #764, Sept 2, 2009
Highlights
NBPDP Benefit Additions - Interchangeable Product Additions: Apo-Amlodipine 5mg, 10mg Tab; Co Amlodipine 5mg, 10mg Tab; GD-Amlodipine 5mg, 10mg Tab; Mylan-Amlodipine 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; pms-Amlodipine 5mg, 10mg Tab; Ran-Amlodipine 5mg, 10mg Tab; ratio-Amlodipine 5mg, 10mg Tab; Sandoz Amlodipine 5mg, 10mg Tab;
Posted September 4, 2009
New Brunswick
NB Formulary, Volume 51, Update 2 - Product Updates, Sept 2,2009
Highlights
Product Updates- New Interchangeable Products: Norvasc 5mg, 10mg Tab; Apo-Amlodipine 5mg, 10mg Tab; Co Amlodipine 5mg, 10mg Tab; GD-Amlodipine 5mg, 10mg Tab; Mylan-Amlodipine 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; pms-Amlodipine 5mg, 10mg Tab; Ran-Amlodipine 5mg, 10mg Tab; ratio-Amlodipine 5mg, 10mg Tab; Sandoz Amlodipine 5mg, 10mg Tab;
Posted September 3, 2009
New Brunswick
NBPDB Bulletin #762, Benefit Changes, August 27, 2009
Highlights
Regular Benefits Additions: Tapazole 10mg Tab; Olmetec 20mg, 40mg Tab; Olmetec Plus 20mg/12.5mg, 40mg/12.5mg, 40mg/25mg Tab; Travatan Z 0.004% Oph Liq; Diovan HCT 320/12.5mg, 320/25mg Tab; Special Authorization Additions: Orencia 250mg/vial Inj; Gen-Clozapine 50mg, 200mg Tab; Enablex 7.5mg, 15mg Tab ER; Eprex 30,000/0.75ml pre-filled syringe; Viread 300mg Tab; Topamax 25mg, 50mg, 100mg and 200mg Tab; Topiramate (generics) 25mg, 50mg, 100mg, 200mg Tab; Botox 100 U/vial; Drugs Reviewed and Not Listed: Remicade 100mg vial Inj; Seasonale 0.15/0.03mg Tab; Advagraf 0.5mg, 1mg, 5mg Cap ER;
Posted September 1, 2009
British Columbia
BC Pharmacare Newsletter #09-011, August 31, 2009
Highlights
Non-Benefits: Rasilez 150mg, 300mg Tab; Benefits: Cipralex 10mg, 20mg Tab; Invega 3mg, 6mg, 9mg Tab ER; Limited Coverage Benefits: Co-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Pms-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Requip 0.25mg, 1mg, 2mg, 5mg Tab;
Posted August 28, 2009
New Brunswick
NBPDP Bulletin #761, Aug 27, 2009
Highlights
CHOLINESTERASE INHIBITORS (ChEIs); Special Authorization Criteria and Process; See Bulletin for Details
Posted August 20, 2009
Alberta
Additions to the AHWDBL August 15, 2009
Highlights
New Interchangeable Products Affected by LCA Pricing: Apo-Amlodipine 5mg, 10mg Tab; Co Amlodipine 5mg, 10mg Tab; Gen-Amlodipine 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; Pms-Amlodipine 5mg, 10mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Sandoz Amlodipine 5mg, 10mg Tab; Norvasc 5mg, 10mg Tab; Ran-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; Requip 0.25mg, 1mg, 2mg, 5mg Tab; Drug Products with New Criteria: Apo-Lansoprazole 15mg, 30mg Cap DR; Prevacid 15mg, 30mg Cap DR;
Posted August 19, 2009
Quebec
Modification No 2 to Edition 25, effective Aug 19, 2009
Highlights
Additions: Apo-Amlodipine 5mg, 10mg Tab; Co Amlodipine 5mg, 10mg Tab; GD-Amlodipine 5mg, 10mg Tab; Gen-Amlodipine 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; Phl-Amlodipine 5mg, 10mg Tab; Pms-Amlodipine 5mg, 10mg Tab; Ran-Amlodipine 5mg, 10mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Sandoz Amlodipine 5mg, 10mg Tab; Zym-Amlodipine 5mg, 10mg Tab; Price Changes: Norvasc 5mg, 10mg Tab;
Posted August 19, 2009
Quebec
Modification #3 to Edition 25, effective Aug 19, 2009
Highlights
Prices Changes: Zaditen 1mg Tab; Novo-Levofloxacin 250mg, 500mg Tab; Duvoid 10mg, 25mg, 50mg Tab; Sintrom 1mg, 4mg Tab; pms-ISMN 60mg Tab; Trandate 100mg, 200mg Tab; Anafranil 10mg, 25mg, 50mg Tab; Zym-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Diastat 5mg/ml Rect Gel; Sandomigran 0.5mg Tab; pms-Benztropine 2mg Tab; Elite Strip; Maglucate 500mg Tab; pms-Hydrochlorothiazide 12.5mg Tab; pms-Pantoprazole 40mg Tab EC; Ridaura 3mg Cap; Cortifoam 10% Rect Aer; Thelin 100mg Tab; Zanaflex 4mg Tab;
Posted August 7, 2009
British Columbia
BC Pharmacare Newsletter Edition 09-010, August 6, 2009
Highlights
New Drugs Categorized to LCA and/or RDP: Accel Pioglitazone HCL 15mg, 30mg, 45mg Tab; Co-Pramipexole 0.25mg, 0.5mg, 1.0mg, 1.5mg Tab; Novo-Cilazapril 5/12.5mg Tab; Novo-Fentanyl 25mcg/h, 50mcg/h, 75mcg/h, 100mcg/h Patch; PMS-Omeprazole 20mg Cap. New LCA Categories: Amlodipine Besylate 5mg, 10mg Tab; Desogestrel-Ethinyl Estradiol 0.15/0.03mg (21), 0.15/0.03mg (28) Tab; Granisetron 1mg Tab; Levodopa/Carbidopa 100mg/25mg Tab CR; Lansoprazole 15mg, 30mg Cap. Benefits – Amlodipine Besylate: Amlodipine Besylate 5mg, 10mg Tab.
Posted August 17, 2009
Newfoundland
New Categories and Additions NIDPF Vol 56, Aug 14, 2009
Highlights
New Catergories: Apo-Lansoprazole 15mg, 30mg Cap; Prevacid 15mg, 30mg Cap; Medroxyprogesterone Acetate 150mg/ml Inj Susp; Depo-Provera Inj. Additions to an Existing Catergory: Co Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; PMS-Bupropion SR 100mg Tab; Gen-Combo Sterinebs 0.5mg/2.5mg Inhalation Sol; Novo-Raloxifene 60mg Tab; Apo-Oxycodone/Acet 5mg/325mg Tab.
Posted August 17, 2009
Newfoundland
NLPDP Benefit Additions, Bulletin #49, Aug 13, 2009
Highlights
Open Benefit for All Plans and Special Authorization for the Cystic Fibrosis Program: Medroxyprogesterone Acetate Inj Susp 150mg/ml; Co Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Apo-Oxycodone/Acet 5mg/325mg Tab. Special Authorization for All Plans and the Cystic Fibrosis Program: Apo-Lansoprazole 15mg, 30mg Cap; PMS-Bupropion SR 100mg Tab; Gen-Combo Sterinebs 0.5mg/2.5mg Inhalation Sol; Novo-Raloxifene 60mg Tab.
Posted August 14, 2009
Nova Scotia
NS Pharmacare Bulletin Vol #09-06, August 2009
Highlights
New Interchangeable Products: Cefepime 2g/vial Inj; Maxipime 2g/vial Inj; Apo-Granisetron 1mg Tab; Kytril 1mg Tab; Apo-Lansoprazole 15mg DR Cap; Prevacid 30mg Cap; Apo-Levocarb CR 100/25mg Tab; Apo-Levofloxacin 250mg, 500mg, 750mg Tab; CO Levofloxacin 250mg, 500mg, 750mg Tab; Gen-Levofloxacin 250mg, 500mg, 750mg Tab; Novo-Levofloxacin 250mg, 500mg, 750mg Tab; PMS-Levofloxacin 250mg, 500mg, 750mg Tab; Sandoz Levofloxacin 250mg, 500mg, 750mg Tab; Levaquin 250mg, 500mg, 750mg Tab; Medroxyprogesterone Acetate 150mg/ml Inj; Depo-Provera 150mg/ml Inj; Pamidronate Disodium Omega 90mg/vial Inj; Aredia 90mg/vial Inj; APO-Raloxifene 60mg Tab; Novo-Raloxifene 60mg Tab; Evista 60mg Tab; APO-Ramipril 15mg Cap; Ratio-Ramipril 15mg Cap; Altace 15mg Cap. Existing Categories: Apo-Oxycodone/Acet 5/325mg Tab; Novo-Benzydamine 0.15% Oral Rinse; Novo-Cilazapril/HCTZ 5mg/12.5mg Tab; Jamp-Citalopram 20mg, 40mg Tab; Fentanyl 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Patch; Methylphenidate 20mg SR Tab; Omeprazole 20mg Cap; Ondansetron 4mg, 8mg Tab; Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Ramipril 1.25mg Cap; Thiamine 100mg/ml Inj; Topiramate 200mg Tab. Product Name Change for Interchangeable Products: Jamp-Lactulose 667mg/ml O/L; ZYM-Metformin HCl 500mg, 850mg Tab. Correction to Special MAC Pricing: Ondansetron 4mg Tab. Removal of MAC Catergory: APO-Digoxin 0.0625mg Tab; Lanoxin 0.0625mg Tab. PMS-Amantadine 10mg/ml O/L; Symmetrel 10mg/ml Syr.
Posted August 13, 2009
Prince Edward Island
PEI MAC Memo August 10, 2009
Highlights
New Interchangeable/MAC Categories: Norvasc 5mg, 10mg Tab; Novo-Amlodipine 5mg, 10mg Tab; Ratio-Amlodipine 5mg, 10mg Tab; Gen-Amlodipine 5mg, 10mg Tab; APO-Amlodipine 5mg, 10mg Tab; PMS-Amlodipine 5mg, 10mg Tab; Sandoz-Amlodipine 5mg, 10mg Tab; RAN-Amlodipine 5mg, 10mg Tab; CO Amlodipine 5mg, 10mg Tab; PMS-Hydrochlorothiazide 12.5mg Tab; APO-Hydro 12.5mg Tab; Hycodan 1mg/ml Syrup; PMS-Hydro-Codone 1mg/ml Syrup; Sinemet CR 100mg & 25mg CR Tab; APO-Levocarb CR 100mg & 25mg CR Tab; Novo-Pen-VK 60mg/ml Oral Solution; APO-Pen- VK 60mg/ml Oral Solution; Requip 0.25mg, 1mg, 2mg, 5mg Tab; RAN-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; CO Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab; PMS-Ropinirole 0.25mg, 1mg, 2mg, 5mg Tab. Products added to the Interchangeable/MAC list: Accel Pioglitazone 15mg, 30mg, 45mg Tab; APO-Oxycodone/acet 5&325mg Tab; CO Fluconazole 150mg Cap; GEN-Ondansetron 4mg, 8mg Tab; Ibuprofen 400mg Tab; Mint-Ciprofloxacin 250mg 500mg 750mg Tab; Mint-Pioglitazone 15mg, 30mg, 45mg Tab; Mint-Pravastatin 10mg, 20mg, 40mg Tab; PMS-Terbinafine 250mg Tab; RAN-Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab; Sandoz Fentanyl MTX 12ug/hr, 25 ug/hr, 50 ug/hr, 75 ug/hr, 100 ug/hr Transdermal Patch. Changes to MAC Prices: Cipro 250mg Tab; Novo-Ciprofloxacin 250mg Tab; APO-Ciproflox 250mg Tab; GEN-Ciprofloxacin 250mg Tab; Ratio-Ciprofloxacin 250mg Tab; CO Ciprofloxacin 250mg Tab; PMS-Ciprofloxacin 250mg Tab; Sandoz Ciprofloxacin 250mg Tab; RAN-Ciproflox 250mg Tab; Mint-Ciprofloxacin 250mg Tab. Deleted Interchangeable/MAC Categories: Lanoxin 0.0625mg Tab; PMS-Digoxin 0.0625mg Tab; APO-Digoxin 0.0625mg Tab. Discontinued Products: Betaloc 50mg, 100mg Tab.
Posted August 6, 2009
Ontario
ODB Edition 41, Update K, August 18, 2009
Highlights
New Single Source Drugs: Travatan Z 0.004% Oph Sol 2.5mL Pk, 5mL Pk; New Multi-Source Drugs: Apo-Lansoprazole 15mg, 30mg DR Cap; Apo-Levocarb CR 100mg & 25mg Tab; Manufacturer Requested Discontinued Drugs: Apo-Digoxin 0.0625mg Tab; Covera-HS 180mg, 240mg SR Tab; K-Lyte/Cl 25mEq/Pouch O/Pd 7.8g Pk; Ratio-Clindamycin 150mg, 300mg Cap; Drug Benefit Prices: Eligard 45mg Pd Susp Inj-Pref Syr Kit; Haloperidol LA 50mg/ml Oily Inj Sol 5ml Pk; Piportil L4 50mg/ml Inj Sol 1ml Pk; PMS-Azithromycin 100mg/5ml O/L 15ml Pk, 200mg/5ml O/L 15ml Pk, 22.5ml Pk; Sab-Indomethacin 50mg Supp; New Manufacturer Names: Bezalip 400mg SR Tab; Dantrium 25mg, 100mg Cap; Soriatane 10mg, 25mg Cap; Not a Benefit Drug: Kenalog-Orabase Oral Top-Oint; Off-Formulary Interchangeable Products: Sandoz-Fenefibrate S 100mg Tab; Discontinued Drugs Removed from Payment & Listing: Apo-Salvent Ipravent Sterules 500mcg/2.5mg/2.5ml Inh Sol 2.5ml Pk; Kaletra 133.3/33.3mg Cap; Novolin ge 10/90, 20/80 Penfill 100U/ml Inj Susp 5x3ml Pk; Nutren 2.0 2kcal/ml Liq 250ml Pk; Nutren fibre 1kcal/ml Liq 250ml Pk; Nutren VHP 1kcal/ml Liq 1500ml Pk; Nutren VHP Fibre 1kcal/ml 1500ml, 250ml Pk; Oxyderm 20% Lot; Pediatric Peptinex DT 1kcal/ml Liq 250ml Pk; Peptinex 1kcal/ml 237ml Pk; Peptinex DT 1kcal/ml 250ml, 1500ml Pk; Resource Just for Kids Liq 235ml Pk; Resource Just for Kids with Fibre 1kcal/ml Liq 237ml Pk; Sandoz Risperidone 0.25mg, 0.5mg Tab; Reinstated Drugs Added to Payment: Novo-Levofloxacin 250mg, 500mg Tab; Status Change from Limited Use to General Benefit: Thyrogen 0.9mg/ml Inj Pd 2x1.1mg Vial Pk;
Posted August 5, 2009
Newfoundland
NLPDP Bulletin #48, Benefit Additions effective July 30, 2009
Highlights
Addition Open Benefit: Olmetec 20mg, 40mg; Olmetec Plus 20mg/12.5mg, 40mg/12.5mg, 40mg/25mg; Atacand 32mg; Addition Special Authorization: Stelara 25mg/0.5ml SC Inj; Fosavance 70/5600; Orencia 25mg Vial for Inj; Enablex 7.5mg, 15mg Tab; Apidra 100U/ml Vial, 100U/ml Cartridge; Reviewed and Not Recommended: Remicade 100mg for Ulcerative Colitis; Adalat XL Plus 20mg/81mg, 30mg/81mg, 60mg/81mg;
Posted August 5, 2009
Alberta
Additions to the AHWDBL, Aug 1, 2009
Highlights
New Interchangeable Products Affected by LCA Pricing: Prevacid 15mg, 30mg DR Cap; Apo-Lansoprazole 15mg, 30mg DR Cap; New Single Source Products: Apidra 100U/ml Inj, Inj Syr; New Interchangeable Products Available by Optional Special Authorization: Apo-Levofloxacin 250mg, 500mg, 750mg Tab; Co Levofloxacin 250mg, 500mg, 750mg Tab; Gen-Levofloxacin 250mg, 500mg Tab; Novo-Levofloxacin 250mg, 500mg, 750mg Tab; PMS-Levofloxacin 250mg, 500mg, 750mg Tab; Sandoz Levofloxacin 250mg, 500mg, 750mg Tab; Levaquin 250mg, 500mg, 750mg Tab;
Posted July 29, 2009
Newfoundland
NLPDP Bulletin No. 46 July 27, 2009
Highlights
Lucentis Rule in place effective July 27, 2009
Posted July 29, 2009
Newfoundland
NLPDP Bulletin No. 45 July 24, 2009
Highlights
The following products have been moved from Special Authorization to Open Benefit: EZ Health Talking Blood Glucose Test Strips 50, 100; EZ Health Lancets 100.
Posted July 21, 2009
Manitoba
Manitoba Bulletin #61, Effective August 17, 2009
Highlights
Additions: Apo-Bicalutamide 50mg Tab; Apo-Cilazapril 1mg, 2.5mg, 5mg Tab; Apo-Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg Cap; Apo-Gabapentin 600mg; Apo-Ramipril 15mg Cap; Apri 21 0.15mg/0.03mg Tab; Apri 28 0.15/0.03mg Tab; Co Famciclovir 125mg, 250mg, 500mg Tab; Gen-Bicalutamide 50mg Tab; Gen-Nifedipine 60mg Tab ER; Gen-Odansetron 4mg, 8mg Tab; Gen-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Gen-Venlafaxine XR 37.5mg, 75mg, 150mg Tab; Jamp-Citalopram 20mg, 40mg Tab; Jamp-Odansetron 4mg, 8mg Tab; Medroxyprogesterone Acetate Injectable Suspension 150mg/ml Inj; Novo-Cilazapril/HCTZ 5mg/12.5mg Tab; Novo-Clonidine 0.025mg Tab; Novo-Etidronatecal 400mg/500mg Tab; Novo-Morphine SR 15mg, 30mg Tab; Novo-Oxycodone/Acetaminophen 5mg/325mg Tab; pms-Oxycodone 5mg, 10mg, 20mg Tab; Ran-Gabapentin 100mg, 300g, 400mg Cap; Ran-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; ratio-Ramipril 15mg Cap; Apo-Desmopressin 0.1mg, 0.2mg Tab; Apo-Levofloxacin 250mg, 500mg Tab; Apo-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Co Levofloxacin 250mg, 500mg Tab; Co Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Gen-Levofloxacin 250mg, 500mg Tab; Novo-Azithromycin 20mg/ml, 40mg/ml Susp; Novo-Fentanyl 25mcg, 50mcg, 75mcg, 100mcg Patch; Novo-Levofloxacin 250mg, 500mg Tab; pms-Levofloxacin 250mg, 500mg Tab; Sandoz Levofloxacin 250mg, 500mg Tab; Sandoz Methylphenidate SR 20mg Tab; Apo-Glimepiride 1mg, 2mg, 4mg Tab; Apo-Raloxifene 60mg Tab; Celsentri 150mg, 300mg Tab; Gen-Leflunomide 10mg, 20mg Tab; Jamp-Loperamide 2mg Tab; Novo-Cyproterone/Ethinyl Estradiol 2mg/0.035mg Tab; Novo-Raloxifene 60mg Tab; Pamidronate Disodium Omega 3mg/ml, 9mg/ml Inj; Risperdal Consta 25mg, 37.5mg, 50mg Inj; Truvada 200/300mg Tab; Xarelto 10mg Tab; New Interchangeable Categories: Marvelon 21, Apri 21 0.15/0.03mg Tab; Marvelon 28, Apri 28 0.15/0.03mg Tab; Levaquin, Sandoz Levofloxacin, Apo-Levofloxacin, Co Levofloxacin, Gen-Levofloxacin, Novo-Levofloxacin, pms-Levofloxacin 250mg Tab; Levaquin, Sandoz Levofloxacin, Apo-Levofloxacin, Co Levofloxacin, Gen-Levofloxacin, Novo-Levofloxacin, pms-Levofloxacin 500mg Tab; Depo-Provera, Medroxyprogesterone Acetate Injectable Suspension 150mg/ml Inj; Adalat XL, Gen-Nifedipine 60mg Tab ER; Oxy IR, pms-Oxycodone 5mg Tab; Oxy IR, pms-Oxycodone 10mg Tab; Evista, Apo-Raloxifene, Novo-Raloxifene 60mg Tab; Altace, Apo-Ramipril, ratio-Ramipril 15mg Cap; New Interchangeable Products: Novo-Azithromycin 20mg/ml, 40mg/ml Oral Susp; Apo-Bicalutamide, Gen-Bicalutamide 50mg Tab; Apo-Cilazapril 1mg, 2.5mg, 5mg Tab; Novo-Cilazapril/HCTZ 5mg/12.5mg Tab; Jamp-Citalopram 20mg, 40mg Tab; Novo-Clonidine 0.025mg Tab; Novo-Cyproterone/Ethinyl Estradiol 2mg/0.035 Tab; Apo-Desmopressin 0.1mg, 0.2mg Tab; Apo-Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg Cap; Novo-Etidronatecal 400mg/500mg Tab; Co Famciclovir 125mg, 250mg, 500mg Tab; Novo-Fentanyl 25mcg, 50mcg, 75mcg, 100mcg Tab; Ran-Gabapentin 100mg, 300mg, 400mg Cap; Apo-Gabapentin 600mg Cap; Apo-Glimepiride 1mg, 2mg, 4mg Tab; Gen-Leflunomide 10mg, 20mg Tab; Jamp-Loperamide 2mg Tab; Sandoz Methylphenidate SR 20mg Tab; Novo-Morphine SR 15mg, 30mg Tab; Gen-Odansetron 4mg, 8mg Tab; Jamp-Ondansetron 4mg, 8mg Tab; Novo-Oxycodone/Acetaminophen 5mg/325mg Tab; pms-Oxycodone 20mg Tab; Pamidronate Disodium Omega 3mg/ml, 9mg/ml Inj; Apo-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5 mg Tab; Co Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Gen-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Ran Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Gen-Venlafaxine XR 37.5mg, 75mg, 150mg Cap; Product Deletions: Anturan 200mg Tab; Blocadren 20mg Tab; Cardizem 60mg Tab; C.E.S 1.25mg Tab; Cytoxan 1g, 2g Pws, 25mg Tab; Estalis-Sequi 250/50 mcg Patch; Kaletra 133.3/33.3mg Cap; Kenalog 1mg/g Oral Oint; Marinol 10mg Cap; M.O.S 5mg/ml Liq; Mycostatin 100,000 U/g Pwd; pms-Flavoxate 200mg Tab; pms-Nifedipine 10mg Cap; ratio-Fosinopril 10mg, 20mg Tab; Stemetil 5mg Tab; Surgam 300mg Tab; Surmontil 50mg Tab; Symmetrel 100mg Cap; Vitamin A 0.01%, 0.05%, 0.25%, 0.1% Crm; Vitamin B1 100mg Tab; Vitamin B6 25mg, 100mg Tab; Wellbutrin SR 100mg Tab; Westcort 0.2% Oint; Zaditen 1mg/5ml Oral Liq; Zyloprim 300mg Tab; Category Deletions: Allopurinol 300mg Tabs; Amantadine HCl 10mg/ml Syrup; Cylclophosphamide 50mg Tabs; Hydrocortisone Valerate 0.2% Oint; Interchangeable Product Price Changes: See Bulletin for Details; Discontinued Products: Apo-Loxapine 5mg, 10mg, 25mg, 50mg Tab; Apo-Phenylbutazone 100mg Tab; Covera-HS 180mg, 240mg Tab; Cytoxan 50mg Tab; Didronel 200mg Tab; Duricef 500mg Tab; Eligard 7.5mg Inj; Eprex 20,000 IU/ml Vial; Fucidin 250mg Tab; Heparin Leo 1,000 IU/ml Vial; Hycomine 1mg/ml Syrup; Megace 160mg Tab; Nimotop 30mg Cap; Nu-Alpraz 0.25mg, 0.5mg Tab; Nu-Bromazepam 1.5mg, 3mg, 6mg Tab; Novo-Cefaclor 250mg, 500mg Cap; Nu-Clonazepam 0.5mg, 1mg Tab; Nou-Ipratropium Plastic Ampoules 250mcg/ml Unit Dose Vial; Nu-Ketotifen 1mg/5ml Oral Liq; Nu-Loraz 0.5mg, 1mg, 2mg Tab; Nu-Loxapine 5mg, 10mg, 25mg, 50mg Tab; Nu-Prochlor 5mg, 10mg Tab; Nu-Salbutamol 2mg, 4mg Tab, 2.5ml/2.5ml, 5mg/2.5ml Nebulizer Sol; Nu-Cromolyn Plastic Ampoules 1% Nebulizer Sol; Nu-Temazepam 15mg, 30mg Cap; Nu-Cotrimex 40mg/200mg/5ml Oral Susp; pms-Digoxin 0.0625mg, 0.125mg, 0.25mg Tab; Sandoz Gliclazide 80mg Tab; Sibelium 5mg Cap; Symmetrel 10mg/ml Syrup; Ultravate 0.05% Oint;
Posted July 21, 2009
Newfoundland
NLPDP Bulletin #43, July 20, 2009
Highlights
Special Authorization Coverage for All Plans: EZ Health Talking Blood Glucose Test Strips 50, 100; EZ Health Lancets 100.
Posted July 21, 2009
Newfoundland
NLPDP Bulletin #42, July 17, 2009
Highlights
Notice to Providers: Coverage of Lucentis under the NLPDP is effective April 1, 2009.
Posted July 22, 2009
British Columbia
BC Pharmacare Newsletter Edition 09-009, July 17, 2009
Highlights
Frequency of Dispensing - Pharmanet Solution Details. Benefits: Apo-Raloxifene 60mg Tab; Novo-Raloxifene 60mg Tab. New interchangeable: Evista 60mg Tab as of Aug 20, 2009
Posted July 1, 2009
Alberta
AEIDBS Quarterly Update July 1, 2009
Highlights
Highlights to follow shortly
Posted July 1, 2009
Alberta
Alberta DBL Quarterly Update July 1, 2009
Highlights
Additions: Altace 1.25mg Cap; Apo-Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Apo-Levocarb CR 100/25mg Tab SR; Apo-Lisinopril 5mg, 10mg, 20mg Tab; Apo-Pravastatin 10mg, 20mg, 40mg Tab; Apo-Ramipril 1.25mg Cap; Co Lisinopril 5mg, 10mg, 20mg Tab; Co Pravastatin 10mg, 20mg, 40mg Tab; Co Ramipril 1.25mg Cap; Gen-Lisinopril 5mg, 10mg, 20mg Tab; Gen-Pravastatin 10mg, 20mg, 40mg Tab; Gen-Ramipril 1.25mg Cap; Medroxyprogesterone Acetate 150mg/ml Inj; Micardis Plus 80mg/25mg Tab; Mint-Lisinopril 5mg, 10mg, 20mg Tab; Mint-Pravastatin 10mg, 20mg, 40mg Tab; Novo-Azithromycin 20mg/ml, 40mg/ml O/Susp; Novo-Diltiazem HCL 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Novo-Lisinopril Type P 5mg, 10mg, 20mg Tab; Novo-Lisinopril Type Z 5mg Tab; Novo-Lisinopril 10mg, 20mg, Tab; Novo-Pravastatin 10mg, 20mg, 40mg Tab; Nu-Pravastatin 10mg, 20mg, 40mg Tab; Pravachol 10mg, 20mg, 40mg Tab; PMS-Azithromycin 20mg/ml, 40mg/ml O/Susp; PMS-Lisinopril 5mg, 10mg, 20mg Tab; PMS-Oxycodone 5mg, 10mg, 20mg Tab; PMS-Pravastatin 10mg, 20mg, 40mg Tab; Prinivil 5mg, 10mg, 20mg Tab; Ran-Lisinopril 5mg, 10mg, 20mg Tab; Ramipril 1.25mg Cap; Ran-Pravastatin 10mg, 20mg, 40mg Tab; Ran-Ramipril 1.25mg Cap; Ratio-Pravastatin 10mg, 20mg, 40mg Tab; Ratio-Lisinopril P 5mg, 10mg, 20mg Tab; Ratio-Lisinopril Z 5mg, 10mg, 20mg Tab; Ratio-Ramipril 1.25mg Cap; Sandoz Diltiazem T 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Sandoz Lisinopril 5mg, 10mg, 20mg Tab; Sandoz Methylphenidate 20mg Tab ER; Sandoz Pravastatin 10mg, 20mg, 40mg Tab; Sandoz Ramipril 1.25mg Tab; Sinemet CR 100/25 100mg/25mg Tab SR; Supeudol 5mg, 10mg, 20mg Tab; Tiazac 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Xamiol 50mcg/g Top Gel; Zestril 5mg, 10mg, 20mg Tab; Zithromax 20mg/ml, 40mg/ml O/Susp; Change in Status from Special Authorization to Unrestricted: Amatine 2.5mg, 5mg Tab; Apo-Midodrine 2.5mg, 5mg Tab; Co Etidronate 200mg Tab; Cosopt Preservative-Free 2%/0.5% Oph Sol; Didronel 200mg Tab; Flovent HFA 50mcg/Dose Metered Dose Aer; Gen-Etidronate 200mg Tab; Mepron 150mg/ml O/Susp; Trusopt (Preservative-Free) 2% Oph Sol; Deleted Listings: Norflex 30mg/ml Inj; Discontinued Listings: Estracomb 50mcg/day / 250mcg/day / 50mcg/day Trans Patch; Fenomax 160mg Cap; Levate 75mg Tab; Nu-Prochlor 5mg, 10mg Tab; Sandoz Risperidone 0.25mg Tab; Restricted Benefits: Viread 300mg Tab; Change in Status from Unrestricted to Restricted: Apo-Cyclobenzaprine 10mg Tab; Dom-Cyclobenzaprine 10mg Tab; Gen-Cyclobenzaprine 10mg Tab; Novo-Cycloprine 10mg Tab; Nu-Cycloprine 10mg Tab; PMS-Cyclobenzaprine 10mg Tab; Ratio-Cyclobenzaprine 10mg Tab; Change in Status from Special Authorization to Restricted: Apo-Leflunomide 10mg, 20mg Tab; Arava 10mg, 20mg Tab; Novo-Leflunomide 10mg, 20mg Tab; Sandoz-Leflunomide 10mg, 20mg Tab; Special Authorization: Drug Products with Changes to Criteria for Coverage: Aricept 5mg, 10mg Tab; Exelon 1.5mg, 3mg, 4.5mg, 6mg, Cap, 2mg/ml O/Sol; Reminyl ER 8mg, 16mg, 24mg Cap ER; Deleted Listings: Duovent UDV 0.125mg/ml / 0.3125mg/ml Inh Sol; Optional Special Authorization: Additional Brands or Strengths of Drug Products Already Available by Optional Special Authorization: Mint-Ciprofloxacin 250mg, 500mg, 750mg Tab; New Drug Products Available Under the Multiple Sclerosis Drug Coverage Program: Tysabri 20mg/ml Inj; Special Authorization Additions: Apo-Alendronate 10mg, 70mg Tab; Co Alendronate 40mg, 70mg Tab; Gen-Alendronate 10mg, 70mg Tab; Novo-Alendronate 10mg, 70mg Tab; PMS-Alendronate-FC 70mg Tab; Ratio-Alendronate 70mg Tab; Sandoz Alendronate 10mg, 70mg Tab; Fosamax 10mg, 40mg, 70mg Tab; Apo-Alfuzosin 10mg Tab SR; Sandoz Alfuzosin 10mg Tab SR; Xatral 10mg Tab SR; Axert 6.25mg, 12.5mg Tab; Co Azithromycin 600mg Tab; PMS-Azithromycin 600mg Tab; Zithromax 600mg Tab; Benoxyl 10%, 20% Lot; Panoxyl 10%, 20% Gel, 10% Bar; Entocort 3mg Cap CR; Suprefact Intranasal 1mg/ml Nas Sol; Suprefact 1mg/ml Inj; Suprefact Depot 6.3mg Inj Imp; Co Cabergoline 0.5mg Tab; Dostinex 0.5mg Tab; Celebrex 100mg, 200mg Cap; Benzaclin 1%, 5% Top Gel; Clindoxyl 1%, 5% Top Gel; Neoral 10mg, 25mg, 50mg, 100mg Cap, 100mg/ml O/Sol; Sandoz Cyclosporine 25mg, 50mg, 100mg Cap; Apo-Cyclosporine 100mg/ml O/Sol; Androcur 50mg Tab; Androcur Depot 100mg/ml Inj; Apo-Cyproterone 50mg Tab; Gen-Cyproterone 50mg Tab; Exjade 125mg, 250mg, 500mg Dispersible Tab for Susp; Apo-Diltiaz SR 60mg, 90mg, 120mg Cap SR; Aricept 5mg, 10mg Tab; Stievamycin Mild, Reg, Forte 0.01%, 0.025%, 0.05% Top Gel; Ezetrol 10mg Tab; Ratio-Fentanyl 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Ran-Fentanyl 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Duragesic 12, 25, 50, 75, 100 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Patch; Fentanyl Citrate 0.05mg/ml Inj; Apo-Flutamide 250mg Tab; Euflex 250mg Tab; Novo-Flutamide 250mg Tab; PMS-Flutamide 250mg Tab; Reminyl ER 8mg, 16mg, 24mg Cap ER; Zoladex 3.6mg/Syr Inj Syr; Zoladex LA 10.8mg/Syr Inj Syr; Aldara 50mcg/g Top Crm; PMS-Ipratropium 125mcg/ml, 250mcg/ml (1ml, 2ml) Inh Unit Dose Sol; Ratio-Ipratropium UDV 125mcg/ml, 250mcg/ml Inh Unit Dose Sol; Gen-Ipratropium Sterinebs 250mcg/ml Inh Unit Dose Sol; Somatuline Autogel 60mg/Syr, 90mg/Syr, 120mg/Syr Inj Syringe; Lupron Depot 3.75mg/Vial, 5mg/Vial, 7.5mg/Vial, 11.25mg/Vial, 22.5mg/Vial Inj; Carnitor 330mg Tab, 100mg/ml O/Sol, 200mg/ml Inj; Megace OS 40mg/ml O/Susp; Megace 160mg Tab; Apo-Megestrol 40mg, 160mg Tab; Nu-Megestrol 40mg, 160mg Tab; Medrol Acne 2.5mg/ml, 50mg/ml, 100mg/ml Top Lot; Neo-Medrol Acne 2.5mg/ml, 2.5mg/ml, 100mg/ml, 50mg/ml Top Lot; Apo-Modafil 100mg Tab; Alertec 100mg Tab; Singulair 10mg Tab; 5mg Chew Tab; Amerge 1mg, 2.5mg Tab; Octreotide Acetate Omega 50mcg/ml, 100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Sandostatin 50mcg/ml, 100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Octreotide100mcg/ml, 200mcg/ml, 500mcg/ml Inj; Sandostatin LAR 10mg/Vial, 20mg/Vial, 30mg/Vial Inj; Papaverine Hcl 32.5mg/ml Inj; Norprolac 0.075mg 0.15mg Tab; Evista 60mg Tab; Mycobutin 150mg Cap; Actonel 5mg, 30mg, 35mg Tab; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap, 2mg/ml O/Sol; Maxalt 5mg, 10mg Tab; Maxalt Rpd 5mg, 10mg O/Wafer; Humatrope 6mg/Vial, 12mg/Vial Inj; Saizen 3.3mg/Vial, 5mg/Vial, 8.8mg/Vial Inj; Sulfacet-R 5%, 10% Top Lot; Imitrex 5mg/Dose, 20mg/Dose Unit Dose Nas Spr; Apo-Sumatriptan 50mg, 100mg Tab; Co Sumatriptan 50mg, 100mg Tab; Gen-Sumatriptan 50mg, 100mg Tab; Novo-Sumatriptan 100mg; Novo-Sumatriptan DF 50mg, 100mg Tab; PMS-Sumatriptan 50mg, 100mg Tab; Ratio-Sumatriptan 50mg, 100mg Tab; Sandoz Sumatriptan 50mg, 100mg Tab; Imitrex DF 50mg, 100mg Tab; Imitrex 6mg/Syringe; Apo-Calcitonin 200IU/Dose Metered Dose Nas Spr; Sandoz Calcitonin NS 200IU/Dose Metered Dose Nasal Spr; Miacalcin 200IU/Dose Metered Dose Spr; Protopic 0.1%, 0.3% Top Oint; Androderm 2.5mg/day, 5mg/day Trans Patch; Andriol 40mg Cap; Nitoman 25mg Tab; Apo-Tizanidine 4mg Tab; Gen-Tizanidine 4mg Tab; Zanaflex 4mg Tab; Detrol LA 2mg, 4mg Cap ER; Stieva-A, Stieva-A Forte 0.01%, 0.025%, 0.05%, 0.1% Top Crm, 0.025% Top Sol; Retin-A 0.05%, 0.1% Top Crm, 0.01%, 0.025% Top Gel; Vitamin A Acid 0.01%, 0.025%, 0.05% Top Gel; Trosec 20mg Tab; Accolate 20mg Tab; Zometa Concentrate 0.8mg/ml Inj; Zomig 2.5mg Tab, 5mg/Dose Unit Dose Nas Spr; Zomig Rapimelt 2.5mg Dispersible Tab; Optional Special Authorization Additions: Apo-Ciproflox 250mg, 500mg, 750mg Tab; Co Ciprofloxacin 250mg, 500mg, 750mg Tab; Gen-Ciprofloxacin 250mg, 500mg, 750mg Tab; Novo-Ciprofloxacin 250mg, 500mg, 750mg Tab; PMS-Ciprofloxacin 250mg, 500mg, 750mg Tab; Ran-Ciproflox 250mg, 500mg, 750mg Tab; Ran-Ciprofloxacin 250mg, 500mg, 750mg Tab; Ratio-Ciprofloxacin 250mg, 500mg, 750mg Tab; Sandoz Ciprofloxacin 250mg, 500mg, 750mg Tab; Taro-Ciprofloxacin 250mg, 500mg Tab; Cipro 250mg, 500mg, 750mg Tab; Multiple Sclerosis Drug Coverage Additions:Tysabri 20mg/ml Inj;
Posted July 10, 2009
Prince Edward Island
PEI MAC Memo July 8, 2009
Highlights
New Interchangeable/MAC Categories: Prevacid 15mg, 30mg Cap DR; APO-Lansoprazole 15mg, 30mg Cap DR; Levaquin 250mg, 500mg, 750mg Tab; Novo-Levofloxacin 250mg, 500mg, 750mg Tab; PMS-Levofloxacin 250mg, 500mg, 750mg Tab; APO-Levofloxacin 250mg, 500mg, 750mg Tab; Sandoz Levofloxacin 250mg, 500mg, 750mg Tab; GEN-Levofloxacin 250mg, 500mg Tab; CO Levofloxacin 250mg, 500mg, 750mg Tab. Products added to the Interchangeable/MAC list: APO-Methylphenidate SR 20mg Tab SR; CO Ondansetron 4mg, 8mg Tab; Novo-Benzydamine 0.15% O/L; Novo-Etidronatecal 400mg/500mg Tab; Ratio-Ramipril 15mg Cap. Changes to MAC Prices: Altace 15mg Cap; APO-Ramipril 15mg Cap; Ratio-Ramipril 15mg Cap. Deleted Interchangeable/MAC Categories: Nizoral 2% Top Crm; Ketoderm 2% Top Crm. Discontinued Products: Novo-Benzydamine 0.15% O/L; Sandoz Mirtazapine FC 30mg Tab.
Posted July 10, 2009
Newfoundland
Bulletin #40, July 8, 2009
Highlights
Update on 5mg Oxycodone Tab
Posted July 10, 2009
Newfoundland
Bulletin #39, July 7, 2009
Highlights
Products added as open benefits under The Foundation Plan, The 65Plus Plan, The Access Plan, and The Assurance Plan, effective July 1 2009: PMS-Oxycodone 10mg, 20mg Tab; Oxy-IR 10mg, 20mg Tab.
Posted July 10, 2009
New Brunswick
Benefit changes to NBPDP, Bulletin #757, July 7, 2009
Highlights
Special Authorization Additions: Zyprexa Zydis 20mg Tab; Andriol 40mg Cap; Androderm 12.2mg, 24.3mg Patches; Androgel 2.5g, 5g Packets; Testim 1% gel. Special Authorization – Revised Criteria: Imitrex, Imitrex DF and generic brands 50mg, 100mg Tab; Axert 6.25mg, 12.5mg Tab; Amerge 1mg, 2.5mg Tab; Maxalt and Maxalt RDP 5mg, 10mg Tab; Imitrex 5mg, 20mg Nasal Spray; Zomig and Zomig Rapidmelt 2.5mg Tab; Zomig 2.5mg, 5mg Nasal Spray; Imitrex 6mg Injection. Drugs Reviewed and Not Listed: Clindoxyl 5% Gel, Levaquin 750mg Tab.
Posted July 10, 2009
New Brunswick
Benefit Changes to NBPDP, Bulletin #755, June 24, 2009
Highlights
NBPDP Benefit Additions: Apo-Oxycodone/Acet 325mg/5mg Tab; Novo-Cilazapril/HCTZ 5mg/12.5mg Tab; Gen-Eti-Cal Carepac 400mg/500mg Tab; Novo-Etidronatecal 400mg/500mg Tab; Novo-Fentanyl 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Pad; Super Strength Motrin IB 400mg Tab; Pms-Ibuprofen 400mg Tab; Novo-Profen 600mg Tab; Pms-Ibuprofen 600mg Tab; Apo-Lansoprazole 15mg, 30mg Cap SR; Apo-Levocarb CR 100mg/25mg Tab SR; Apo-Levofloxacin 250mg, 500mg Tab; Co-Levofloxacin 250mg, 500mg Tab; Gen-Levofloxacin 250mg, 500mg Tab; Novo-Levofloxacin (relisting) 250mg, 500mg Tab; Pms-Levofloxacin 250mg, 500mg Tab; Sandoz-Levofloxacin 250mg, 500mg Tab; Sandoz-Medroxyprogesterone Acetate 150mg/ml Inj Susp; Sandoz-Methylphenidate SR 20mg Tab SR; Novo-Morphine SR 15mg, 30mg Tab SR; Pms-Omeprazole 20mg Cap SR; Co-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Apo-Raloxifene 60mg Tab; Novo-Raloxifene 60mg Tab; Apo-Ramipril 15mg Cap; Non-Listed Products Subject to Map: Sandoz-Alfuzosin 10mg Tab ER; Motrin IB 200mg Tab; Novo-Profen 200mg Tab; Apo-Levofloxacin 750mg Tab; Co-Levofloxacin 750mg Tab; Pms-Levofloxacin 750mg Tab; Sandoz-Levofloxacin 750mg Tab; Mint-Topiramate 25mg, 100mg, 200mg Tab;
Posted July 3, 2009
New Brunswick
Benefit Changes to NBPDP, Bulletin #756, June 29, 2009
Highlights
Regular Benefit Additions: Dalacin C 300mg Cap; Novo-Clindamycin 300mg Cap; Apo-Clindamycin 300mg Cap; Gen-Clindamycin 300mg Cap; Pms-Clindamycin 300mg Cap; Apidra 10ml Vial, 3ml Cartridge, 3ml optiset; Apidra Solostar 3ml pre-filled disposable; Drugs No Longer Requiring Special Authorization: Atripla 200mg, 300mg, 600mg Tab; Truvada 200mg, 300mg Tab; Special Authorization Additions: Volibris 5mg, 10mg Tab; Apidra 100IU/ml vials and SoloSTAR pre-filled pens; Xarelto 10mg Tab; Drugs Reviewed and Not Listed: Pradax 75mg, 110mg Cap; Relistor 20mg/ml Vial; Thelin 100mg Tab; Xyrem 500mg/ml Oral Sol.;
Posted July 3, 2009
New Brunswick
New Brunswick Formulary Volume 51, Update No.1, June 24, 2009
Highlights
Interchangeable Additions: Apo-Oxycodone/Acet 325mg/5mg Tab; Sandoz-Alfuzosin 10mg Tab ER; Novo-Cilazapril/HCTZ 5mg/12.5mg Tab; Gen-Eti-Cal Carepac 400mg/500mg Tab; Novo-Etidronatecal 400mg/500mg Tab; Novo-Fentanyl 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr Trans Pad; Motrin IB 200mg Tab; Novo-Profen 200mg Tab; Super Strength Motrin IB 400mg Tab; Pms-Ibuprofen 400mg Tab; Novo-Profen 600mg Tab; Pms-Ibuprofen 600mg Tab; Prevacid 15mg, 30mg Cap SR; Apo-Lansoprazole 15mg, 30mg Cap SR; Sinemet CR 100mg/25mg Tab SR; Apo-Levocarb CR 100mg/25mg Tab SR; Levaquin 250mg, 500mg, 750mg Tab; Apo-Levofloxacin 250mg, 500mg, 750mg Tab; Co-Levofloxacin 250mg, 500mg, 750mg Tab; Gen-Levofloxacin 250mg, 500mg Tab; Novo-Levofloxacin (relisting) 250mg, 500mg Tab; Pms-Levofloxacin 250mg, 500mg, 750mg Tab; Sandoz-Levofloxacin 250mg, 500mg, 750mg Tab; Depo-Provera 150mg/ml Inj Susp; Sandoz-Medroxyprogesterone Acetate 150mg/ml Inj Susp; Sandoz-Methylphenidate SR 20mg Tab SR; Novo-Morphine SR 15mg, 30mg Tab SR; Pms-Omeprazole 20mg Cap SR; Co-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Evista 60mg Tab; Apo-Raloxifene 60mg Tab; Novo-Raloxifene 60mg Tab; Altace 15mg Cap; Apo-Ramipril 15mg Cap; Mint-Topiramate 25mg, 100mg, 200mg Tab;
Posted July 3, 2009
New Brunswick
NBPDP Formulary June 2009
Highlights
Full Formulary Release
Posted June 29, 2009
Saskatchewan
Saskatchewan Formulary Update Bulletin #119, July 2009
Highlights
New Full Formulary Listings: YAZ 0.02mg/3mg Tab; Lipidil EZ 48mg, 145mg Tab; New Exception Drug Status Listings Effective July 1, 2009: Cymbalta 30mg, 60mg Cap DR; Telzir 50mg/ml Oral Susp; Levemir 100U/ml Inj Sol; Tysabri 20mg/ml IV Sol; Tecta 40mg Ent Tab; Lyrica 25mg, 50mg, 75mg, 150mg, 300mg Cap; Revised Exception Drug Status Criteria: Botox 100IU Pwd; NovoRapid 100U/ml (5x3ml), (10ml) Inj Sol; Apidra 100U/ml (10ml), Pre-filled pen SoloSTAR (3ml) Inj Sol; Humalog 100U/ml (5x3ml), (10ml) Inj Sol; Spiriva 18ug/dose Pwd Cap; New Interchangeable Full Formulary or EDS Listings Effective June 1, 2009: Novo Cilazapril/HCTZ 5mg/12.5mg Tab; Apri 0.03mg/0.15mg Tab; Novo-Fentanyl 25ug/hr, 50ug/hr, 75ug/hr, 100ug/hr Transdermal System; Sandoz Medroxyprogesterone Acetate 150mg/ml (1ml) Inj Susp; Sandoz Methylphenidate SR 20mg Tab SR; Pms-Omeprazole DR 20mg Cap; Co Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Apo-Raloxifene 60mg; Jamp-Vitamin B1 50mg, 100mg Tab; New Interchangeable Full Formulary or EDS Listings Effective July 1, 2009: Sig-Enalapril 2.5mg, 5mg, 10mg, 20mg Tab; Novo-Etidronatecal 400mg/1250mg Tab; Jamp-Ibuprofen 400mg Tab; Apo-Lansoprazole 15mg, 30mg Cap DR; Apo-Levocarb CR Tab CR; Novo-Levofloxacin 250mg, 500mg Tab; Pms-Levofloxacin 250mg, 500mg, 750mg Tab; Accel Pioglitazone 15mg, 30mg, 45mg Tab; From the Advisory Committee On Institutional Pharmacy Practice: Lovenox 30mg/ml, 40mg/ml, 60mg/ml, 80mg/ml, 100mg/ml Syr; Xarelto 10mg Tab;
Posted June 26, 2009
NIHB
NIHB Updates to the Drug Benefit List Spring 2009
Highlights
Additions to the Open Benefit List: Single Source Drug Products: Citro Mag 15gm/300ml O/L; DDAVP Melt 240mg Cap; Jamp-Docusate Calcium 240mg Cap; Omniflex Diaphragm 75; Sterile Water for Injection; Super-Fine Micro 31G-5MM Needle; Super-Fine Standard 29G-12.7MM Needle; Super-Fine Xtra 31G-8MM Needle; Multi-Source Drug Products: 167 Products Added See Bulletin for Details; New Limited Use Benefits: Single-Source Drug Products: Humira 40mg/0.8ml Prefilled Pen; Atripla 600/300/200mg Tab; Multi-Source Products: Alendronate 70mg Tab; Zym-Alendronate FC 70mg Tab; Gen-Leflunomide 10mg, 20mg Tab; Pro-Pioglitazone 15mg, 30mg, 45mg Tab; Gen-Tamsulosin 0.4mg Tab; Changes in Benefit Status: Premarin 0.3mg, 0.625mg, 0.9mg, 1.25mg Tab; Delisting of Glucometers: Accu-Chek Compact; Accu-Chek Compact Plus; Accusoft; Accutrend GC; Ascensia Breeze; Ascensia Contour; Ascensia Elite; Ascensia Elite XL; BD Latitude; Dex; Freestyle; Freestyle Mini; Induo; One Touch Fasttake; One Touch Ultra; One Touch Ultrasmart; Precision QID; Precision QID Colour W/O Electrodes Blue; Precision QID Colour W/O Electrodes Red; Precision QID Pen; Precision QID W/O Electrodes; Precision Xtra; Prestige Smart System; ;Not Added to Formulary: Adderall XR 10mg, 15mg, 20mg, 25mg, 30mg, 5mg Cap ER; Fosrenol 250mg, 500mg, 750mg, 1000mg Chew Tab; Invega 3mg, 6mg, 9mg, 12mg Tab ER, Januvia 100mg Tab; Levemir, Pro-Diclo Rapide 50mg Tab; Pro-ISMN 60mg Latablet; Pro-Quinine 200mg Cap; Ralivia 100mg, 200mg, 300mg Tab ER; Rasilez 150mg, 300mg Tab; Zyprexa 20mg Tab; Zyprexa Zydis 20mg Tab; Indications not added to the NIHB Drug Benefit List: Botox; Drugs Discontinued by the Manufacturer: Apo-Loxapine 5mg, 10mg, 25mg, 50mg Tab; Eprex 20,000 IU/ml Inj; Sibelium 5mg Cap; Acetylsalicylic Acid 80mg DR Tab; Apo-Alfluzosin ER 10mg Tab; Apo-ASA 325mg Tab; Apo-ASEN 325mg Tab; Apo-Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg ER Cap; ASA 325mg Tab; ASA 81mg Tab; Asadol 650mg Tab; Asaphen 80mg Chew Tab; Asaphen 80mg, 162mg EC Tab; Aspirin 325mg Coated Tab; Aspirin 325mg Tab; Aspirin 81mg ECT; Baby Aspirin 80mg Tab; Ent Coated ASA 650mg Tab; Entrophen 81mg Tab; Entrophen-10 650mg EC Tab; Entrophen-5 325mg EC Tab; Euro-ASA Chew Tab; Gen-Ramipril 1.25mg, 2,5mg, 5mg, 10mg Cap; Life Brand ASA 81mg Tab; Novasen ECT 650mg Tab; Novasen 325mg Tab; pms-ASA EC 325mg, 650mg Tab; pms-Cetirizine 20mg Tab; Ran Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Riva-Metoprolol L 25mg, 50mg, 100mg Tab; Riva-Oxybutynin 5mg Tab; Riva-Pantoprazole 40mg Tab; Rivasa 80mg Chew Tab; Rivasa 80mg Tab; Sandoz Alfuzosin 10mg Tab; Sandoz-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Sandoz-Rabeprazole 10mg, 20mg EC Tab; Zym-Pantoprazole 40mg Tab; Removals from the Short-Term Dispensing Policy Drug List: Acetaminophen 160mg/5ml, 80mg/5ml; Atasol 80mg/ml Drops; Feverhalt 80mg/ml Drops; Pediaphen 80mg/5ml, 160/5ml Liq; Pediaphen 80mg/5ml Drops; Pediatrix 80mg/ml, 160mg/5ml Liq; pms-Acetaminophen 160mg/5ml, 80mg/5ml Liq; pms-Acetaminophen 80mg/ml Drops; Robigesic Elixir 80mg/5ml; Tantaphen Acet Inf Drops; Tempra 160mg/5ml, 80mg/5ml Syrup; Tempra 80mg/ml Drops; Tylenol 160mg/5ml Liq; Tylenol 80mg/ml Drops;
Posted June 26, 2009
Newfoundland
NDIPF Volume 56, effective July 1, 2009
Highlights
Full Interchangeable Drug Formulary Release
Posted June 22, 2009
British Columbia
BC Pharmacare Newsletter, Edition #09-008, June 19, 2009
Highlights
New Drugs Categorized to LCA and/or RDP: Gen-Nifedipine SL 60mg Tab. Benefits: Apidra 100IU/ml vial, 100IU/ml pen. Limited Coverage Program: Stalevo 50mg/12.5mg/200mg, 100mg/25mg/200mg, 150mg/37.5mg/200mg Tab; Risperdal Consta 12.5mg Powder for injection.
Posted June 19, 2009
Nova Scotia
NS Pharmacare Bulletin Vol #09-05, June 2009
Highlights
New Product Added to the NS Formulary: Atacand 32mg Tab. New Diabetic Products: Insupen 29g x 12mm, 30g x 8mm, 31g x 6mm, 31g x 8mm, 32g x 6mm, 32g x 8mm. New Diabetic Products – Special MAC: EZ Health Lancets 100; EZ Oracle Test Strips 100. Exceptions Status Criteria of New Benefits: Apidra 3mL prefilled pen 10mL Vial; Viread 300mg Tab. Addition to Exception Status Criteria for Tacrolimus: Protopic 0.1% Oint. Non-Insured Products: Adalat XL Plus 81mg & 20mg Tab Kit, 81mg & 30mg Tab Kit, 81 & 60mg Tab Kit. Delisted Products: Premarin 0.3mg Tab, 0.625mg Tab, 1.25mg Tab; Premplus 0.625/2.5mg Tab, 0.625/5mg Tab; Co Sumatriptan 25mg Tab; Gen-Sumatriptan 25mg Tab; Imitrex DF 25mg Tab; Novo Sumatriptan DF 25mg Tab; pms-Sumatriptan 25mg Tab. Discontinued Products: Cytoxan 25mg Tab, 50mg Tab; Gravol 10mg/mL IV Inj; Vaseretic 5/12.5mg Tab; Sibelium 5mg Cap; Lidex 0.05% Cr, 0.05% Oint; pms-Methotrimeprazine 5mg Tab; Tobramycin 40mg/mL Inj; Kenalog in Orabase 0.1% Oral Paste.
Posted June 16, 2009
Ontario
ODB Update J, Edition 41, June 23, 3009
Highlights
New Single Source Drugs: Actonel 150mg Tab; Fosavance 70mg/140mcg Tab; Levemir Penfill 100U/ml Inj Sol-5x3ml pk; Xarelto 10mg Tab; New Multi Source Drugs: Co-Pramipexole 0.25mg, 1mg, 1.5mg Tab; Novo-Azithromycin Pedriatric 100mg/5ml, 200mg/5ml O/L 15ml-pk; Novo-Azithromycin Pedriatric 200mg/5ml O/L 22.5ml-pk; Novo-Morphine SR 30mg ER Tab; Pms-Omeprazole DR 20mg Cap; Pms-Oxycodone-Acetaminophen 5mg and 325mg Tab; Manufacturer Requested Discontinued Drugs: Capoten 12.5mg Tab; Duricef 500mg Cap; Endantadine 100mg Cap; Vitamin B6 25mg Tab; Delisted Drugs: Nu-Cromolyn 1% Inh-Sol 2-ml pk; Nu-Cotrimax 40mg and 8mg/ml O/L; Nu-Loxapine 5mg, 10mg, 25mg, 50mg Tab; Nu-Prochlor 5mg, 10mg Tab; Drug Benefit Prices: Apo-Cilazopril/HCTZ 5mg/12.5mg Tab; Apo-Fenofibrate 100mg Cap; Apo-Funisolide 0.025% Nas-Sp-25ml pk; Apo-Keto-E 50mg Ent Tab; Apo-Megestrol 160mg Tab; Apo-Methylphenidate SR 20mg ER Tab; Apo-Nifed 10mg Cap; Apo-Trimip 25mg, 50mg, 100mg Tab; Coversyl 2mg, 4mg, 8mg Tab; Coversyl Plus 4mg and 1.25mg Tab; Coversyl Plus LD 2mg and 0.625mg Tab; Didrocal 400mg/500mg Tab-90 Tablets Kit; Fosavance 70mg/70mcg Tab; MacroBID 100mg Cap; Novolin ge 30/70 1000U/10ml Inj Susp-10ml pk; Novolin ge 30/70 Penfill 100U/ml Inj Susp-5x3ml pk; Novolin ge 40/60 Penfill 100U/ml Inj Susp-5x3ml pk; Novolin ge 50/50 Penfill 100U/ml Inj Susp-5x3ml pk; Novolin ge NPH 1000U/10ml Inj Susp-10ml pk; Novolin ge NPH penfill 100U/ml Inj Susp-5x3ml pk; Novolin ge Toronto 1000U/10ml Inj Sol-10ml pk; Novolin ge Toronto Penfill 100U/ml Inj Sol-5x3ml pk; NovoMix 30 Penfill 100U/ml Inj Susp-5x3ml pk; NovoRapid 100U/ml Inj Sol-10ml pk; NovoRapid Penfill 100U/ml Inj Sol-5x3ml pk; Suprax 400mg Tab; Vagifem 25mcg Vag Tab; Therapeutic Notes: Fosavance 70mg/70mcg Tab; Off Formulary Interchangeable Products: Apo-Ipravent 0.06% Nas Sp; Apo-Ramipril 15mg Cap; Apo-Zidovudine 100mg Cap; Co-Pramipexole 0.5mg Tab; Ratio-Ramipril 15mg Cap; Trade Name Changes: Contour Blood Glucose Strip; Gen-Nifedipine Extended Release 60mg ER Tab; Consolidated Index: See Bulletin
Posted June 8, 2009
Prince Edward Island
PEI MAC Memo June 2009
Highlights
Interchangeable/Maximum Allowable Cost List Changes: Zyloprim 300mg Tab; Novo-Purol 300mg Tab; Apo-Allopurinol 300mg Tab; Apo-Bromocriptine 5mg Cap; Pms-Bromocriptine 5mg Cap; Gravol 10mg/ml, 50mg/ml IV Inj Sol; Dimenhydrinate 10mg/ml, 50mg/ml IV Inj Sol; Gravol 50mg, 100mg Supp; Dimenhydrinate 50mg, 100mg Supp; Duragesic 25ug/hr, 50ug/hr, 75ug/hr, 100ug/hr Transdermal Patch; Duragesic Mat 25ug/hr, 50ug/hr, 75ug/hr, 100ug/hr Transdermal Patch; Novo-Fentanyl 25ug/hr, 50ug/hr, 75ug/hr, 100ug/hr Transdermal Patch; Ferrous Gluconate 300mg Tab; Ferrous Sulphate 300mg Tab; Apo-Nadol 40mg, 80mg Tab; Novo-Nadolol 40mg, 80mg Tab; Optimyxin 10000u & 500u/g Opth Oint; Optimyxin 10000u & 0.025mg/ml Opth/Otic Sol; Polysporin 10000u & 500u/g Opth Oint; Polysporin 10000u & 0.025mg/ml Opth/Otic Sol; Altace 15mg Cap; Apo-Ramipril 15mg Cap; Senokot 8.6mg Tab; Pms-Sennosides 8.6mg Tab; Sandoz-Sennosides 8.6mg Tab;
Posted June 3, 2009
Nova Scotia
NS Pharmacare Bulletin , Vol #09-04, May 2009
Highlights
Exception Status Criteria of New Benefits: Volibris 5mg Tab, 10mg Tab; Xarelto 10mg Tab. Non-Insured Products: Pradax 75mg Cap, 110mg Cap; Relistor 20mg/ml Injection.
Posted June 3, 2009
Newfoundland
NIDPF New Categories and Additions Vol 55, Bulletin No 31, June 1, 2009
Highlights
New Category: Raloxifene Hydrochloride, 60mg: Apo-Raloxifene Tab, Evista Tab; Additions to Existing Categories: Ratio-Diltiazem CD 120mg, 180mg, 240mg, 300mg Cap; Novo-Cilazapril/HCTZ 5mg/12.5mg Tab; Pms-Ibuprofen 400mg, 600mg Tab; Pms-Omeprazole 20mg Cap; Novo-Etidronatecal 400mg/500mg Tab; MINT-Topiramate 25mg, 100mg, 200mg Tab; Ran-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Ran-Lisinopril 5mg, 10mg, 20mg Tab; Ran-Ondansetron 4mg, 8mg Tab; Supeudol 10mg, 20mg Tab;
Posted June 3, 2009
Newfoundland
NLPDP Benefit Status Bulletin No. 30, June 1 2009
Highlights
Open Benefit for All Plans and Special Authorization for the Cystic Fibrosis Program: Ratio-Diltiazem CD 120mg, 180mg, 240mg, 300mg Cap; Novo-Cilazapril/HCTZ 5mg/12.5mg Tab; Pms-Ibuprofen 400mg, 600mg Tab; Pms-Omeprazole 20mg Cap; Novo-Etidronatecal 400mg/500mg Tab; Ran-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Ran-Lisinopril 5mg, 10mg, 20mg Tab; Supeudol 10mg, 20mg Tab; Special Authorization for All Plans and the Cystic Fibrosis Program: Apo-Raloxifene 60mg Tab; MINT-Topiramate 25mg, 100mg, 200mg Tab; Ran-Ondansetron 4mg, 8mg Tab;
Posted June 3, 2009
Quebec
Capsules CDM, June 1, 2009
Highlights
Addition to Formulary: Celsentri; Olmetec; Olmetec Plus; Revlimid; Xarelto; Zeftera; Declined due to economic and pharmacoeconomic reasons: Activelle LD; Alimta; Angeliq; Erbitux; Criteria Update: Aptivus; Intelence; Concerta; Renagel; Declined due to Cost: Velcade; Declined due to Therapeutic Value: Forteo; Duodopa;
Posted June 3, 2009
Quebec
CDM Express, Volume 6, #2 - June 2009
Highlights
See Bulletin for Details.
Posted June 3, 2009
British Columbia
BC Pharmacare Newsletter, Edition #09-007 - June 1, 2009
Highlights
Coverage of Zeldox described
Posted June 1, 2009
Alberta
Additions to AHWDBL, May 1, 2009
Highlights
Newly Interchangeable Products Affected by LCA Pricing: Gen-Clozapine 25mg, 100mg Tab; Apo-Clozapine 25mg, 100mg Tab; Clozaril 25mg, 100mg Tab.
Posted June 1, 2009
Nova Scotia
NS Pharmacare Bulletin , Vol #09-04, May 2009
Highlights
Exception Status Criteria of New Benefits: Volibris 5mg Tab, 10mg Tab; Xarelto 10mg Tab. Non-Insured Products: Pradax 75mg Cap, 110mg Cap; Relistor 20mg/ml Injection.
Posted June 1, 2009
Prince Edward Island
PEI MAC Memo May 4, 2009
Highlights
New Interchangeable/MAC Categories: PMS-Methylphenidate 5mg Tab; Apo-Methylphenidate 5mg Tab; Ritalin SR 20mg Tab SR; Sandoz Methylphenidate SR 20mg Tab SR. Products added to the Interchangeable/MAC list: Co Pramipexole 0.25mg, 0.5mg, 1.0mg, 1.5mg Tab; Pms-Omeprazole 20mg Cap. Changes to MAC Prices: Neoral 25mg, 50mg, 100mg Cap; Sandoz Cyclosporine 25mg, 50mg, 100mg Cap; Estradot 50UG, 75UG, 100UG Trans Pad; Sofracort 0.5MG & 0.05MG & 0.5MG per ml OPH/OTIC Solution; Depo-Medrol 40mg/ml (1ML), 40mg/ml (2ML), 80mg/ml (1ML) Inj; Methylprednisolone 40mg/ml (1ML), 40mg/ml (2ML), 80mg/ml (1ML) Inj; Pred Mild 0.12% OPH SUSP; Sandoz Prednisolone 0.12%; Pred Forte 1% OPH SUSP; Ratio-Prednisolone 1% OPH SUSP; Sandoz Prednisolone 1% OPH SOL; Diopred 1% OPH SUSP; Mychrysine 10mg/ml, 25mg/ml, 50mg/ml Inj; Sodium Aurothiomalate 10mg/ml, 25mg/ml, 50mg/ml Inj; Cyklokapron 100mg/ml Inj; Tranexamic Acid 100mg/ml Inj; Retrovir 100mg Cap; Apo-Zidovudine 100mg Cap. Deleted Interchangeable/MAC Categories: Ratio-Oxycodan 5MG & 325MG Tab; Percodan 5Mg & 325MG Tab; Apo-Prochlorazine 5mg, 10mg Tab; Nu-Prochlor 5mg, 10mg Tab. Discontinued Products: Capoten 12.5mg Tab.
Posted May 21, 2009
British Columbia
BC Pharmacare Newsletter, Edition #09-006, May 20, 2009
Highlights
Multi-Source Generics Pricing Policy Products-Changes to Cost Reduction Factors for Specific Products: Gen-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Apo-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Novo-Quetiapine 25mg, 100mg, 200mg, 300mg Tab;
Posted May 8, 2009
Ontario
ODB Edition 41, Update I, effective May 20, 2009
Highlights
Ontario Drug Benefit Formulary Update 1: Single Source Drugs: Atacand 32mg Tab; Humira 40mg/0.8mL Inj. Sol; New Multi-Source Drugs: Apo-Granisetron 1mg Tab; Apo-Ondansetron 4mg/5mL O/L; Apo-Raloxifene 60mg Tab; Novo-Cilazapril/HCTZ 5mg/12.5mg Tab; Novo-Etidronatecal 400mg/500mg Tab-90 Tablets Kit; Sandoz Methylphenidate SR 20mg ER Tab; Manufacturer Requested Discontinued Drugs: Didronel 200mg Tab; Dipentum 250mg Cap; Eprex 20,000IU/mL Inj. Sol-1mL Vial Pk; Magace 160mg Tab; Delisted Drugs: Apo-Cefaclor 375mg/5mL O/Susp; Nu-Fenofibrate 100mg Cap; Nu-Megestrol 160mg Tab; Nu-Nifed 10mg Cap; Nu-Trimipramine 25mg, 50mg, 100mg Tab; Ratio-Flunisolide Nasal Mist 0.025% Nas Sp-25mL Pk; New Drug Identification Numbers: Dipentum 250mg Cap; Drug Benefit Prices: Celexa 20mg, 40mg Tab; Cipralex 10mg, 20mg Tab; Fluanxol 0.5mg, 3mg Tab; Fluanxol Depot 20mg/mL, 100mg/mL Inj. Sol-1mL Amp Pk; New Manufacturer Names: Dipentum 250mg Cap; Not-A-Benefit Drugs: Premarin 0.625mg, 1.25mg Tab; Therapeutic Note Changes: Enbrel 50mg/mL Inj. Pref Syr; Off Formulary Interchangeable Products: Apo-Doxy-Tabs 100mg Tab; Cefepime for Injection 1g, 2g Inj. Pd-Vial Pk; Ondansetron Injection 2mg/mL Inj. Sol- 2mL, 4mL, 20mL Vial Pk; PMS-Tryptophan 500mg Tab; Sandoz Omeprazole 10mg DR Cap; Sandoz Pramipexole 0.5mg Tab; New Package Sizes: Fluanxol Depot 20mg/mL, 100mg/mL Inj. Sol-1mL Amp Pk; Limited Use Changes: Plavix 75mg Tab; Trade Name Changes: Ratio-Cyclobenzaprine 10mg Tab;
Posted May 8, 2009
Newfoundland
NLPDP Bulletin No. 27, May 1, 2009
Highlights
Benefit List Updates: Open Benefit (All Plans except CF): Diovan HCT 320mg/12.5mg, 320mg/25mg; Travatan Z 0.004% Oph Sol.; Tapazole 10mg; Special Authorization (All Plans): Pms-topiramate 50mg; Gen-clozapine 50mg, 200mg; Eprex 30,000 units; Volibris 5mg, 10mg; Viread 300mg; Xarelto 10mg; Celsentri 150mg, 300mg; Not Recommended (Non-Funded All Plans): Seasonale; Thelin 100mg; Relistor 20mg/ml Sol.; Xyrem 500mg/ml; Pradax 75mg, 110mg; Paliperidone 3mg, 6mg, 9mg;
Posted April 29, 2009
New Brunswick
Benefit Changes to NBPDP, Bulletin #750, April 24, 2009
Highlights
Regular Benefit Additions: Entocort 3mg Cap; CPT 30 30mg Tab; Resultz 50% Top Sol; Mezavant 1.2gm Tab; No longer requiring special authorization: Neurontin 100mg, 300mg, 400mg Cap and 600mg, 800mg Tab; pms-Gabapentin 100mg, 300mg, 400mg Cap and 600mg, 800mg Tab; Apo-Gabapentin 100mg, 300mg, 400mg Cap and 600mg, 800mg Tab; Novo-Gabapentin 100mg, 300mg, 400mg Cap and 600mg, 800mg Tab; Gen-Gabapentin 100mg, 300mg, 400mg Cap; Co-Gabapentin 100mg, 300mg, 400mg Cap; ratio-Gabapentin 100mg, 300mg, 400mg Cap; Revised Criteria: For LAAC and LABA in COPD; Spiriva 18mcg Inh Caps; Foradil 12mcg Inh Caps; Oxeze Turbohaler 6mcg, 12mcg Metered Dose Inhaler; Serevent Diskhaler Disk 25mcg/actuation Metered Dose Inhaler; Serevent Diskus 50mcg Discus; Symbicort Turbuhaler 6/100mcg, 6/200mcg Metered Dose Inhaler; Advair Diskus 50/100mcg, 50/250mcg, 50/500mcg Discus and 25/125mcg, 25/250mcg Metered Dose Inhaler; Drugs Reviewed and Not Listed: CyEstra-35 2mg/0.035 Tab; Humatrope (in idiopathic short stature) 5mg Vial and 6, 12, 24mg SC Inj Cartridge
Posted April 27, 2009
British Columbia
BC Pharmacare Newsletter Edition 09-005, April 23, 2009
Highlights
New Drugs Categorized to LCA and/or RDP: Ceftriaxone 1gm, 2gm Vial Inj USP; Co-Famciclovir 500mg Tab; Diopred 1%; Gen-Leflunomide 10mg, 20mg Tab; Jamp Citalopram 20mg, 40mg Tab; Jamp Enteric Coated ASA 650mg Tab; Jamp Ferrous Gluconate 300mg Tab; Jamp Ferrous Sulphate 75mg/ml, 150mg/ml Liquid and 300mg Tab; Jamp Ibuprofen 200mg Tab; Jamp Ondansetron 4mg, 8mg Tab; Mint Topiramate 25mg, 100mg, 200mg Tab; Novo Morphine SR 15mg, 30mg Tab; Pamidronate Disodium Omega 3mg/ml, 9mg/ml Vial; Pms-Ibuprofen 600mg Tab; Pms-Morphine Sulphate SR 100mg, 200mg Tab; Pms-Oxycodone IR 5mg, 10mg, 20mg Tab; Ran-Gabapentin 100mg, 300mg, 400mg Cap; Ran-Ondansetron 4mg, 8mg Tab; Sandoz Diclofenac 50mg, 100mg Supp; Thiamiject 100mg/ml Inj; Jamp Acetaminophen 500mg Tab; Jamp Lactulose 667mg/ml Sol; Pms-Buproprion SR 150mg Tab; New LCA Categories: Ceftriaxone 250mg, 10gm Inj USP; Rocephin 250mg, 10gm Pws Inj; Novo-Citalopram 10mg Tab; Pms-Citalopram 10mg Tab; Apo-Ibuprofen 400mg Tab; Novo-Profen 400mg Tab; Nu-Ibuprofen 400mg Tab; Pms-Ibuprofen 400mg Tab; Phenobarbitol Sodium 30mg/ml, 120mg/ml Inj; Phenobarbital Sodium 30mg/ml, 120mg/ml Inj USP; Benefits: Cefazolin 500mg, 1g, 10g Vial Inj USP; Pms-Topiramate 50mg Tab; Travatan Z (Travaprost) 0.004% w/v; Benefits – Permanent Residents of Residential Care Facilities (Plan B) Only: Jamp Enteric Coated ASA 325mg Tab; Benefits – Palliative Care Drug Plan (Plan P) Only: Co-Famciclovir 125mg, 250mg Tab; Jamp Acetaminophen 325mg Tab; Jamp Sennosides 8.6mg Tab; Benefits – Blood Glucose Test Strips: Nova Max BG Test Strips; On-Call Plus BG Test Strips; EZ Health Oracle Talking BG Test Strips; Benefits – Limited Coverage Drug Program: Ciprodex 0.3%/0.1% Otic Susp; Benefits – Clarification for Coverage: Enbrel; Non-Benefits: Apo-Alfuzosin 10mg Tab; Piperacillin and Tazobactam 2g/0.25g, 3g/0.375g, 4g/0.5g Vial; Ralivia 100mg, 200mg, 300mg ER Tab; Spriafil 40mg/ml O/Susp; Tridural 100mg, 200mg, 300mg ER Tab; Changes to Pharmacare Benefit Status: Tazorac 0.05%, 0.1%, gel and 0.05%, 0.1% cream; Trusopt preservative-free 2% drops; Sandoz-Ranitidine 150mg, 300mg Tab; Nu-Ranit 150mg, 300mg Tab; Zantac 150mg, 300mg Tab; Apo-Ranitidine 150mg, 300mg Tab; Novo-Ranitidine 150mg, 300mg Tab; Co Ranitidine 150mg, 300mg Tab; Pms-Ranitidine 150mg, 300mg Tab; Ratio-Ranitidine 150mg, 300mg Tab; Gen-Ranitidine 150mg, 300mg Tab;
Posted April 27, 2009
Nova Scotia
NS Pharmacare Bulletin , Vol #09-03, April 2009
Highlights
Program Information: Change to Nurse Practitioner Prescribing; Reminder and Update on Proton Pump Inhibitor Policy; Inhaled Respiratory Medications: Dry Delivery versus Wet Nebulizer; Added as Non Benefit: Revlimid 5mg, 10mg Caps; Now Insured: Magic Mouthwash Formulas; Manufacturer Shortage of Lowest Price Brand: Apo-Misoprostol 200mcg Tab; Change in MAC Pricing: 34 products, see bulletin for details.
Posted April 24, 2009
Prince Edward Island
PEI MAC Memo - April 2009 Update
Highlights
New Interchangeable/MAC Categories: Marvelon 21, Apri 21; Marvelon 28, Apri 28; Depo-Provera, Medroxyprogesterone Acetate 150mg/ml Inj. Products Added to the Interchangeable/MAC List: Novo-Clizapril/HCTZ 5MG, 12.5MG Tab; Novo-Morphine SR 15MG, 30MG Tab SR. Changes to MAC Prices: Inhibace Plus, Apo-Cilazapril/HCTZ, Novo-Cilazapril/HCTZ 5MG & 12.5MG Tab; DDAVP, Apo-Desmopressin 10MCG/Dose; Persantine, Apo-Dipyridamole-FC 50MG Tab; Persantine, Apo-Dipyridamole-FC 75MG Tab; Sinequan, Apo-Doxepin 10MG Cap; Eryc, Apo-Erythro-EC 250MG Cap ENT; Eryc, Apo-Erythro-EC 333MG Cap ENT; Tambocor, Apo-Flecainide 50MG Tab; Tambocor, Apo-Flecainide 100MG Tab; Rhinalar, Apo-Flunisolide 0.025% Nasal Spray; Tofranil, Apo-Imipramine 50MG Tab; Trandate, Apo-Labetalol 100MG Tab; Trandate, Apo-Labetalol 200MG Tab; Sinemet CR, Apo-Levocarb CR 200MG & 50MG Tab CR; Provera, Apo-Medroxy 100mg Tab; Megace, Nu-Megestrol, Apo-Megesterol 160MG Tab; Amatine, Apo-Midodrine 2.5MG Tab; Apo-Midodrine 5MG Tab; Naprosyn SR, Apo-Naproxen SR 750MG Tab SR; Modulon, Apo-Trimebutine 200MG Tab; Depakene, Novo-Valproic, PMS-Valproic 500MG Cap Ent. Deleted Interhcangeable/MAC Categories: PMS-Loxapine, Nu-Loxapine, Apo-Loxapine 5MG Tab; PMS-Loxapine, Nu-Loxapine, Apo-Loxapine 10MG Tab; PMS-Loxapine, Nu-Loxapine, Apo-Loxapine 25MG Tab; PMS-Loxapine, Nu-Loxapine, Apo-Loxapine 50MG Tab; Novo-Misoprostol, Apo-Misoprostol 100MCG Tab; Novo-Misoprostol, Apo-Misoprostol, PMS-Misoprostol 200MCG Tab; Neosporin, Optimyxin Plus 10000U & 0.25MG & 0.25MG/ML. Discontinued Products: Lin-Megestrol 160mg Tab; Ratio-Flunisolide 0.025% Nasal Spray; Rhinaris-F 0.025% Nasal Spray. Change in Manufacturer: Rhinalar 0.025% Nasal Spray.
Posted April 17, 2009
Newfoundland
NLPDP Behind the Scenes Spring 2009
Highlights
All Updates as per Benefits List Updates Bulletin #08-2009-01-30: Open Benefit: Clindoxyl gel; Stalevo 12.5mg/50mg/200mg; Stalevo 25mg/100mg/200mg; Stalevo 37.5mg/150mg/200mg; Gen-metoprolol 25mg; Gen-atenolol 25mg. Special Authorization: Zeldox 20mg, 40mg, 60mg, 80mg; Zyprexa Zydis 20mg; Androgel 2.5g/packet, 5g/packet; Testim 1% gel; Androderm 2.5mg/24hr patch, 5mg/24hr patch. Special Authorization Drugs with Updated Criteria: Generic Sumatriptan tablets 50mg, 100mg; Novo-Sumatriptan DF Tabs 50mg, 100mg; Imitrex Injection 6mg/0.5ml; Zolmitriptan tabs and rapidmelt 2.5mg; Zolmitriptan nasal 2.5mg, 5mg; Rizatriptan tabs & RPD5 & 10mg; Naratriptan 1mg, 2.5mg Tab; Almotriptan Tab 6.25mg, 12.5mg; Sumatriptan nasal 5mg, 20mg; Humira 40mg/0.8ml kit; Andriol 40mg Cap. Drugs reviewed and Not Recommended: Levaquin 750mg tab; Exelon 5 4.6mg/24hr patch; Exelon 10 9.5mg/24hr patch; Cymbalta 30mg, 60mg Cap; Omnaris 50mcg Nasal Spray; Androgel Pump 1% Gel.
Posted April 17, 2009
Alberta
Summary of Changes to AHWDBL, April 1, 2009
Highlights
Additions: Apo Alfuzosin 10mg tab ER, Octreotide 100mcg/ml, 200mcg/ml, 500mcg/ml inj sol, Pipercillin & Tazobactam 2g/250mg, 3g/375mg, 4g/500mg inj sol, Sandoz Alfuzosin 10mg tab ER, Apri 21 tab, Apri 28 tab, Cefazolin 1g, 10g inj sol, Diovan HCT 320mg/12.5mg, 320mg/25mg tab, Dovobet 50mcg/0.5mg top oint, Jamp Citalopram 20mg, 40mg tab, Jamp Lactulose 667mg/ml o/syr, Jamp Ondansetron 4mg, 8mg tab, Novo Morphine 15mg, 30mg tab SR, Novo Quetiapine 150mg tab, Pamidronate Disodium Omega 60mg, 90mg inj sol, pms Bupropion SR 150mg tab SR, Ran Ondansetron 4mg, 8mg tab, Sabril 500mg tab, 500mg o/pd, Sandoz Diclofenac 50mg, 100mg rect supp, Sandoz Paroxetine 20mg tab, Sandoz Pramipexole 1mg, 1.5mg tab, Suboxone 2mg/0.5mg tab SL, Travatan Z 0.004% oph sol, Aerochamber AC Boys Chamber, Aerochamber AC Girls Chamber, Xarelto 10mg tab; Criteria Change: Aldara 5% top crm, Pegasys (0.5ml syringe) 180mcg/syr inj sol, 180mg/ml inj sol, Plavix 75mg tab; Discontinued: pms Alendronate 70mg tab, Cipro IV Minibags 2mg/ml inj sol; Status Change: Baraclude 0.5mg tab, Hepsera 10mg tab, Heptovir 100mg tab, Pegasys (0.5ml syringe) 180mcg/syr inj sol, 180mg/ml inj sol, Aggrenox 200mg & 25mg cap, Apo Levetiracetam 250mg, 500mg, 750mg tab, Co Levetiracetam 250mg, 500mg, 750mg tab, Keppra 250mg, 500mg, 750mg tab, pms Levetiracetam 250mg, 500mg, 750mg tab; Discontinued: Apo Ipravent 0.03% nas sol, Apo Perindopril 8mg tab, Atropine 1% oph oint, C.E.S 1.25mg tab, Etrafon 4-10 tab, Fudicin 250mg tab, K-Lyte.CL 25 MEQ o/pd, M.O.S-5 5mg.ml o/syr, M.O.S-10 10mg/ml o/syr, M.O.S-20 20mg tab, Novo Bupropion SR 150mg tab SR, Novo Citalopram 20mg, 40mg tab, Novo Fluconazole-150 150mg cap, Novo Propamide 250mg tab, Nu Alpraz 0.25mg, 0.5 tab, Nu Bromazepam 1.5mg, 3mg, 6mg tab, Nu Clonazepam 0.5mg, 2mg tab, Nu Cromolyn 1% inh sol, Nu Loraz 0.5mg, 1mg, 2mg tab, Nu Salbutamol 1mg/ml, 2mg/ml inh sol, Nu Temazepam 15mg, 30MG cap, pms Buspirone 5mg tab, pms Fosinopril 20mg tab, pms Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg tab, ratio Dexamethasone 0.75mg tab, ratio Flunisolide 0.025% nas sol, Sandoz Diclofenac 100mg rect supp, Sandoz Paroxetine 20mg tab, Sansert 2mg tab, Space Chamber Adult Large Mask, Statex 10mg/ml o/syr, Symmetrel 10mg/ml o/syr, Tuinal 100mg, 200mg cap, Ultravate 0.05% top oint, Vaseretic 5mg&12.5mg tab, Ventolin 400mcg/ml o/l, Zaditen 0.2mg/ml o/syr.
Posted April 8, 2009
Saskatchewan
Saskatchewan Formulary Bulletin #118, April 2009
Highlights
New Full Formulary Listings: EZ Health Oracle Test Strip; Dovobet Oint 50mcg/0.5mg/g; EZ Health Oracle Lancet. New Exception Drug Status Listings Effective January 1, 2009: Eprex 20,000IU/0.5ml INJ-SC SOL; Monurol 3g oral powder sachet; IV Skin Preparation wipe. New Exception Drug Status Listings Effective March 1, 2009: Lucentis 10mg/ml INJ-SOL. New Exception Drug Status Listings Effective April 1, 2009: Volibris 5mg, 10mg tab; DDAVP Melt 240mcg; Apidra 100U/ml INJ-SOL; Apidra 100U/ml pre-filled pen Solostar; Kaletra 100mg/25mg tab; Celsentri 150mg, 300mg tab; Xarelto 10mg tab. Revised Exception Drug Status Criteria: Atripla 600mg/200mg/300mg Tab; Truvada 200mg/300mg Tab; Venofer 20mg/ml IV SOL. New Interchangeable Full Formulary or EDS Listings: Novo-Azithromycin 20mg/ml, 40mg/ml Oral Suspension; Dexamethasone Omega 4mg/ml INJ SOL; Novo-Morphine 15mg, 30mg Tab SR; Jamp-Niacin 500mg Tab. Drugs Recently Reviewed and Not Recommended: Campral 333mg Tab DR; Omnaris 50ug/actuation metered dose inhaler; Pradax 75mg, 110mg Cap; Relistor 20mg/ml INJ SOL; Januvia 100mg Tab; Xyrem 500mg/ml Oral SOL. Health Canada Recommendation to Suspend Raptiva in Canada: Raptiva 150mg/vial KIT.
Posted April 8, 2009
Nova Scotia
NS Pharmacare Bulletin Vol #09-02 March 2009
Highlights
New Products Added to the NS Formulary: Diovan HCT 320mg/12.5mg, 320mg/25mg Tab; Eprex 30,000iu/0.75ml Syr Inj; pms-Topiramate 50mg Tab; Tapazole 10mg Tab; Travatan Z 0.004% Oph Sol. Exception Status Criteria of New Benefits: Androderm 2.5mg(12.2mg)/24 hr patch, 5mg(24.3mg)/24 hr patch; Androgel 2.5g gel/Packet, 5g gel/Packet; Testim 1% Topical Gel. New Criteria: Imitrex, Imitrex DF and generics 500mg, 100mg Tab; Amerge 1mg, 2.5mg Tab; Axert 6.25mg, 12.5mg Tab; Imitrex 5mg, 20mg Nasal Spray; Maxalt/ Maxalt RPD 5mg, 10mg Tab, 5mg, 10mg Wafers; Zomig 2.5mg Tab, Rapidmelt 2.5mg Tab, 2.5mg Nasal Spray, 5mg Nasal Spray, Imitrex 6mg/0.5ml Injection. Delisted Products: Co Sumatriptan 25mg Tab; Gen-Sumatriptan 25mg Tab; Imitrex DF 25mg Tab; Novo Sumatriptan DF 25mg Tab; pms-Sumatriptan 25mg Tab. Addition to Exception Status Criteria: Botox 100iu/vial Injection. Non-Insured Products: Advagraf 0.5mg ER Caps, 1mg ER Caps, 5mg ER Caps; Gen-Clozapine 50mg, 200mg Tab; Seasonale 0.15mg/0.03mg. New Interchangeable Products Added to the NS Formulary: Apri 21 Tab 21 Day; Marvelon Tab 21 Day; Apri 28 Tab 28 Day; Marvelon Tab 28 Day; Co Famiciclovir 125mg, 250mg, 500mg Tab. Amendment to Pharmacare Reimbursement Level: Ran-Ramipril 10mg Cap. MAC Categories Removed From the Pharmacare Reimbursement List: Loxapine 5mg, 10mg, 25mg, 50mg Tab. Corrections: Premier Lock’n Roll Product Numbers – 8596, 8597, 8598, 8599, 85116, 85117, 85118, 85119.
Posted April 3, 2009
Alberta
Alberta Health and Wellness Drug Benefit List - April 1, 2009
Highlights
Full Formulary Release
Posted April 3, 2009
Alberta
Summary of Changes to AEIDBS, April 1, 2009
Highlights
Additions: Apo Alfuzosin 10mg tab ER, Octreotide 100mcg/ml, 200mcg/ml, 500mcg/ml inj sol, Pipercillin & Tazobactam 2g/250mg, 3g/375mg, 4g/500mg inj sol, Sandoz Alfuzosin 10mg tab ER; Criteria Change: Aldara 5% top crm, Pegasys (0.5ml syringe) 180mcg/syr inj sol, 180mg/ml inj sol, Plavix 75mg tab; Discontinued: Pediatric Peptinex DT Liquid, Peptinex 1.0 Oral Liquid, Peptinex 1.5 Oral Liquid, Peptinex DT Liquid, Promod Oral Powder, pms Alendronate 70mg tab, Cipro IV Minibags 2mg/ml inj sol, Nutren 1.5 Prebio 1 Oral Liquid, Nutren Fibre with Prebio 1 Oral Liquid, Resource Just for Kids Oral Liquid, Resource Just for Kids with Fibre Liquid.
Posted April 3, 2009
Alberta
Alberta DBL Report April 1, 2009
Highlights
Highlights of Products Added: Sabril 500mg tab, 500mg o/pd, Travatan Z 0.004% oph sol, Gen Nifedipine XL 60mg tab ER, Diovan HCT 320mg & 12.5mg, 320mg & 25mg tab, Dovobet 50mcg/g & 0.5mg/g top oint, Novo Quetiapine 150mg tab, Stalevo 50mg & 12.5mg & 200mg, 100mg & 25mg & 200mg, 150mg & 375mg & 200mg tab, Suboxone 2mg & 0.5mg, 8mg & 2mg tab SL, Zeldox 20mg, 40mg, 60mg, 80mg tab, AC Boyz and AC Girlz aerosol holding chambers, Xarelto 10mg tab; Changes in Status or Criteria: Aggrenox 200mg & 25mg cap, Aldara 50mg/g top crm, Keppra 250mg, 500mg, 750mg tab, Apo Levetiracetam 250mg, 500mg, 750mg tab, Co Levetiracetam 250mg, 500mg, 750mg tab, pms Levetiracetam 250mg, 500mg, 750mg tab, Humira 40mg inj sol, Rituxan 10mg/ml inj sol, Heptovir 100mg tab, Baraclude 0.5mg tab, Hepsera 10mg tab, Pegaysy 180mcg/ml, 180mcg/syringe inj sol.
Posted March 30, 2009
New Brunswick
NBPDP Formulary March 2009
Highlights
Full Formulary Release
Posted March 27, 2009
Quebec
Communique - Modification No. 1 to the Liste de Medicaments 23rd Edition - Effective March 25, 2009.
Highlights
Addition: Gen Nifedipine XL 60mg tab ER; Price change: Adalat XL 60mg tab SR.
Posted March 27, 2009
Quebec
Communique - Correction No. 2 to the Liste de Medicaments - Effective March 25, 2009
Highlights
Price Changes: BD Latitude Test Strip, phl Indapamide 2.5mg tab, Strattera 10mg, 18mg tab.
Posted March 27, 2009
New Brunswick
Prescription Drug Program - Bulletin #746 - Benefit Changes to NBPDP
Highlights
Additions: Hyzaar 100mg & 12.5mg tab, Suboxone 2mg & 0.5mg, 2mg & 2mg tab SL, Eprex 20 000u/0.5mg inj sol, Stalevo 50mg & 12.5mg & 200mg, 100mg & 25mg & 200mg, 150mg & 37.5mg & 200mg tab, Celsentri 150mg, 300mg tab, Humira 40mg/0.8ml inj sol, Enbrel 50mg inj sol, Remicade 100mg inj; Revised Criteria: Duragesic and generics 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr trans pad, Risperdal Consta 25mg, 37.5mg, 50mg inj sol, Pulmozyme 1mg/ml inj sol; Drugs Reviewed and Not Listed: Omnaris 50mcg nasal spray, Cubicin 50mg/10ml sol; Delisted: Raptiva 150mg in sol.
Posted March 27, 2009
Ontario
ODB Edition #41, Update H, effective April 1, 2009
Highlights
Additions: Adderall XR 5mg, 10mg, 15mg, 20mg, 25mg, 30mg Cap ER. Advagraf 0.5mg, 1mg, 5mg cap ER, Concerta 18mg, 27mg, 36mg, 54mg Tab SR, Kaletra 100mg & 25mg tab, Lantus Solostar 100u/ml inj sol, Mezavant 1.2g Tab O/DIS, 1.2g Tab ER, Prograf 0.5mg cap, April 21 0.15mg & 0.03mg tab, April 28 0.15mg & 0.03mg tab, Novo Morphine SR 15mg tab SR, Capoten 100mg tab, Sibelium 5mg cap, Timoptic 0.25% oph sol, Volbris 5mg, 10mg tab; Added as Off Formulary Interchangeable Product: pms Tryptophan 500mg cap, 1g tab; Discontinued: Agenerase 50mg, 150mg cap, 15mg/ml O/L, Apo Ipravent 0.03% nas sol, Apo Lozapine 5mg, 10mg, 25mg, 50mg tab, Fluanxol Depot 200mg/2ml, 200mg/10ml inj sol, Fluotic 20mg tab, pms Digoxin 0.0625mg, 0.125mg, 0.25mg tab, Promod Pd, Sab Diclofenac 50mg, 100mg sup, Sansert 2mg tab, Ventolin 0.4mg/ml O/L; Price Changes: See bulletin for details; Delisted: Premarin 0.3mg, 0.625mg, 1.25mg tab, Premplus 0.625mg & 2.5mg tab, Premplus 0.625mg & 5mg tab, Apo Cromolyn 1% inh sol, Apo Salvent Sterule 1mg/ml, 2mg/ml inh sol, Combivent 20mcg & 100mcg/md aero inh, Desquam X10 10% gel, Froben 50mg tab, Gen Clomipramine 10mg, 25mg, 50mg tab, Geb Diltiazem 30mg, 60mg tab, Halog 0.1% cr, 0.1% oint, Novo Citalopram 40mg tab, Novo Clopate 3.75mg, 7.5mg, 15mg cap, Novo Cyproterone 50mg tab, Novo Misoprostol 100mcg tab, Osteoforte 50000U cap, Oxybutyn 5mg tab, Pancrease 4500 & 20000 & 25000USP unit cap SR, PCE Dispertab 333mg tab, Pediazole 40mg & 120mg/ml O/L, PegLyte Sol, pms Cholestyramine pd, pms Cholestyramine (sugar free) pd, pms Ketoprofen E-50 50mg tab ent, pms Loxapine 25mg/ml O/L, pms Oxtriphylline 10mg/ml O/L, pms Propafenone 150mg, 300mg tab, pms Temazepam 15mg, 30mg cap, pms Theophylline 5.3mg/ml O/L, Sustiva 100mg cap, Trasicor 40mg tab, Westcort 0.2% oint; Not a Benefit (Removed from Formulary): Choledyl 10mg/ml O/L, Loxapac 25mg/ml O/L, Panoxyl Aquagel 10% Gel, Questran pd; Status Change: Atripla 600mg & 300mg & 200mg tab.
Posted March 27, 2009
Quebec
Quebec Capsule, March 25, 2009
Highlights
Addition to Hospital - Exception Medication: Erbitux 2mg/ml IV SOL
Posted March 27, 2009
Alberta
Alberta - Additions to the AHWDBL, effective Mar 4, 2009
Highlights
Deleted from the AHWDBL: Raptiva 150mg/vial inj sol; Additions: Rituxan 10mg/ml inj sol; Criteria Change: Enbrel 25mg/vial, 50mg/ml inj sol, Humira 40mg/0.8ml inj sol, Kineret 100mg inj sol, Orencia 250mg/vial inj sol.
Posted March 27, 2009
New Brunswick
NB Bulletin #748, Quantitive Limits Review, March 25, 2009
Highlights
Quantitive Limits Review - Policy and Procedure Update
Posted March 12, 2009
Newfoundland
Newfoundland Bulletin #14- 2009 02 26
Highlights
Addition: Magic Bullet 10mg Suppository
Posted March 12, 2009
Prince Edward Island
PEI MAC Memo March 2, 2009
Highlights
New Interchangeable/MAC Categories: PMS-Citalopram, Novo-Citalopram 10MG Tab. Discontinued Products: Apo-Ipravent 0.03% Nasal Spray; Apo-Loxapine 5MG, 10MG, 25MG, 50MG Tab; PMS-Digoxin 0.0625MG, 0.125MG, 0.25MG Tab. Additions: Atacand 32MG Tab; Diovan HCT 320MG/12.5MG, 320MG/25MG Tab; Gen-Clozapine 50MG, 200MG Tab; PMS-Amiodarone 100MG Tab; PMA-Paroxetine 40MG Tab; PMS-Topiramate 50MG Tab, Tapazole 10MG Tab; Travatan Z 40MCG/ML Oph Sol.
Posted March 11, 2009
New Brunswick
New Brunswick Formulary, Volume 50, Update No. 3, March 4, 2009
Highlights
Additions: Novo-Azithromycin 100mg/5ml, 200mg/5ml O/PD Susp; Cipro IV, Ciprofloxacin IV 2mg/ml IV Sol; Novo-Citalopram; PMS-Citalopram 10mg Tab; Marvelon 21, Apri 21 0.15mg/0.03mmg Tab; Marvelon 28, Apri 28 0.15mg/0.03mmg Tab; PMS-Diclofenac 25mg, 50mg Tab DRGemzar, Gemcitabine 200mg IV PWS, Gemzar, Gemcitabine 1g IV PWS; Kytril, Apo-Granisetron 1mg Tab; Adalat XL, Gen-Nifedipine XL 60mg Tab SR; Jamp-Ondansetron, Ran-Ondansetron 4mg Tab; Jamp-Ondansetron, Ran-Ondansetron 8mg Tab; Oxy-IR, pms-Oxycodone IR 5mg Tab; pms-Oxycodone IR 10mg Tab; pms-Oxycodone 20mg Tab; Ran-Ramipril, Ramipril 1.25mg Cap; Ran-Ramipril 2.5mg Cap; Ran-Ramipril 5mg Cap; Ran-Ramipril 10mg Cap.
Posted March 11, 2009
New Brunswick
Benefit Changes to NBPDP, Bulletin #745, Mar 4, 2009
Highlights
Benefit Additions: Novo-Azithromycin 100MG/5ML, 200MG/5ML O/PD Susp; Ciprofloxacin 2MG/ML IV Sol; Novo-Citalopram, PMS-Citalopram 10MG Tab; Marvelon 21, Apri 21 0.15MG/0.03MG Tab; Marvelon 28, Apri 28 0.15MG/0.03MG Tab; PMS-Diclofenac 25MG, 50MG Tab DR; Apo-Granisetron 1mg Tab; Gen-Nifedipine XL 60MG Tab ER; Jamp-Ondansetron, Ran-Ondansetron 4mg Tab; Jamp-Ondansetron, Ran-Ondansetron 8mg Tab; PMS-Oxycodone IR 5MG, 10MG, 20MG Tab; Ran-Ramipril, Ramipril 1.25MG Cap; Ran-Ramipril 2.5MG Cap; Ran-Ramipril 5MG Cap; Ran-Ramipril 10MG Cap.
Posted March 11, 2009
British Columbia
BCPharmaCare Newsletter, Edition#09-003, March 10, 2009
Highlights
Interim Agreement Update
Posted March 4, 2009
NIHB
Updates to the Drug Benefit List - Winter 2008/2009
Highlights
Additions to Drug Benefit List: Single-Source Drug Products: Kaletra 25mg, 100mg Tab; Travatan Z 0.004% Opth Sol; Multi-Source Drug Products: See Bulletin; New Limited Use Benefits: Single-Source Drug Products: Emend 80mg; 125mg Cap; Emend Tripack; Multi-Source Drug Products: Apo-Alfusozin ER 10mg Tab; Sandoz-Alfusozin 10mg Tab; Apo-Brimonidine P 0.15% Opth Sol; Pms-Buproprion SR 150mg Tab; Riva-Pantoprazole 40mg EC Tab; Additions of Alzheimer’s Medication to the Drug Benefit List: Aricept 5mg, 10mg Tab; Exelon 1.5mg, 3mg, 4.5mg, 6mg Cap; Exelon O/Sol; Reminyl ER 8mg, 16mg, 24mg Cap; New Indications: Enbrel 25mg, 50mg Inj; Humira 40mg/0.8ml Inj; Not Added to Formulary: Piperacillin/Tazobactam 2g/0.25g, 3g/0.375g, 4g/0.5g Vial; Drugs Discontinued by the Manufacturer: C.E.S. 1.25mg Tab; Cardizem 60mg Tab; Cytoxan 25mg Tab; Duonale 70% Sol; Estalis-Sequi Patch; Kenalog in Orabase 0.1% Oint; M.O.S. 5mg/ml Syrup; Surgam 300mg Tab; Symmetrel 100mg Cap; Terazol 3 80mg Ovules; Vitamin A Acid 0.01%, 0.025%, 0.05%, 0.1% Cream; Vitamin B1 100mg Tab; Vitamin B6 25mg, 100mg Tab; Wellbutrin SR 100mg Tab; Status Change for Proton Pump Inhibitors: Apo-Omeprazole 20mg Cap; Apo-Pantoprazole 40mg Tab; Co-Pantoprazole 40mg Tab; Gen-Pantoprazole 40mg Tab; Losec 10mg, 20mg Cap; Losec 10mg Tab; Losec 20mg SR Tab; Novo-Pantoprazole 40mg Tab; Novo-Rabeprazole 10mg, 20mg Tab; Pantoloc 40mg Tab; Pariet 10mg, 20mg Tab; Pms-Pantoprazole 40mg Tab; Pms-Rabeprazole 10mg, 20mg Tab; Prevacid 15mg, 30mg Cap; Ran-Pantoprazole 40mg Tab; Ran-Rabeprazole 10mg, 20mg Tab; Ratio-Omeprazole 10mg Tab; Ratio-Omeprazole 20mg SR Tab; Ratio-Pantoprazole 40mg Tab; Sandoz-Omeprazole 10mg, 20mg Cap; Sandoz-Pantoprazole 40mg Tab; Sandoz- Rabeprazole 10mg, 20mg Tab; Palliative Care Formulary: See Bulletin; Manufacturer Changes: Dilaudid 1mg, 2mg Tab; Dilaudid 1mg/ml O/Liq; Dilaudid 2mg/ml Inj; Dilaudid 3mg Supp; Dilaudid XP 50mg/ml Inj; Dilaudid HP 10mg/ml Inj; Dilaudid HP Plus 20mg/ml Inj; Euthyrox 25mcg, 50mcg, 75mcg, 88mcg, 100mcg, 112mcg, 125mcg, 137mcg, 150mcg, 175mcg, 200mcg, 300mcg; Name Changes: Breeze 2 Blood Glucose Test Strips; Contour Blood Glucose Test; Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap;
Posted March 4, 2009
Ontario
ODB Update G1, Effective Mar 2, 2009
Highlights
Delisted: Raptiva 150mg/vial
Posted March 3, 2009
Prince Edward Island
PEI Formulary Update, Issue #09-01, Feb 20, 2009
Highlights
Additions: Sprycel 20mg, 50mg, 70mg tab, Tarceva 25mg, 100mg, 150mg tab, Fludara 10mg tab, Nexavar 200mg tab, Sutent 12.5mg, 25mg, 50mg cap, Emend 80mg, 125mg, 80mg & 125mg cap, Marinol 2.5mg, 5mg cap, Thyrogen 0.9mg/ml inj sol, Oxeze Turbuhaler 6u inh pd, , Symbicort Tubuhaler 6u & 200u inh pd, Spiriva 18u inh cap, Didrocal 400mg & 1250mg tab, Gen Eti Cal Carepac 400mg & 1250mg tab, Co Etidrocal 400mg & 1250mg tab, Fosamax 10mg, 70mg tab, Novo Alendronate 10mg, 70mg tab, Apo Alendronate 10mg, 70mg tab, Gen Alendronate 10mg, 70mg tab, Sandoz Alendronate 10mg, 70mg tab, Co Alendronate 70mg tab, Ratio Alendronate 70mg tab, pms Alendronate 70mg tab, Actonel 5mg, 35mg tab, Miacalcin 200u nas sol, Apo Calcitonin 200u nas sol, Fosamax 40mg tab, Co Alendronate 40mg tab, Actonel 30mg tab, Atripla 600mg & 200mg & 300mg tab, Intelence 100mg tab, Celsentri 150mg, 300mg tab, Isentress 400mg tab; Criteria Change: Viread 300mg tab, 300mg & 200mg tab, Aclasta 5mg/100ml inj sol, Sandoz Calcitonin NS 200u nas sol, Foradil 12u inh cap, Oxeze Turbuhaler 12u inh pd, Symbicort Tubuhaler 6u & 100u inh pd, Serevent 50u inh pd, Serevent Diskus 50u inh pd, Advair 25u & 125u inh aem, 25u & 250u inh aem, Advair Diskus 50u & 100u, 50u & 250u, 50u & 500u inh pd.
Posted February 24, 2009
Nova Scotia
Nova Scotia Formulary Jan 2009
Highlights
Full Formulary Release
Posted February 24, 2009
Nova Scotia
Nova Scotia Pharmacare February 2009 Bulletin Vol #09-01
Highlights
Additions: Gen Atenolol 25mg tab, Gen Metoprolol (type L) 25mg tab, Zyprexa Zydis 20mg tab, Celsentri 150mg, 300mg tab, Clindoxl Gel 1% & 5% top gel, Levaquin 750mg tab, Omnaris 50mcg/dose nas spray, Premier Lock N Roll # 8596, 8597, 8598, 8599, 85116, Gen Nifedipine XL 60mg tab, pms Oxycodone 5mg, 10mg, 20mg tab, Supeudol 20mg tab, Apo Ranitidine 75mg tab, Zantac 75mg tab, Sandoz Alfuzosin 10mg tab, Novo Azithromycin Pediatric 100mg/5ml, 200mg/5ml susp, Novo Cyproterone/Ethinyl Estradiol 2mg & 0.035mg tab, pms Diclofenac 25mg, 50mg tab 50mg, 100mg supp, pms ibuprofen 400mg tab, Gen Leflunomide 10mg, 20mg tab, Novo Morphine SR 15mg, 30mg tabm Ondansetron Odan 4mg, 8mg, Ran Ondansetron 4mg, 8mg tab, pms Rabeprazole EC 10mg tab, Ran Ramipril 1.25mg, 2.5mg, 5mg, 10mg cap, Mint Topiramate 25mg, 100mg, 200mg tab, Sandoz Venlafaxine XR 37.5mg, 75mg, 150mg cap; Criteria change: Nexavar 200mg tab; Discontinued: 64 products listed. Please see bulletin for details; Now Interchangeable: Adalat XR 60mg tab, Oxy IR 5mg, 10mg, 20mg tab, Supeudol 5mg, 10mg tab, Flomax CR 0.4mg tab; No Longer Interchangeable: Apo Flunariziine 5mg cap; Change in MAC Pricing: Azithromycin POS 100mg/5ml, 200mg/5ml pws.
Posted February 23, 2009
Alberta
Additions to AHWDBL Effective February 1, 2009
Highlights
New Interchangeable Products: Gen-Nifedipine XL 60MG Tab ER; Adalat XL 60MG Tab ER. New Single Source Products: Zeldox 20MG Cap; Zeldox 40MG Cap; Zeldox 60MG Cap; Zeldox 80MG Cap.
Posted February 23, 2009
Ontario
ODB Formulary Update G effective March 2, 2009.
Highlights
New Single Source Drugs: Diovan-HCT 320mg & 12.5mg, 320mg & 25mg Tab; Eprex 20,000IU/0.5ml Pref Syr-0.5ml Pk; Stalevo 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg Tab. New Multi-Source Drugs: Gen-Nifedipine XL 60mg Tab ER; Jamp-Ondansetron 8mg Tab; Mint-Topiramate 25mg, 100mg, 200mg Tab; Sandoz Diclofenac 50mg, 100mg Sup. Manufacturer Requested Discontinued Drugs: Lin-Fosinopril 10mg, 20mg Tab. Off Formulary Interchangeable Products: Apo-Dipyridamole 25mg, 50mg, 75mg Tab. Status Change from Discontinued to Active: Kwellada-P 1%, 5% Cr Rinse; Nix Dermal Cream 5% Cr; R & C Shampoo/Conditioner 0.3% & 3% & 1.2% Top Sol. Drug Benefit Prices: 40 Price Changes – see Formulary for full list.
Posted February 23, 2009
Newfoundland
Newfoundland and Labrador Prescription Drug Program - Bulletin No. 12 - February 16, 2009
Highlights
Correction to Bulletin #10: Apo Diclo Rapide is an addition to an existing category and is not a new category as indicated in Bulletin #10.
Posted February 23, 2009
Newfoundland
Newfoundland and Labrador Prescription Drug Program - Bulletin No. 11 - February 12, 2009
Highlights
Benefit Additions: Special Authorization for All Plans and the Cystic Fibrosis Plan: pms Oxycodone 5mg, 10mg, 20mg tab, Gen Leflunimide 10mg, 20mg tab, pms Gabapentin 600mg, 800mg tab, pms Bupropion SR 150mg tab; Open Benefit for All Plans and Special Authorization for the Cystic Fibrosis Plan: Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 150mg, 200mg, 300mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, ratio Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, pms Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Trifluridine 1% oph sol, Co Famciclovir 125mg, 250mg, 500mg tab, Apo Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg cap, Sandoz Paroxetine 20mg, 30mg tab, ratio Tecnal caps, Fiorinal caps, ratio Tecnal ¼ caps, ratio Tecnal ½ caps, Fiorinal ¼ caps, Fiorinal ½ caps, Sandoz Risperidone 0.25mg, 0.5mg tab; Not Covered for All Plans or the Cystic Fibrosis Program: Apo Diclo Rapide 50mg tab, Voltaren Rapide 50mg tab, Apo Oxaprozin 600mg tab, Daypro 600mg tab, Apo Mefloquine 250mg tab, Lariam 250mg tab, Apo Gliclazide MR 30mg tab, Diamicron MR 30mg tab, Apo Alfuzosin 10mg tab, Xatral 10mg tab, Apo Brimonidine P 0.15% oph sol, Alphagan P 0.15% oph sol, Apo Ranitidine 75mg tab, Zantac 75mg tab.
Posted February 19, 2009
Quebec
Correction No 1 to the Liste de Medicaments effective February 18, 2009
Highlights
Price Changes: Trinipatch 0.2mg/hr, 0.4mg/hr, 0.6mg/hr Trans Pad; Vasotec 2.5mg, 5mg, 10mg, 20mg Tab; Diovan-HCT 320 & 12.5mg, 320 & 25mg Tab; Novo-Calcium 500mg Tab; O-Calcium with Vitamin D 200mg & 200UI Tab; Pro-Glyburide 5mg Tab; Oesclim 25 0.025mg/24hr; Oesclim 50 0.05mg/24hr.
Posted February 23, 2009
Newfoundland
Newfoundland and Labrador Prescription Drug Program - Bulletin No. 10 - February 12, 2009
Highlights
Additions: pms Oxycodone 5mg, 10mg, 20mg tab, Apo Diclo Rapide 50mg tab, Apo Oxaprozin 600mg tab, Daypro 600mg tab, Apo Mefloquine 250mg tab, Lariam 250mg tab, Apo Ranitidine 75mg tab, Zantac 75mg tab, Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 150mg, 200mg, 300mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, ratio Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, pms Quetiapine 25mg, 100mg, 200mg, 300mg tab, Apo Gliclazide mR 30mg tab, Diamicron MR 30mg tab, Apo Alfuzosin 10mg tab, Xatral 10mg tab, Apo Brimonidone P 0.15% oph sol, Alphagan P 0.15% oph sol, Sandoz Trifluridine 1% oph sol, Co Famciclovir 125mg, 250mg, 500mg tab, Gen Leflunomide 10mg, 20mg tab, pms Gabapentin 600mg, 800mg tab, Apo Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg cap, Sandoz Paroxetine 20mg, 30mg tab, Sandoz Risperidone 0.25mg, 0.5mg tab, pms bupropion 150mg tab; Now Interchangeable: Oxy IR 5mg, 10mg, 20mg tab, Votaren Rapide 50mg tab, Seroquel 25mg, 100mg, 150mg, 200mg, 300mg tab, ratio tecnal caps, Fiorinal caps, ratio Tecnal C ¼ caps, Fiorinal C ¼ caps, ratio Tecnal ½ caps, Fiorinal ½ caps, Viroptic 1% oph sol.
Posted February 10, 2009
New Brunswick
NB Benefit Changes to NBPDP - Bulletin #743 - Feb 9, 2009
Highlights
Regular Benefits Additions: pms-Amiodarone 100mg Tab; Reyataz 300mg Cap; pms-Hydrochlorothiazide 12.5mg Tab; pms-Paroxetine 40mg Tab; Tecta 40mg Tab; Special Authorization Additions: Cymbalta 30mg, 60mg Cap; Intelence 100mg Tab; Zeldox 20mg, 40mg, 60mg, 80mg Cap; Changes in Benefit Status: Zyprexa 5mg, 10mg, 15mg Tab; Zydis 5mg, 10mg, 15mg Tab; Drugs Reviewed and Not Listed: Cymbalta 30mg, 60mg Cap; Remicade 100mg Inj; Exelon Patch 4.6mg/24hrs, 9.5mg/24hrs patches;
Posted February 6, 2009
Newfoundland
Benefit List Updates - Bulletin #08- 2009 01 30
Highlights
Open Benefit: Clindoxyl gel; Stalevo 12.5mg/50mg/200mg; Stalevo 25mg/100mg/200mg; Stalevo 37.5mg/150mg/200mg; Gen-metoprolol 25mg; Gen-atenolol 25mg. Special Authorization: Zeldox 20mg, 40mg, 60mg, 80mg; Zyprexa Zydis 20mg; Androgel 2.5g/packet, 5g/packet; Testim 1% gel; Androderm 2.5mg/24hr patch, 5mg/24hr patch. Special Authorization Drugs with Updated Criteria: Generic Sumatriptan tablets 50mg, 100mg; Novo-Sumatriptan DF Tabs 50mg, 100mg; Imitrex Injection 6mg/0.5ml; Zolmitriptan tabs and rapidmelt 2.5mg; Zolmitriptan nasal 2.5mg, 5mg; Rizatriptan tabs & RPD5 & 10mg; Naratriptan 1mg, 2.5mg Tab; Almotriptan Tab 6.25mg, 12.5mg; Sumatriptan nasal 5mg, 20mg; Humira 40mg/0.8ml kit; Andriol 40mg Cap. Drugs reviewed and Not Recommended: Levaquin 750mg tab; Exelon 5 4.6mg/24hr patch; Exelon 10 9.5mg/24hr patch; Cymbalta 30mg, 60mg Cap; Omnaris 50mcg Nasal Spray; Androgel Pump 1% Gel.
Posted February 4, 2009
Quebec
Quebec Capsule Feb 2009
Highlights
Additions: Apidra 100u/ml inj sol, Apidra Solostar 100u/ml inj sol, Avamys 27.5mcg nas/aem, BD Saline SP 0.9% ir sol, Climara Pro 0.045mg & 0.015mg trans pad, Clindesse 2% vag crm, Dovobet 50mcg/g & 0.5mg/g top oint, Fosrenol 250mg, 500mg, 750mg 1000mg tab chew, Metadol 1mg/ml, 10mg/ml o/l; Criteria Change: Aptivus 250mg tab, Intelence 100mg tab, Raltegravir 400mg tab, Baraclude 0.5mg tab, 0.05mg/ml o/l, Hepsera 10mg tab, Humira 40mg inj-sc sol, Orencia 250mg iv pws, Prezista 300mg tab, Rasilez 150mg, 300mg tab, Rituxan 10mg/ml iv sol; Declined: Concerta 18mg, 27mg, 36mg, 54mg tab sr, Pradax 75mg, 110mg cap, Relistor 20mg/ml inj sc sol, Xyrem 500mg/ml o/l.
Posted January 29, 2009
Manitoba
Manitoba Bulletin #60, effective February 23, 2009
Highlights
Additions: Apo Alfuzosin 10mg tab, Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 150mg, 200mg, 300mg tab, pms Quetiapine 25mg, 100mg, 200mg, 300mg tab, ratio Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, Apo Gliclazide MR 30mg tab, Atacand 32mg tab, Cefazolin for Injection 1g inj sol, Citalopram Odan 20mg, 40mg tab, Concerta 18mg, 27mg, 36mg, 54mg tab, DDAVP Melt 60mcg, 120mcg tab, Kaletra 100mg & 25mg tab, Metrogel 1% gel, Mint Citalopram 20mg, 40mg tab, Mint Ondansetron 4mg, 8mg tab, Mint Topiramate 25mg, 100mg, 200mg tab, Ondansetron Odan 4mg, 8mg tab, pms ibuprofen 600mg tab, pms Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg tab, Sandoz Alfuzosin 10mg tab, Sandoz Diclofenac 50mg, 100mg supp, Sandoz Metoprolol SR 100mg, 200mg tab, Sandoz Venlafaxine XR 37.5mg, 75mg, 150mg cap, Sodium Sulamyd 100mg/ml oph sol, Travatan Z 0.004% oph sol, Zeldox 20mg, 40mg, 60mg 80mg cap, Ratio Fentanyl 12mch trans pad, Sandoz Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg, Apo Pantoprazole 40mg tab, Atripla 300mg & 200mg & 600mg tab, Caduet 5mg & 10mg, 10mg & 10mg, 5mg & 20mg, 10mg & 20mg, 5mg & 40mg, 10mg & 40mg, 5mg & 80mg, 10mg & 80mg tab, Co Pantoprazole 40mg tab, Gen Pantoprazole 40mg tab, Intelence 100mg tab, Isentress 400mg tab, Nexavar 200mg tab, Novo Pantoprazole 40mg tab, Novo Rabeprazole EC 10mg, 20mg tab, pms Pantoprazole 40mg tab, pms Rabeprazole EC 10mg, 20mg tab, Ran Pantoprazole 40mg tab, ran Rabeprazole 10mg, 20mg tab, ratio Pantoprazole 40mg tab, Rituxan 10mg/ml inj sol, Sandoz Pantoprazole 40mg tab, Sandoz Rabeprazole 10mg, 20mg tab, Truvada 200mg & 300mg tab; Not Recommended: Elaprase 2mg/ml inj sol, Fosrenol 250mg, 600mg, 750mg, 1000mg tab, Ralivia 100mg, 200mg 300mg tab, Rasilez 150mg, 300mg tab, Sativex 27mg/ml spray, Sebivo 600mg tab, Spirafil 40mg/ml o/susp, Tridural 100mg, 200mg, 300mg tab, Adalat XL Plus 20mg & 81mg, 30mg & 81mg, 60mg & 81mg tab, Androgel 1% gel, Metadol 1mg/ml o/l; Now Interchangeable: Xatral 10mg tab, Cefazolin for Injection 1g inj sol, Duragesic 12mcg trans pad, Diamicron MR 30mg tab, Zyprexa 2.5mg, 5mg, 7.5mg, 10mg, 15mg tab, Pantoloc 20mg, 40mg tab, Seroquel 25mg, 100mg, 150mg, 200mg, 300mg tab, Pariet 10mg, 20mg tab; Product Deletions: Apo Cromolyn 1% inh sol, Apo Salvent Ipravent 1mg & 0.2mg/ml liguid, Climacteron inj, Co Buspirone 10mg tab, Nebcin 40mg/ml inj, Novo Levobunolol 0.25% & 0.5% oph sol, ratio Famotidine 20mg tab, Sibelium 5mg cap, Statex 10mg/ml o/l, Tridsilon 0.05% oint; Category Deletions: Desonide 0.05% oint, Flunarizine 5mg cap, Tobramycin 40mg/ml inj; Price Changes: 95 see bulletin for full details; Discontinued Products: Cardizem 60mg tab, C.E.S 1.25mg tab, Cytoxan 1g, 2g pws, 25mg tab, Estalis Sequi 250mcg & 50mcg trans pad, Kaletra 133.3mg & 33.3mg cap, Kenalog 1mg.g oint, Marinol 10mg cap, M.O.S 5mg/ml liquid, Mycostatin 100 000u/g pd, pms Flavoxate 200mg tab, ratio Fosinopril 10mg, 20mg tab, Surgam 300mg tab, Vitamin A 0.01%, 0.05%, 0.25% cream, Vitamin B1 100mg tab, Vitamin B6 25mg, 100mg tab, Wellbutrin SR 100mg tab, Westcort 0.2% oint, Zaditen 1mg/5ml o/l, Zyloprim 300mg tab; Name Change: Ascensia Breeze 2 to Breeze 2, Ascensia Contour to Contour.
Posted January 23, 2009
Ontario
ODB Formulary Update F effective Jan 30, 2009
Highlights
Additions: DuoTrav 0.5% & 0.004% oph sol, Intelence 100mg tab, Niaspan 500mg, 750mg, 1000mg tab, Telzir 50mg/ml o/susp, Apo Cyclosporine 100mg/ml o/l, Apo Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg Cap SR, Gen Leflunomide 10mg, 20mg tab, Jamp Citalopram 20mg, 40mg tab, Jamp Ondansetron 4mg tab, Pms Ciprofloxacin 0.3% oph sol, pms oxycodone 5mg, 10mg, 20mg tab; Discontinued: Combigan 0.2% & 0.5% oph sol, Cytoxan 50mg tab, Pondocillin 500mg tab, Sandoz Ramipril 1.25mg, 2.5mg, 5mg, 10mg tab, Symmetrel 10mg/ml o/l, Nutrisure Pudding, Percocet 5mg & 325 mg tab, Percodan 5mg & 325mg tab; Delisted: 5-Benzagel 5% gel, Anthranol 0.1%, 0.2%, 0.4% top crm, Anthraforte 1 1% top oint, Anthraforte 2 2% top oint, Ratio Fosinopril 10mg tab, Ratio Fosinopril 20mg tab; Price Changes: 136 – see bulletin for details.
Posted January 21, 2009
Newfoundland
Newfoundland Bulletin #04- 2009 01 15
Highlights
Novo-Acyclovir Tab, DIN 2285975, Price $3.1127: It has been brought to our attention by Teva Novopharm Limited that an incorrect price was submitted for the product Novo-Acyclovir 800mg Tab (DIN 2285975). The pricing included in the submission for the NIDPF was $2.2664; however, it should have been $2.8557.
Posted January 16, 2009
British Columbia
BC Pharmacare Newsletter, Edition 09-001, Jan 15, 2009
Highlights
Benefits: Altace HCT 2.5mg/12.5mg Tab; Altace HCT 5mg/12.5mg Tab; Altace HCT 5mg/25mg Tab; Altace HCT 10mg/12.5mg Tab; Altace HCT 10mg/25mg Tab; Avelox 400mg Tab. Limited Coverage Program: Atacand 32mg Tab. Non-Benefits: Betaseron 0.3mg/vial; Levaquin 750mg Tab; Sativex 2.5mg/2.7mg Spray Pump; Posanol 200mg/5ml Oral Susp; Testim 1% gel; Thelin 100mg Tab; Tramacet 37.5mg/325mg Tab.
Posted January 15, 2009
Newfoundland
Newfoundland Bulletin #03- 2009-01-15
Highlights
Delisted: Ran Ramipril 1.25mg, 2.5mg, 5mg, 10mg tab
Posted January 16, 2009
Newfoundland
Newfoundland and Labrador Prescription Drug Program Bulletin #02 2009-01-07
Highlights
Discontinued: Sandoz Ramipril 1.25mg, 2.5mg, 5mg, 10mg tab
Posted January 16, 2009
Newfoundland
Newfoundland and Labrador Prescription Drug Program Bulletin #01 2009-01-06
Highlights
Discontinued: pms Flavoxate 200mg tab
Posted January 16, 2009
Prince Edward Island
January 2009 Update to the Maximum Allowable Cost List
Highlights
New Interchangeable/MAC Categories: Miacalcin, Apo-Calcitonin, Sandoz Calcitonin NS 200UI/Dose; Adalat XL, Gen-Nifedipine XL 60MG Tab ER; Supeudol, OXY-IR, PMS-Oxycodone 5MG Tab; Supeudol, OXY-IR, PMS-Oxycodone 10MG Tab; OXY-IR, Supeudol, PMS-Oxycodone 20MG Tab. Products Added to the Interchangeable/MAC List: Gen-Leflunomide 10MG Tab; Gen-Leflunomide 20MG Tab; Jamp-Citalopram 20MG Tab; Jamp-Citalopram 40MG Tab; Jamp-Ondansetron 4MG Tab; Jamp-Ondansetron 8MG Tab; Novo-Azithromycin 20MG/ML ORL SUSP; Novo-Azithromycin 40MG/ML ORL SUSP. Changes to MAC Prices: Sun-Benz, PMS-Benzydamine, Novo-Benzydamine, Ratio- Benzydamine, Apo-Benzydamine 0.15% Oral rinse; Sandoz Bupropion SR, Ratio-Bupropion SR 100MG Tab SR; Apo-Capto, Nu-Capto, Novo-Captoril, Gen-Captopril, Pms-Captopril 100MG Tab; Peridex, Perichlor 0.12% Oral Rinse; Neoral, Sandoz Cyclosporine 25MG Cap; Neoral, Sandoz Cyclosporine 50MG Cap; Desocort, Pms-Desonide 0.05% Top Oint; Apo-Diltiaz, Novo-Diltazem, Nu-Diltiaz 30MG Tab; FML Liquifilm, Pms-Fluorometholone 0.1% OPH Sol; Dilaudid, Pms-Hydromorphone 1MG/ML Orl Sol; Atarax, Pms-Hydroxyzine 2Mg/ML Orl Syrup; Pediapred, Pms-Prednisolone 1MG/ML Orl Liquid; Pms-Salbutamol, Ventolin 0.4MG/ML Liquid; Pms-Sulfasalazine, Salazopyrin En-Tabs 500MG Tab ENT; Pms-Sulfasalazine, Salazopyrin En-Tabs 500MG Tab; Novo-Tamsulosin, Ratio-Tamsulosin, Ran-Tamsulosin, Sandoz Tamsulosin, Gen-Tamsulosin 0.4MG Cap SR; Urso, Pms-Ursodiol C 250MG Tab; Urso, Pms-Ursodiol C 500MG Tab; Novo-Valproic, Pms-Valproic Acid 500 Cap ENT Coated. Deleted Interchangeable/MAC Categories: Symmetrel, PMS-Amantadine 10MG/ML Syrup; Cytoxan, Procytox 50MG Tab; Desocort, PMS-Desonide 0.05% Top Crm. Discontinued Products: Ratio-Fosinopril 10MG Tab, Ratio-Fosinopril 20MG Tab, Sandoz Ramipril 1.25MG Tab, Sandoz Ramipril 2.5MG Tab, Sandoz Ramipril 5MG Tab, Sandoz Ramipril 10MG Tab, Valisone 0.1% Scalp Lot.
Posted January 9, 2009
Alberta
Alberta Employment and Immigration Drug Benefit Supplement Quarterly Update Effective January 1, 2009
Highlights
Special Authorization: Apo-Cyclosporine, Neoral 100MG/ML Orl Sol; Ratio-Fentanyl, Duragesic 12 12MCG/HR Trans Pad; Nutramigen, Neocate Infant Formulas; Xalacom 0.005% OPH SOL.
Posted January 9, 2009
Saskatchewan
Saskatchewan Formulary Bulletin #117, Jan. 2009
Highlights
New Formulary Listings: Atacand 32mg tab, Co Famciclovir 125mg, 250mg, 500mg tab, Apo Gliclazide MR 30mg tab, Lantus cartridge, Lantus Solostar, Jamp Lactulose 667mg/ml, Gen Leflunomide 10mg, 20mg tab, Stalevo 50mg & 12.5mg & 200mg, 100mg & 25mg & 200mg, 150mg & 37.5mg & 200mg tab, pms Oxycodone 5mg, 10mg, 20mg tab, Pam Disodium Omega 30mg, 60mg inj, Seroquel XR 50mg, 200mg, 300mg, 400mg tab ER, ran Ramipril 1.25mg, 2.5mg, 5mg, 10mg cap, Micro 31 diabetic needle, Xtra 31 diabetic needle, Standard 29 diabetic needle, pms Topiramate 50mg tab, Travatan Z 0.004% oph sol, Valcyte 50mg/ml pws, Sandoz Alfuzosin 10mg XR tab, Jamp Citalopram 20mg, 40mg tab, Sandoz Diclofenac 50mg, 100mg supp, Apo Patoprazole 20mg tab ent, Novo Pantoprazole 20mg tab ent, Ran Pantoprazole 20mg tab ent, Mint Topiramate 25mg, 100mg, 200mg tab; Status Change: Intelence 100mg tab, Diamicron MR 30mg tab, Lantus (vial), Zeldox 20mg, 40mg, 60mg, 80mg cap; Revised Criteria: Humira Pre Filled Pen, Humira pre filled Syringe 40mg & 0.8ml inj sol, Enbrel 25mg inj pws, 50mg pre filled syringe, Remicade 100mg/vial inj sol, Raptiva 150mg.vial inj pws, Stattera 10mg, 18mg, 25mg, 40mg, 60mg cap, Fragmin 2500u.ml, 25000u/ml inj sol, 10000u/ml, 25000u/ml inj sol, Fraxiparine 9500u/ml inj sol, Fraxiparine Forte19000u/ml inj sol, Innohep 10000u/ml, 20000u/ml inj sol, Lovenox 30mg/ml, 40mg/ml, 60mg/ml, 80mg/ml, 100mg/ml inj sol, Lovenox HP 100mg/ml, 150mg/ml inj sol, Actonel 5mg, 35mg, 70mg tab; Drugs Reviewed and Not Recommended: Adalat XL Plus 20mg, 30mg, 60mg tab o/dis, Cymbalta 30mg, 60mg cap, Sativex 27mg/ml & 25mg/ml buccal spray, Adderall XR 5mg, 10mg, 15mg, 20mg, 25mg, 30mg cap er.
PMPRB News - Regulations
Update from the July PMPRB Newsletter
PMPRB 2008 Annual Report Tabled in Parliament
Changes in the 2010 Guidelines compared to March 2009 Proposals
Update on the Consultation Process and other information from the PMPRB Newsletter
PMPRB Releases Draft New Compendium
Strattera Voluntary Compliance Undertaking
PMPRB NEWSletter - January 2009 Summary
|
